Page last updated: 2024-11-03

primaquine and Plasmodium vivax Malaria

primaquine has been researched along with Plasmodium vivax Malaria in 470 studies

Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.

Research Excerpts

ExcerptRelevanceReference
"5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment."9.69Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. ( Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P, 2023)
"Tafenoquine, co-administered with chloroquine, is approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria."9.69Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. ( Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M, 2023)
"The World Health Organization recommends that primaquine should be given once weekly for 8-weeks to patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) deficiency, but data on its antirelapse efficacy and safety are limited."9.69Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency. ( Assefa, A; Baird, JK; Bancone, G; Chand, K; Chau, NH; Day, NP; Degaga, TS; Dhorda, M; Dondorp, A; Ekawati, LL; Hailu, A; Hasanzai, MA; Ley, B; Meagher, N; Naddim, MN; Pasaribu, AP; Price, RN; Rahim, AG; Satyagraha, A; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A, 2023)
"Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria."9.41Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. ( Aung, AA; Blessborn, D; Chu, CS; Hanpithakpong, W; Imwong, M; Kraft, K; Ling, C; Nosten, FH; Phyo, AP; Proux, S; Soe, NL; Tarning, J; Thinraow, S; Watson, JA; White, NJ; Wilaisrisak, P; Win, HH; Yotyingaphiram, W, 2021)
"Ophthalmic safety observations are reported from a clinical trial comparing tafenoquine (TQ) efficacy and safety versus sequential chloroquine (CQ)/primaquine (PQ) for acute Plasmodium vivax malaria."9.30Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. ( Euswas, A; Fukuda, MM; Ittiverakul, M; Krudsood, S; Miller, RS; Ohrt, C; Warrasak, S, 2019)
"Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P."9.30Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM, 2019)
"Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain."9.30Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019)
"Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor."9.30Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019)
" Artesunate cleared parasitemia significantly faster than chloroquine."9.27Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018)
"Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency."9.24Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. ( Bancone, G; Charunwatthana, P; Chowwiwat, N; Chu, CS; Keereecharoen, L; Moore, KA; Nosten, F; Phyo, AP; Po, C; Proux, S; Raksapraidee, R; Thitipanawan, N; White, NJ; Wilairisak, P; Win, HH, 2017)
"Primaquine (PQ) is recommended to prevent relapses in patients with Plasmodium vivax malaria infection."9.14Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. ( Alvarez, G; Carmona-Fonseca, J; Maestre, A, 2009)
"Thai adult males (N = 85) with acute Plasmodium vivax malaria and normal glucose-6-phosphate dehydrogenase screening were randomized to receive 30 mg or 60 mg primaquine daily for 7 days (N = 43 and 42, respectively)."9.14A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. ( Chotivanich, K; Day, NP; Imwong, M; Pukrittayakamee, S; Singhasivanon, P; White, NJ, 2010)
"Tafenoquine is being developed for radical cure and post-exposure prophylaxis of Plasmodium vivax malaria."9.13The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. ( Edstein, MD; Elmes, NJ; Kitchener, SJ; Kocisko, DA; Nasveld, PE, 2008)
" In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine."9.11Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. ( Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P, 2004)
"For over 4 decades the antimalarial program in India has been prescribing a 5-day primaquine regimen as an antirelapse therapy to treat Plasmodium vivax malaria."9.10Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. ( Ghosh, SK; Yadav, RS, 2002)
"To improve upon the efficacy of primaquine prophylaxis for malaria (94%, Plasmodium falciparum malaria; 85%, Plasmodium vivax malaria), we administered chloroquine (300 mg weekly) in combination with primaquine (30 mg daily) to nonimmune Colombian soldiers during 16 weeks of patrol in a region of endemicity and for a further 1 week in base camp."9.09Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. ( Berman, J; Herrera, R; Padilla, J; Rodriquez, M; Sanchez, J; Soto, J; Toledo, J, 1999)
", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study."9.09Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999)
"25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria."9.07Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994)
"primaquine (PQ) is the only drug available in the market to prevent Plasmodium vivax malaria recurrence, but several aspects are still unknown."8.88[Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies]. ( Carmona-Fonseca, J, 2012)
"Primaquine is essential for the radical cure of Plasmodium vivax malaria, but it poses a potential danger of severe hemolysis in G6PD-deficient (G6PDd) patients."8.31Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency. ( Cui, L; Kim, K; Lakshmi, S; Liu, H; Malla, P; Menezes, L; Wang, C; Yang, Z; Zeng, W, 2023)
"Primaquine prevents relapses of Plasmodium vivax malaria but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency."8.31Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function. ( Anstey, NM; Douglas, NM; Ley, B; Piera, KA; Price, RN; Rumaseb, A, 2023)
"Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency."8.31Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses. ( Brito-Sousa, JD; Chu, C; Commons, RJ; Douglas, NM; Groves, ES; Lacerda, MVG; Monteiro, WM; Price, RN; Thriemer, K; Yilma, D, 2023)
"Plasmodium vivax malaria elimination requires radical cure with chloroquine/primaquine."8.12Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India. ( Ahmed, N; Anvikar, AR; Duparc, S; Grewal Daumerie, P; Pradhan, MM; Pradhan, S; Sahu, P; Sharma, S; Valecha, N; Yadav, CP, 2022)
"Primaquine and tafenoquine are the only licensed drugs that effectively kill the hypnozoite stage and are used to prevent Plasmodium vivax malaria relapse."8.12Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure. ( Boonyuen, U; Chamchoy, K; Krudsood, S; Patrapuvich, R; Sudsumrit, S; Thita, T, 2022)
"Primaquine and tafenoquine are the two 8-aminoquinoline (8-AQ) antimalarial drugs approved for malarial radical cure - the elimination of liver stage hypnozoites after infection with Plasmodium vivax."8.02Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure. ( Burke, PA; Chavas, TEJ; Flaherty, SM; Ho, DK; Huber, HE; Jackson, C; LeGuyader, CLM; Li, Q; Lin, H; Maktabi, M; Pottenger, A; Pybus, B; Rochford, R; Roy, D; Srinivasan, S; Stayton, PS; Strauch, P; Vlaskin, V; Wesche, D; Zhang, J, 2021)
"We reviewed the clinical efficacy of chloroquine for Plasmodium vivax malaria, the changing trend of parasite clearance time, and fever clearance time during 2000-2016 in South Korea."7.96Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016. ( Cho, SH; Kwak, YG; Lee, KS; Lee, SE; Park, SY; Park, Y; Park, YS; Shin, HI; Song, JE; Yeom, JS, 2020)
"Primaquine (PQ) is the only drug used to prevent relapse of malaria due to P."7.85Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents. ( Anand, N; Azad, CS; Bhardwaj, J; Dutta, GP; Puri, SK; Saxena, AK; Saxena, M; Siddiqui, AJ, 2017)
"Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published."7.83Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India. ( Ashok, H; Kamath, A; Kamath, V; Kumar, R; Kundapura, P; Mukhopadhyay, C; Saravu, K, 2016)
"We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014."7.83Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016)
"Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria."7.81Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. ( Baird, JK; Cao, Y; Cui, L; Fan, Q; Gupta, B; Lee, MC; Liu, H; Parker, DM; Wang, Y; Xiao, Y; Yan, G; Yang, Z; Yuan, L; Zhou, G, 2015)
"Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax malaria especially from Southeast Asian regions."7.81Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. ( Acharya, RV; Acharya, V; Belle, J; Hande, MH; Kamath, A; Rishikesh, K; Saravu, K; Shastry, AB; Vidyasagar, S, 2015)
"Relapse of Plasmodium vivax malaria following standard primaquine dosing has been reported from many areas, and more recently from sub-Saharan Africa."7.70Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. ( Kurnik, D; Regev-Yochay, G; Schwartz, E, 2000)
"The antimalarial effects of rifampin in 60 adults with Plasmodium vivax malaria were assessed."7.69Antimalarial effects of rifampin in Plasmodium vivax malaria. ( Charoenlarp, P; Pukrittayakamee, S; Viravan, C; White, NJ; Wilson, RJ; Yeamput, C, 1994)
"The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed."7.69Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. ( Kain, KC; Keystone, JS; Phillips, EJ, 1996)
"Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery."7.01Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. ( Baird, JK; Christophel, E; Kerleguer, A; Kheng, S; Kim, S; Luzzatto, L; Menard, D; Mukaka, M; Muth, S; Taylor, WRJ; Tor, P, 2021)
"Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P."6.90Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A, 2019)
" Most of the adverse events were mild in all treatment arms."6.87Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( Alexandre, MAA; Alves de Lima E Silva, JC; Daher, A; Dos Santos, TC; Lacerda, MVG; Lalloo, DG; Maia, I; Marchesini, P; Nascimento, CT; Pereira, D; Ruffato, R; Santelli, AC; Tada, M, 2018)
" There were no serious adverse events, with most adverse events classified as mild."6.82Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ( Daher, A; Fonseca, L; Fontes, CJ; Maia, I; Marchesini, P; Pereira, D; Pitta, L; Ruffato, R; Zanini, G, 2016)
"vivax malaria were eligible for study."6.78Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. ( Baird, JK; Basri, H; Ekawati, LL; Elyazar, I; Farrar, J; Meilia, RA; Nurleila, S; Putri, FA; Setiabudy, R; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2013)
" Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2."6.75Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. ( Day, NP; Imwong, M; Kaewkungwal, J; Kobayashi, J; Lawpoolsri, S; Maneeboonyang, W; Puangsa-art, S; Pukrittayakamee, S; Singhasivanon, P; Takeuchi, R; Thanyavanich, N, 2010)
" We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P."6.73High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008)
" We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P."6.72Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. ( Alvarez, G; Blair, S; Carmona-Fonseca, J; Maestre, A; Piñeros, JG; Ríos, A; Tobón, A, 2006)
"Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment."6.66Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020)
"Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0."6.61Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019)
"Primaquine has the potential to reduce malaria-related anaemia at day 42 and beyond by preventing recurrent parasitaemia."6.61The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Aseffa, A; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Douglas, NM; Erhart, A; Gomes, MSM; Grigg, MJ; Guerin, PJ; Hien, TT; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Vieira, JLF; Wangchuk, S; Watson, J; White, NJ; William, T; Woodrow, CJ, 2019)
"vivax relapse is a major global public health concern."6.53Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016)
"Tafenoquine is a new alternative with a longer half-life."6.52Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015)
"Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia."6.52Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015)
"Randomized controlled trials (RCTs) and quasi-RCTs comparing various primaquine dosing regimens with the standard primaquine regimen (15 mg/day for 14 days), or with no primaquine, in people with vivax malaria treated for blood stage infection with chloroquine."6.49Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. ( Galappaththy, GN; Kirubakaran, R; Tharyan, P, 2013)
" Different primaquine dosing regimens are in use."6.44Primaquine for preventing relapses in people with Plasmodium vivax malaria. ( Galappaththy, GN; Omari, AA; Tharyan, P, 2007)
"Plasmodium vivax malaria is considered a major threat to malaria eradication."5.91Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023)
"Malaria is a major cause of death in low-income countries."5.72Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022)
"The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes."5.72Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022)
"We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020."5.72Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022)
"Primaquine was effective in preventing P."5.72Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022)
"5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment."5.69Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. ( Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P, 2023)
"Tafenoquine, co-administered with chloroquine, is approved for the radical cure (prevention of relapse) of Plasmodium vivax malaria."5.69Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study. ( Baird, JK; Berni, A; Budiman, W; Cedar, E; Chand, K; Crenna-Darusallam, C; Duparc, S; Ekawati, LL; Elyazar, I; Fernando, D; Fletcher, K; Goyal, N; Green, JA; Instiaty, I; Jones, S; Kleim, JP; Lardo, S; Martin, A; Noviyanti, R; Prasetya, CB; Rolfe, K; Santy, YW; Satyagraha, AW; Sharma, H; Soebandrio, A; Subekti, D; Sutanto, I; Tan, LK; Taylor, M, 2023)
"The World Health Organization recommends that primaquine should be given once weekly for 8-weeks to patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) deficiency, but data on its antirelapse efficacy and safety are limited."5.69Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency. ( Assefa, A; Baird, JK; Bancone, G; Chand, K; Chau, NH; Day, NP; Degaga, TS; Dhorda, M; Dondorp, A; Ekawati, LL; Hailu, A; Hasanzai, MA; Ley, B; Meagher, N; Naddim, MN; Pasaribu, AP; Price, RN; Rahim, AG; Satyagraha, A; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A, 2023)
"Chloroquine was measured in plasma samples by high-performance liquid chromatography with fluorescence detection."5.56Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ( Mello, AGCN; Sena, LWP; Vieira, JLF; Vieira, MVDF, 2020)
" Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio."5.51Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA). ( Abate, DT; Alam, MS; Anose, RT; Baird, K; Christian, M; Degaga, TS; Hailu, A; Hossain, MS; Karahalios, A; Kibria, MG; Kidane, FG; Lee, G; Ley, B; Mnjala, H; Price, RN; Rajasekhar, M; Rumaseb, A; Simpson, JA; Sutanto, I; Tego, TT; Thriemer, K; Weston, S; Woyessa, A, 2022)
"vivax malaria was higher in children 1 to <5 years of age (49."5.46Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017)
"Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria."5.41Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. ( Aung, AA; Blessborn, D; Chu, CS; Hanpithakpong, W; Imwong, M; Kraft, K; Ling, C; Nosten, FH; Phyo, AP; Proux, S; Soe, NL; Tarning, J; Thinraow, S; Watson, JA; White, NJ; Wilaisrisak, P; Win, HH; Yotyingaphiram, W, 2021)
" We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine."5.40Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014)
"Primaquine dosing was classified as no dose, low dose (<420 mg), high dose (≥420 mg), or unknown."5.38Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. ( Looke, D; McCarthy, JS; McDougall, D; Townell, N, 2012)
"Ophthalmic safety observations are reported from a clinical trial comparing tafenoquine (TQ) efficacy and safety versus sequential chloroquine (CQ)/primaquine (PQ) for acute Plasmodium vivax malaria."5.30Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. ( Euswas, A; Fukuda, MM; Ittiverakul, M; Krudsood, S; Miller, RS; Ohrt, C; Warrasak, S, 2019)
"Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P."5.30Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM, 2019)
"Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain."5.30Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019)
"Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor."5.30Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019)
"The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine."5.30[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997)
" Artesunate cleared parasitemia significantly faster than chloroquine."5.27Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018)
"Radical cure of Plasmodium vivax malaria requires treatment with a blood schizonticide and a hypnozoitocide (primaquine) to eradicate the dormant liver stages."5.27A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. ( Bava, A; Bhat, K; Brahmarouphu, G; Channabasavaiah, JP; Guddattu, V; Kulavalli, S; Saadi, AV; Saravu, K; Satyamoorthy, K; Srinivas, NK; Tellapragada, C; Umakanth, S; Xavier, W, 2018)
"Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency."5.24Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. ( Bancone, G; Charunwatthana, P; Chowwiwat, N; Chu, CS; Keereecharoen, L; Moore, KA; Nosten, F; Phyo, AP; Po, C; Proux, S; Raksapraidee, R; Thitipanawan, N; White, NJ; Wilairisak, P; Win, HH, 2017)
"Chloroquine combined with primaquine has been the standard radical curative regimen for Plasmodium vivax and Plasmodium ovale malaria for over half a century."5.19Pharmacokinetic interactions between primaquine and chloroquine. ( Ashley, EA; Charunwatthana, P; Day, NP; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Lawpoolsri, S; Lee, SJ; Pukrittayakamee, S; Tarning, J; White, NJ, 2014)
"Primaquine (PQ) is recommended to prevent relapses in patients with Plasmodium vivax malaria infection."5.14Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. ( Alvarez, G; Carmona-Fonseca, J; Maestre, A, 2009)
"Thai adult males (N = 85) with acute Plasmodium vivax malaria and normal glucose-6-phosphate dehydrogenase screening were randomized to receive 30 mg or 60 mg primaquine daily for 7 days (N = 43 and 42, respectively)."5.14A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. ( Chotivanich, K; Day, NP; Imwong, M; Pukrittayakamee, S; Singhasivanon, P; White, NJ, 2010)
"Tafenoquine is being developed for radical cure and post-exposure prophylaxis of Plasmodium vivax malaria."5.13The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. ( Edstein, MD; Elmes, NJ; Kitchener, SJ; Kocisko, DA; Nasveld, PE, 2008)
"We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria."5.12Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand. ( Brittenham, GM; Chalermrut, K; Krudsood, S; Looareesuwan, S; Luplertlop, N; Muangnoicharoen, S; Srivilairit, S; Tangpukdee, N; Thanachartwet, V; Wilairatana, P, 2006)
" In a previous dose-ranging study in Thailand, 3 tafenoquine regimens with total doses ranging from 500 mg to 3000 mg prevented relapse of Plasmodium vivax malaria in most patients when administered 2 days after receipt of a blood schizonticidal dose of chloroquine."5.11Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. ( Brewer, TG; Heppner, DG; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Siriyanonda, D; Tang, DB; Walsh, DS; Wilairatana, P, 2004)
"For over 4 decades the antimalarial program in India has been prescribing a 5-day primaquine regimen as an antirelapse therapy to treat Plasmodium vivax malaria."5.10Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. ( Ghosh, SK; Yadav, RS, 2002)
"We studied prospectively 801 Thai patients admitted to the Bangkok Hospital for Tropical Diseases with acute, symptomatic Plasmodium vivax malaria to determine the optimum duration of treatment with oral artesunate and the safety, tolerability, and effectiveness of a high dose of primaquine in prevention of relapse."5.10Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. ( Brittenham, GM; Chalearmrult, K; Gourdeuk, VR; Krudsood, S; Looareesuwan, S; Maneekan, P; Mint, HY; Silachamroon, U; Treeprasertsuk, S; White, NJ; Wilairatana, P, 2003)
"To improve upon the efficacy of primaquine prophylaxis for malaria (94%, Plasmodium falciparum malaria; 85%, Plasmodium vivax malaria), we administered chloroquine (300 mg weekly) in combination with primaquine (30 mg daily) to nonimmune Colombian soldiers during 16 weeks of patrol in a region of endemicity and for a further 1 week in base camp."5.09Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. ( Berman, J; Herrera, R; Padilla, J; Rodriquez, M; Sanchez, J; Soto, J; Toledo, J, 1999)
"Chloroquine has been the standard treatment for Plasmodium vivax malaria for more than 40 years in most regions of the world."5.09Chloroquine sensitivity of Plasmodium vivax in Thailand. ( Bussaratid, V; Chalermrut, K; Chokjindachai, W; Krudsood, S; Looareesuwan, S; Singhasivanon, P; Treeprasertsuk, S; Viriyavejakul, P; Walsh D, S; White, J; Wilairatana, P, 1999)
", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study."5.09Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999)
"In an investigation of relapse patterns, 5541 cases of Plasmodium vivax malaria, from four major industrial complexes, each received at least one, 5-day course of primaquine (at 15 mg/day)."5.09Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. ( Dua, VK; Sharma, VP, 2001)
"25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria."5.07Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994)
"To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria."5.01Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. ( Bancone, G; Douglas, NM; Espino, F; Henriques, G; Karahalios, A; Ley, B; Menard, D; Oo, NN; Parikh, S; Pfeffer, DA; Price, RN; Rahmat, H; von Fricken, ME; von Seidlein, L; Winasti Satyagraha, A, 2019)
"Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure."4.98The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Erhart, A; Gomes, MSM; Gonzalez-Ceron, L; Grigg, MJ; Guerin, PJ; Heidari, A; Humphreys, GS; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Sutanto, I; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Tran, HT; Valecha, N; Vieira, JLF; Wangchuk, S; White, NJ; William, T; Woodrow, CJ; Zuluaga-Idarraga, L, 2018)
" Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria."4.93Management of relapsing Plasmodium vivax malaria. ( Chu, CS; White, NJ, 2016)
"primaquine (PQ) is the only drug available in the market to prevent Plasmodium vivax malaria recurrence, but several aspects are still unknown."4.88[Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies]. ( Carmona-Fonseca, J, 2012)
"Primaquine is essential for the radical cure of Plasmodium vivax malaria, but it poses a potential danger of severe hemolysis in G6PD-deficient (G6PDd) patients."4.31Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency. ( Cui, L; Kim, K; Lakshmi, S; Liu, H; Malla, P; Menezes, L; Wang, C; Yang, Z; Zeng, W, 2023)
"Primaquine prevents relapses of Plasmodium vivax malaria but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency."4.31Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function. ( Anstey, NM; Douglas, NM; Ley, B; Piera, KA; Price, RN; Rumaseb, A, 2023)
"8-Aminoquinoline antimalarial drugs (primaquine, tafenoquine) are required for complete cure of Plasmodium vivax malaria, but they are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency."4.31Performance of a Commercial Multiplex Allele-Specific Polymerase Chain Reaction Kit to Genotype African-Type Glucose-6-Phosphate Dehydrogenase Deficiency. ( Basco, L; Briolant, S; Djigo, OKM; Gomez, N; Ould Ahmedou Salem, MS; Ould Mohamed Salem Boukhary, A, 2023)
"Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030."4.31Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response. ( Abadura, GS; Bayissa, GA; Behaksra, SW; Bulto, MG; Gadisa, E; Mekonnen, DA; Tadesse, FG; Taffese, HS; Tessema, TS, 2023)
"Primaquine (PQ) kills Plasmodium vivax hypnozoites but can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency."4.31Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses. ( Brito-Sousa, JD; Chu, C; Commons, RJ; Douglas, NM; Groves, ES; Lacerda, MVG; Monteiro, WM; Price, RN; Thriemer, K; Yilma, D, 2023)
"Plasmodium vivax malaria elimination requires radical cure with chloroquine/primaquine."4.12Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India. ( Ahmed, N; Anvikar, AR; Duparc, S; Grewal Daumerie, P; Pradhan, MM; Pradhan, S; Sahu, P; Sharma, S; Valecha, N; Yadav, CP, 2022)
" Therefore, malaria patient treatment using primaquine should be monitored closely for any adverse effects."4.12Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia. ( Adamu, A; Feleke, SM; Gebremichael, SG; Gidey, B; Hailu, A; Kebede, T; Kepple, D; Lo, E; Nega, D; Negash, MT; Shenkutie, TT; Tasew, G; Witherspoon, L, 2022)
"v infection by Village Malaria Workers (VMWs) were referred to local health centres for point-of-care G6PD testing and initiation of radical cure treatment with 14-day or 8-week primaquine regimens depending on G6PD status."4.12G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study. ( Ir, P; Kak, N; Kheang, ST; Lek, D; Ngeth, E; Ngor, P; Phon, S; Ridley, R; Sovannaroth, S; Yeung, S, 2022)
"Primaquine and tafenoquine are the only licensed drugs that effectively kill the hypnozoite stage and are used to prevent Plasmodium vivax malaria relapse."4.12Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure. ( Boonyuen, U; Chamchoy, K; Krudsood, S; Patrapuvich, R; Sudsumrit, S; Thita, T, 2022)
"To investigate the impact of Plasmodium vivax malaria and chloroquine-primaquine chemotherapy on CYP2D6 and CYP2C19 activity in patients from the Brazilian Amazon."4.02Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients. ( Almeida, AC; Brasil, LW; da Costa, AG; de Lacerda, MVG; de Melo, GC; Elias, ABR; Figueiredo, EFG; Lanchote, VL; Marques, MP; Monteiro, WM; Rodrigues-Soares, F; Suarez-Kurtz, G, 2021)
"Primaquine and tafenoquine are the two 8-aminoquinoline (8-AQ) antimalarial drugs approved for malarial radical cure - the elimination of liver stage hypnozoites after infection with Plasmodium vivax."4.02Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure. ( Burke, PA; Chavas, TEJ; Flaherty, SM; Ho, DK; Huber, HE; Jackson, C; LeGuyader, CLM; Li, Q; Lin, H; Maktabi, M; Pottenger, A; Pybus, B; Rochford, R; Roy, D; Srinivasan, S; Stayton, PS; Strauch, P; Vlaskin, V; Wesche, D; Zhang, J, 2021)
"Primaquine is an approved radical cure treatment for Plasmodium vivax malaria but treatment can result in life-threatening hemolysis if given to a glucose-6-phosphate dehydrogenase deficient (G6PDd) patient."3.96Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia. ( Boonchan, T; Buathong, N; Chann, S; Dao, V; Feldman, M; Fukuda, MM; Gosi, P; Hom, S; Huy, R; Ittiverakul, M; Kong, N; Kuntawunginn, W; Lek, D; Lon, C; Ly, S; Nou, S; Oung, P; Pheap, V; Sea, D; Smith, P; Sok, C; Sok, S; Spring, M; Sriwichai, S; Thay, K; Uthaimongkol, N; Wojnarski, B; Wojnarski, M, 2020)
"We reviewed the clinical efficacy of chloroquine for Plasmodium vivax malaria, the changing trend of parasite clearance time, and fever clearance time during 2000-2016 in South Korea."3.96Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016. ( Cho, SH; Kwak, YG; Lee, KS; Lee, SE; Park, SY; Park, Y; Park, YS; Shin, HI; Song, JE; Yeom, JS, 2020)
" Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD deficient people."3.91Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. ( Koepfli, C; Lee, MC; Lo, E; Pestana, K; Raya, B; Yan, G; Yewhalaw, D; Zhong, D, 2019)
"Primaquine is the only drug providing radical cure of Plasmodium vivax malaria."3.88Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. ( Bancone, G; Carrara, VI; Chu, CS; Gilder, ME; Hanpithakphong, W; Hilda, N; Hoglund, RM; McGready, R; Nosten, F; Singhasivanon, P; Tarning, J; White, NJ; Win, HH, 2018)
"Primaquine (PQ) is the only drug used to prevent relapse of malaria due to P."3.85Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents. ( Anand, N; Azad, CS; Bhardwaj, J; Dutta, GP; Puri, SK; Saxena, AK; Saxena, M; Siddiqui, AJ, 2017)
"Several reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published."3.83Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India. ( Ashok, H; Kamath, A; Kamath, V; Kumar, R; Kundapura, P; Mukhopadhyay, C; Saravu, K, 2016)
"We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014."3.83Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016)
"Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria."3.81Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. ( Baird, JK; Cao, Y; Cui, L; Fan, Q; Gupta, B; Lee, MC; Liu, H; Parker, DM; Wang, Y; Xiao, Y; Yan, G; Yang, Z; Yuan, L; Zhou, G, 2015)
"Safe treatment of Plasmodium vivax requires diagnosis of both the infection and status of erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity because hypnozoitocidal therapy against relapse requires primaquine, which causes a mild to severe acute hemolytic anemia in G6PD deficient patients."3.81G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria. ( Baird, JK; Baramuli, V; Coutrier, FN; Elvira, R; Elyazar, I; Harahap, AR; Noviyanti, R; Ridenour, C; Sadhewa, A; Satyagraha, AW, 2015)
"Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax malaria especially from Southeast Asian regions."3.81Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. ( Acharya, RV; Acharya, V; Belle, J; Hande, MH; Kamath, A; Rishikesh, K; Saravu, K; Shastry, AB; Vidyasagar, S, 2015)
"Administering primaquine (PQ) to treat malaria patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can pose a serious risk of drug-induced hemolysis (DIH)."3.80Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. ( Beau de Rochars, MV; Eaton, WT; Masse, R; Okech, BA; von Fricken, ME; Weppelmann, TA, 2014)
" This feature could be used as a screening tool for G6PD-deficient persons who are unable to use primaquine for the radical cure of Plasmodium vivax malaria."3.80High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon. ( Alecrim, MG; Brito, MA; Costa, MR; Lacerda, MV; Monteiro, WM; Sampaio, VS; Santana, MS, 2014)
" Radical cure with primaquine was prescribed after the first bout of malaria for 6 patients."3.80Compliance to recommendations for the management of curative treatment of Plasmodium vivax/ovale infections. ( Bellanger, AP; Chirouze, C; Faucher, JF; Hoen, B; Hustache-Mathieu, L; Shaniya, N, 2014)
"Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure."3.80Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). ( Gettyacamin, M; Imerbsin, R; Khemawoot, P; Lanteri, C; Nanayakkara, NP; Ohrt, C; Sampath, A; Saunders, D; Siripokasupkul, R; Teja-Isavadharm, P; Tekwani, BL; Vanachayangkul, P; Walker, L, 2014)
"Primaquine is the only drug available for preventing relapse following a primary attack by Plasmodium vivax malaria."3.80The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. ( Baird, JK; Crenna-Darusallam, C; Ingram, RJ; Noviyanti, R; Soebianto, S, 2014)
"Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections."3.79Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. ( Alenazi, T; Bright, AT; Houston, S; Paganotti, GM; Shokoples, S; Tarning, J; White, NJ; Winzeler, EA; Yanow, SK, 2013)
" After sporozoite inoculation and blood-stage cure of initial parasitemia with chloroquine, rhesus macaques were treated on subsequent relapses with chloroquine in conjunction with test regimens of approved drugs."3.78Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. ( Bennett, K; Deye, GA; Fracisco, S; Gettayacamin, M; Hansukjariya, P; Im-erbsin, R; Macareo, L; Magill, AJ; Ohrt, C; Rothstein, Y; Sattabongkot, J, 2012)
"In Honduras, chloroquine and primaquine are recommended and still appear to be effective for treatment of Plasmodium falciparum and Plasmodium vivax malaria."3.77Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. ( Alger, J; Banegas, E; Bjorkman, A; Enamorado, IG; Ferreira, PE; Fontecha, G; Jovel, IT; Mejía, RE; Piedade, R; Ursing, J; Veiga, MI, 2011)
" knowlesi infection had uncomplicated malaria that responded to chloroquine and primaquine treatment."3.75Clinical and laboratory features of human Plasmodium knowlesi infection. ( Cox-Singh, J; Daneshvar, C; Davis, TM; Divis, PC; Rafa'ee, MZ; Singh, B; Zakaria, SK, 2009)
"The standard adult treatment regimen for Plasmodium vivax malaria is chloroquine (1500 mg over 3 d) plus primaquine (15 or 30 mg daily for 14 d), but patient compliance tends to be poor with the lengthy course."3.74Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. ( Chavchich, M; Cuong, BT; Dai, B; Dao, NV; Duy, DN; Edstein, MD; Ngoa, ND; Rieckmann, KH; Thanh, NX; The, ND; Thuy, le TT, 2007)
"Primaquine is now the only drug available to eradicate Plasmodium vivax malaria."3.73[How much primaquine is needed to eradicate Plasmodium vivax hypnozoites?]. ( Alonso, D; Corachán, M; Gascón, J; Muñoz, J; Valls, ME; Velasco, M, 2006)
"The influence of combinations containing the blood schizontocides chloroquine (CQ) or mefloquine (MEF), together with the 8-aminoquinolines (8AQ) primaquine (PQ) or the new, long-acting compound, tafenoquine (TAF), on the rate of selection of resistance to the individual compounds was examined using the asexual, intra-erythrocytic stages in rodent malaria models."3.72The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines. ( Peters, W; Robinson, BL; Stewart, LB, 2003)
"Relapse of Plasmodium vivax malaria following standard primaquine dosing has been reported from many areas, and more recently from sub-Saharan Africa."3.70Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. ( Kurnik, D; Regev-Yochay, G; Schwartz, E, 2000)
"Seventy-nine adults with Plasmodium vivax malaria, from the Porto Velho area of Rond nia (western Amazon region, Brazil), gave informed consent to participate in a blind, clinical study of two regimens of treatment with chloroquine (CQ) and primaquine."3.70In-vivo sensitivity of Plasmodium vivax isolates from Rond nia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. ( Kimura, E; Menezes, MJ; Pereira da Silva, LH; Tada, MS; Villalobos-Salcedo, JM, 2000)
"The antimalarial effects of rifampin in 60 adults with Plasmodium vivax malaria were assessed."3.69Antimalarial effects of rifampin in Plasmodium vivax malaria. ( Charoenlarp, P; Pukrittayakamee, S; Viravan, C; White, NJ; Wilson, RJ; Yeamput, C, 1994)
"The presence of chloroquine-resistant Plasmodium vivax malaria in the New World has been suspected but not confirmed."3.69Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. ( Kain, KC; Keystone, JS; Phillips, EJ, 1996)
"8 patients with paludism diagnosis due to Plasmodium vivax and deficiency of glucose-6-phosphate dehydrogenase that should receive antipaludism radical treatment with primaquine were studied."3.69[Hemolysis and primaquine treatment. Preliminary report]. ( Díaz Pérez, L; Luzardo Suárez, C; Menéndez Capote, R, 1997)
"Primaquine radical cure has the potential to reduce P vivax recurrences in patients presenting with P falciparum as well as P vivax malaria but is undermined by poor adherence to the currently recommended 14-day regimen."3.11Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. ( Burdam, FH; Candrawati, F; Indrawanti, R; Kenangalem, E; Ley, B; Meagher, N; Poespoprodjo, JR; Price, DJ; Price, RN; Simpson, JA; Thriemer, K; Trianty, L, 2022)
" Herein, the results of three bioequivalence studies are presented, providing individual pharmacokinetic data on chloroquine and primaquine of more than a hundred healthy volunteers and using up-to-date analytical methods."3.11Pharmacokinetics of chloroquine and primaquine in healthy volunteers. ( da Fonseca, LB; da Silva, DMD; da Silva, LSFV; Daher, A; Esteves, AL; Mendonça, JS; Pereira, HM; Pinto, DP; Soares Medeiros, JJ, 2022)
"Acute Plasmodium vivax malaria is associated with haemolysis, bone marrow suppression, reticulocytopenia, and post-treatment reticulocytosis leading to haemoglobin recovery."3.01Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria. ( Baird, JK; Christophel, E; Kerleguer, A; Kheng, S; Kim, S; Luzzatto, L; Menard, D; Mukaka, M; Muth, S; Taylor, WRJ; Tor, P, 2021)
"vivax recurrence between days 7 and 90 was investigated by Cox regression analysis."3.01Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Awab, GR; Baird, JK; Brasil, LW; Chu, CS; Commons, RJ; Cui, L; Daher, A; Dini, S; do Socorro M Gomes, M; Gonzalez-Ceron, L; Guerin, PJ; Hwang, J; Karunajeewa, H; Lacerda, MVG; Ladeia-Andrade, S; Leslie, T; Ley, B; Lidia, K; Llanos-Cuentas, A; Longley, RJ; Mehdipour, P; Monteiro, WM; Pereira, DB; Price, RN; Rajasekhar, M; Rijal, KR; Saravu, K; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, PV; Thriemer, K; Vieira, JLF; White, NJ; Zaloumis, S; Zuluaga-Idarraga, LM, 2023)
"The median time to recurrence of P."2.94The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. ( Adhikari, B; Cobelens, F; Day, NPJ; Dhorda, M; Dondorp, AM; Henriques, G; Imwong, M; Mayxay, M; Mukaka, M; Newton, PN; Peerawaranun, P; Peto, TJ; Phommasone, K; Pongvongsa, T; Promnarate, C; Sirithiranont, P; van Leth, F; von Seidlein, L; White, NJ, 2020)
"We show that individual vivax malaria recurrences can be characterised probabilistically by combined modelling of time-to-event and genetic data within a framework incorporating identity-by-descent."2.90Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. ( Buckee, CO; Chu, CS; Day, NPJ; Duanguppama, J; Imwong, M; Neafsey, DE; Nosten, F; Puaprasert, K; Taylor, AR; Watson, JA; White, NJ, 2019)
"Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P."2.90Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A, 2019)
" Most of the adverse events were mild in all treatment arms."2.87Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( Alexandre, MAA; Alves de Lima E Silva, JC; Daher, A; Dos Santos, TC; Lacerda, MVG; Lalloo, DG; Maia, I; Marchesini, P; Nascimento, CT; Pereira, D; Ruffato, R; Santelli, AC; Tada, M, 2018)
"vivax malaria were treated with AS/SP."2.87Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. ( Abdelbagi, H; Basheir, HM; Boshara, SA; Chen, I; Elobied, ME; Elsafi, HMH; Gosling, R; Gumaa, SA; Hamid, MMA; Hamid, T; Ley, B; Mahgoub, NS; Marfurt, J; Price, RN; Thriemer, K, 2018)
"Characterization of the pharmacokinetic properties of the enantiomers of primaquine and carboxyprimaquine following administration of racemic primaquine given alone and in combination with commonly used antimalarial drugs."2.87Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. ( Blessborn, D; Chairat, K; Day, NPJ; Hanboonkunupakarn, B; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ, 2018)
"Chloroquine serves as a drug of choice, with primaquine as a radical cure."2.82Global scenario of Plasmodium vivax occurrence and resistance pattern. ( Kaur, D; Sehgal, R; Sinha, S, 2022)
" No clear dose-response pattern was evident for heterologous recurrences of P."2.82Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. ( Beck, HP; Carter, N; Duparc, S; Green, JA; Koh, G; Krudsood, S; Lacerda, MV; Llanos-Cuentas, A; Osorio, L; Rubio, JP; Rueangweerayut, R; Wampfler, R, 2016)
" There were no serious adverse events, with most adverse events classified as mild."2.82Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. ( Daher, A; Fonseca, L; Fontes, CJ; Maia, I; Marchesini, P; Pereira, D; Pitta, L; Ruffato, R; Zanini, G, 2016)
"Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine."2.80Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. ( Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015)
"Some parasite recurrences were detected by PCR and/or serological testing."2.80Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. ( Betanzos, AF; Galindo-Virgen, S; Gonzalez-Ceron, L; Palomeque, OL; Rodriguez, MH; Rosales, AF; Sandoval, MA; Santillan, F, 2015)
"Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas."2.80Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. ( , 2015)
" We assessed primaquine (PQ) as hypnozoitocide when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine (Pyramax®, AS-PYR) to affirm its good tolerability and efficacy."2.80Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. ( Baird, JK; Basri, H; Chand, K; Djoko, D; Duparc, S; Ekasari, T; Ekawati, LL; Elyazar, I; Nelwan, EJ; Noviyanti, R; Setiabudy, R; Subekti, D; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2015)
"A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination therapies, combined with primaquine (PQ) for radical cure."2.78A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. ( Chavez, I; Chokejindachai, W; Dondorp, AM; Imwong, M; Pasaribu, AP; Pasaribu, S; Sirivichayakul, C; Tanomsing, N; Tjitra, E; White, NJ, 2013)
"Radical cure of vivax malaria is one of challenges for malaria elimination."2.78Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. ( Li, CF; Liu, H; Nie, RH; Wang, JZ; Xu, JW; Yang, HL, 2013)
"vivax malaria were eligible for study."2.78Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. ( Baird, JK; Basri, H; Ekawati, LL; Elyazar, I; Farrar, J; Meilia, RA; Nurleila, S; Putri, FA; Setiabudy, R; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2013)
" Chloroquine, either alone or in combination with primaquine, is still effective against P."2.78In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes. ( Bera, DK; Biswas, A; Das, S; Ganguly, S; Guha, SK; Kundu, PK; Maji, AK; Ray, K; Saha, B; Saha, P, 2013)
"This suggested that 32 of the 47 recurrences were probable relapses of which 22 (69%) were genetically homologous."2.77Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. ( Addy, M; Day, NP; Dondorp, AM; Imwong, M; Kim, JR; Maji, AK; Nandy, A; Pukrittayakamee, S; White, NJ, 2012)
"Primaquine treatment also reduced the risk of quantitative real-time polymerase chain reaction- and light microscopy-positive P."2.77Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. ( Alonso, PL; Bassat, Q; Betuela, I; de Lazzari, E; Del Portillo, HA; Kiniboro, B; Mueller, I; Rosanas-Urgell, A; Samol, L; Siba, P; Stanisic, DI, 2012)
"A safe and reproducible Plasmodium vivax infectious challenge method is required to evaluate the efficacy of malaria vaccine candidates."2.76Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. ( Arévalo-Herrera, M; Echavarría, JF; Epstein, JE; Herrera, S; Jordán-Villegas, A; Palacios, R; Ramírez, O; Richie, TL; Rocha, L; Solarte, Y; Vélez, JD, 2011)
" The most common adverse events were nausea, abdominal pain, headache and insomnia, many of which were mild in severity (30%; 60/203) and transient; 19% of subjects (39/203) experienced moderate (with some interference with daily duties requiring no or minimal medical therapy) adverse events."2.76Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. ( Baker, J; Ebringer, A; Edstein, MD; Heathcote, G; Shanks, GD; Waller, M, 2011)
" Factors related to the reappearance of vivax malaria included inadequate total primaquine dosage received (< 2."2.75Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. ( Day, NP; Imwong, M; Kaewkungwal, J; Kobayashi, J; Lawpoolsri, S; Maneeboonyang, W; Puangsa-art, S; Pukrittayakamee, S; Singhasivanon, P; Takeuchi, R; Thanyavanich, N, 2010)
"A practical radical treatment for vivax malaria is essential for control and elimination of the disease."2.73A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. ( Erasmus, P; Kolaczinski, J; Leslie, T; Mayan, I; Mohammed, N; Rowland, M; Whitty, CJ, 2008)
" We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P."2.73High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008)
"FDA for the treatment of P."2.72Tafenoquine for ( Gautam, CS; Sharma, J; Singh, H; Singh, J, 2021)
" We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P."2.72Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. ( Alvarez, G; Blair, S; Carmona-Fonseca, J; Maestre, A; Piñeros, JG; Ríos, A; Tobón, A, 2006)
"Vivax malaria was endemic on the Korean peninsula for many centuries until the late 1970's when the Republic of Korea (ROK) was declared "malaria free"."2.71Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. ( Ahn, SY; Cha, JE; Choi, DH; Kim, YA; Lee, JH; Oh, S; Oh, YH; Park, JW; Ryu, SH; Song, KJ; Yang, HY; Yeom, JS, 2005)
"Primaquine was better tolerated than chloroquine."2.68Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Leksana, B; Masbar, S; Richie, TL; Subianto, B; Wiady, I, 1995)
"Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0."2.68Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997)
" We do not know whether there is a difference in adverse events resulting in discontinuation of treatment with the high-standard dosage (RR 4."2.66Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. ( Bergman, H; Daher, A; Graves, PM; Milligan, R; Villanueva, G, 2020)
"Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment."2.66Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020)
"vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan."2.61The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ, 2019)
"Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0."2.61Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019)
"Primaquine has the potential to reduce malaria-related anaemia at day 42 and beyond by preventing recurrent parasitaemia."2.61The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Aseffa, A; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Douglas, NM; Erhart, A; Gomes, MSM; Grigg, MJ; Guerin, PJ; Hien, TT; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Vieira, JLF; Wangchuk, S; Watson, J; White, NJ; William, T; Woodrow, CJ, 2019)
" Another priority is exploring alternative 8-aminoquinoline dosing regimens that are practical and improve safety in G6PD deficient individuals."2.58Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. ( Bancone, G; Chu, CS; Luzzatto, L; Nosten, F; White, NJ, 2018)
"Tafenoquine was recently approved for Plasmodium vivax radical cure (KRINTAFEL™) and malaria prevention (ARAKODA™)."2.58Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines. ( Berman, J; Brown, T; Dow, G; Toovey, S, 2018)
"vivax relapse is a major global public health concern."2.53Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016)
"Primaquine resistance is a complex issue, as the mechanism of resistance is not clear."2.53Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax. ( Cooper, JC; Sundararaj, KG; Tazerouni, H; Thomas, D, 2016)
"Tafenoquine is a new alternative with a longer half-life."2.52Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015)
"Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia."2.52Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015)
"Testing for G6PD deficiency is not widely available, and so whilst it is widely recommended, primaquine is often not prescribed."2.50Mass primaquine treatment to eliminate vivax malaria: lessons from the past. ( Ashley, EA; Baranova, AM; Kondrashin, A; Recht, J; Sergiev, VP; White, NJ, 2014)
"Randomized controlled trials (RCTs) and quasi-RCTs comparing various primaquine dosing regimens with the standard primaquine regimen (15 mg/day for 14 days), or with no primaquine, in people with vivax malaria treated for blood stage infection with chloroquine."2.49Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. ( Galappaththy, GN; Kirubakaran, R; Tharyan, P, 2013)
"G6PD deficiency is a highly variable disorder, in terms of spatial heterogeneity in prevalence and molecular variants, as well as its interactions with P."2.49G6PD deficiency: global distribution, genetic variants and primaquine therapy. ( Baird, JK; Battle, KE; Hay, SI; Howes, RE; Satyagraha, AW, 2013)
"Primaquine regimens were categorized according to the total dose administered: very low (≤2."2.48Primaquine radical cure of Plasmodium vivax: a critical review of the literature. ( Baird, JK; Douglas, NM; John, GK; Nosten, F; Price, RN; von Seidlein, L; White, NJ, 2012)
"Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952."2.47Primaquine in vivax malaria: an update and review on management issues. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2011)
"In the meantime, AL treatment of vivax malaria may be a pragmatic choice for areas with chloroquine-resistant P."2.47The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. ( Bassat, Q, 2011)
" Different primaquine dosing regimens are in use."2.44Primaquine for preventing relapses in people with Plasmodium vivax malaria. ( Galappaththy, GN; Omari, AA; Tharyan, P, 2007)
"Primaquine treatment, the only therapeutic option against relapse, might also be failing."2.44Neglect of Plasmodium vivax malaria. ( Baird, JK, 2007)
"Rarely, cerebral malaria is a presenting complication or occurs during the course of P."2.43Cerebral malaria owing to Plasmodium vivax: case report. ( Atambay, M; Daldal, N; Gungor, S; Ozen, M, 2006)
" For optimal efficacy, treatment regimens must be adjusted with regard to dosage of primaquine and association with halofantrine, mefloquine or other new antimalarial agents."2.41[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax]. ( Granier, H; Klotz, F; Martin, J; Nicolas, X, 2000)
"G6PD deficiency was found among 13."1.91Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020. ( Aung, PL; Cui, L; Kyaw, MP; Okanurak, K; Oo, TL; Parker, DM; Sattabongkot, J; Soe, MT; Soe, TN; Win, KM, 2023)
"Malaria was considered to be cured with 'blue drugs' (referring to dihydroartemisinin-piperaquine)."1.91Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study. ( Burdam, FH; Devine, A; Gryseels, C; Kenangalem, E; Landuwulang, CUR; Ley, B; Peeters Grietens, K; Poespoprodjo, JR; Price, RN; Rahmalia, A; Ronse, M; Thriemer, K, 2023)
"Malaria is caused by parasite of the genus Plasmodium and is still one of the most important infectious diseases in the world."1.91Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi. ( Aguiar, ACC; Andrade, AO; Araújo, JE; Araújo, MS; Bastos, AS; G Teles, CB; Gazzinelli, RT; Lima, AA; Martinez, LN; Medeiros, JF; Pereira, DB; Pontual, JDC; Santos, NAC; Silva, AMV; Vinetz, JM, 2023)
"Malaria is endemic and represents an important public health issue in Brazil."1.91A fatal respiratory complication of malaria caused by Plasmodium vivax. ( Brasil, P; Bressan, CS; Calvet, GA; Daniel-Ribeiro, CT; de Bruycker-Nogueira, F; de Fátima Ferreira-da-Cruz, M; de Pina-Costa, A; Detepo, PJT; Ferreira, MT; Filippis, AMB; López, AR; Lupi, O; Mamani, RF; Martins, EB; Pacheco-Silva, AB; Silva, MFB; Siqueira, A, 2023)
"Plasmodium vivax malaria is considered a major threat to malaria eradication."1.91Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023)
"Screening for G6PD deficiency can inform disease management including malaria."1.91Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis. ( Adissu, W; Alam, MS; Bancone, G; Bansil, P; Brito, M; Bryan, A; Chu, CS; Das, S; Domingo, GJ; Garbin, E; Gerth-Guyette, E; Hann, A; Kublin, J; Lacerda, MVG; Layton, M; Ley, B; Macedo, M; Monteiro, W; Mukherjee, SK; Murphy, SC; Myburg, J; Nosten, F; Pal, S; Pereira, D; Price, RN; Sharma, A; Talukdar, A; Yilma, D; Zobrist, S, 2023)
"Malaria is a major cause of death in low-income countries."1.72Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022)
"According to our findings, testing G6PD deficiency and monitoring the potential PQ toxicity in patients who receive PQ are highly recommended."1.72Prevalence of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency among Malaria Patients in Southern Thailand: 8 Years Retrospective Study. ( Buncherd, H; Khammanee, T; Sawangjaroen, N; Thanapongpichat, S; Tun, AW, 2022)
"The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes."1.72Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022)
"We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020."1.72Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022)
"Therefore, G6PD deficiency testing should precede hypnozoite elimination with 8-aminoquinoline."1.72An Evaluation of a New Quantitative Point-of Care Diagnostic to Measure Glucose-6-phosphate Dehydrogenase Activity. ( Ahn, SK; Bahk, YY; Jeon, HJ; Lee, SK; Na, BK; Shin, HJ, 2022)
"Malaria recurrence was defined as more than one episode of vivax malaria in the same or consecutive years."1.72Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. ( Baek, JH; Cho, SH; Choi, H; Choi, S; Kim, M; Kim, MJ; Kim, YC; Kwak, YG; Kwon, JR; Lee, SE; Oh, HS; Park, S; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022)
"Primaquine was effective in preventing P."1.72Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022)
"Primaquine doses were calculated using allometric scaling to derive a weight-based primaquine regimen over a weight range from 5 to 100 kg."1.62Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. ( Buchy, P; Debackere, M; Dondorp, AM; Dysoley, L; Fairhurst, RM; H Nosten, F; Hien, TT; Hoglund, RM; Kheang, ST; Kheng, S; Landier, J; Mayxay, M; Menard, D; Mukaka, M; Muth, S; Neeraj, K; Nguyen, TN; Peerawaranun, P; Peto, TJ; Phommasone, K; Rithea, L; Roca-Feltrer, A; Say, C; Smithuis, F; Song, N; Tarantola, A; Tarning, J; Taylor, WR; Tripura, R; von Seidlein, L; White, NJ, 2021)
"The prevalence of G6PD deficiency was previously reported negligible in Korea."1.62A Profile of Glucose-6-Phosphate Dehydrogenase Variants and Deficiency of Multicultural Families in Korea. ( Ahn, SK; Bahk, YY; Im, JH; Jang, W; Kan, H; Kim, M; Kim, TS; Kwon, J; Lee, J; Park, S; Yeom, JS, 2021)
" Most HCPs were unaware of G6PD deficiency and primaquine-related adverse effects."1.62Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study). ( Arcanjo, AR; Baia-da-Silva, DC; Bancone, G; Barbosa, LRA; Bassat, Q; Batista, TSB; Brito, MAM; Brito-Sousa, JD; Domingo, GJ; Figueiredo, EFG; Lacerda, MVG; Marques, LLG; Melo, GC; Melo, MM; Mendes, MO; Monteiro, WM; Murta, F; Nakagawa, TH; Recht, J; Rodovalho, S; Sampaio, VS; Santos, APC; Santos, TC; Silva, EL; Silva-Neto, AV; Siqueira, AM; Souza, BKA; Vitor-Silva, S, 2021)
"Relapses in vivax malaria have posed great challenges for malaria control, and they also account for a great proportion of reported cases."1.62Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. ( Brito-Sousa, JD; Dinelly, KMO; Lacerda, MVG; Melo, GC; Monteiro, WM; Omena, AG; Peterka, C; Rodovalho, S; Sampaio, VS; Silva, MGO; Siqueira, AM; Vitor-Silva, S, 2021)
" Higher primaquine dosage was safe and effectively prevented relapses in two patients and should be further investigated as an option in Latin America."1.62Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases. ( Brasil, P; da Rosa Santos, OHL; da Silva, ADT; Daniel-Ribeiro, CT; de Deus Henriques, KM; de Pina-Costa, A; Dos Santos, EM; Moreira, J; Pedro, RS; Silvino, ACR; Siqueira, AM; Sousa, TN; Umana, GL, 2021)
" vivax relapses after a correct treatment and, especially, it should be considered in any study of dosage and duration of primaquine treatment."1.56Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. ( Bernal Fernández, MJ; Domingo García, D; Gutierrez Liarte, Á; Lanza Suárez, M; Lombardia González, C; Martin Ramírez, A; Rubio, JM; Soler Maniega, T, 2020)
"We compare recurrence rates observed after primary P."1.56Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020)
"Chloroquine was measured in plasma samples by high-performance liquid chromatography with fluorescence detection."1.56Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients. ( Mello, AGCN; Sena, LWP; Vieira, JLF; Vieira, MVDF, 2020)
"We report a case of splenic infarction with acute kidney injury in a case of P."1.51Multiple Splenic Infarcts Complicating Plasmodium vivax Malaria. ( Kaur, M; Saha, A; Tripathi, N, 2019)
"Quantitative diagnostic tests for G6PD deficiency are complex and require sophisticated laboratories."1.51Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. ( Advani, N; Cohen, J; Domingo, GJ; Kalnoky, M; Kelley, M; Parker, M; Rowley, E; Satyagraha, AW; Sibley, CH, 2019)
"There was no difference in time to recurrence or recurrence frequency between patients treated with 14-day or 7-9 day primaquine regimens (HR = 1."1.51Evaluation of Plasmodium vivax malaria recurrence in Brazil. ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019)
"In the north, other G6PD deficiency variants might be more prevalent."1.51Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030. ( Araki, H; Brey, PT; Hongvanthong, B; Iwagami, M; Jimba, M; Kano, S; Keomalaphet, S; Khattignavong, P; Lorpachan, L; Ong, KIC; Pongvongsa, T; Prasayasith, P; Soundala, P; Xangsayalath, P, 2019)
"vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0."1.51Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. ( Adhikari, B; Banjara, MR; Chotivanich, K; Das Thakur, G; Day, NPJ; Ghimire, P; Hanboonkunupakarn, B; Imwong, M; Pukrittayakamee, S; Rijal, KR; White, NJ, 2019)
"Time to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for first and recurrent infections were identified by Cox regression models."1.51Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. ( A Cleves, M; Aguirre, AR; D'Alessandro, U; Erhart, A; Hens, N; Le, HX; Nguyen, HV; Nguyen, TT; Nguyen, VV; Nguyen, XX; Pham, TV; Rosanas-Urgell, A; Speybroeck, N; Tran, DT, 2019)
"vivax malaria episode until the recurrence did not differ between patients with AS of ≤ 1 versus ≥ 1."1.48CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( Almeida, ACG; Brasil, LW; Kühn, A; Lacerda, MVG; Monteiro, WM; Ramasawmy, R; Rodrigues-Soares, F; Santoro, AB; Suarez-Kurtz, G, 2018)
"Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment."1.48Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. ( Bancone, G; Chu, CS; Jittamala, P; Taylor, WRJ; Watson, J; White, NJ, 2018)
" This systematically increased dosage needs to be evaluated according to epidemiological context."1.48Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison. ( Abboud, P; Blaise, N; Blanchet, D; Demar, M; Djossou, F; Epelboin, L; Melzani, A; Mosnier, E; Nacher, M; Valdes, A; Vesin, G; Walter, G, 2018)
"vivax malaria is rising."1.46An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. ( Al Mukhaini, SK; Al-Abri, S; Ali, OAM; Bienvenu, AL; Bonnot, G; Petersen, E; Picot, S; Simon, B; Sow, F, 2017)
"vivax malaria was higher in children 1 to <5 years of age (49."1.46Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017)
"The developed model to predict recurrence was found to be of good accuracy and could be a useful tool in targeting patients at a higher risk for recurrence for closer monitoring during follow-up, after treatment with primaquine."1.46A clinical tool to predict Plasmodium vivax recurrence in Malaysia. ( Islahudin, F; Kumolosasi, E; Makmor-Bakry, M; Mat Ariffin, N, 2017)
"Takayasu arteritis, also known as "pulseless disease," causes proximal occlusion of the lumen of large arteries of the neck and arm, leading to impalpable pulses and "pseudohypotension."1.46A Curious Case of "Septic Shock". ( Jain, S; Kumari, S; Lakshman, A; Sharma, N; Singh, C; Singhal, M; Varma, S, 2017)
"1."1.43UK malaria treatment guidelines 2016. ( Beeching, NJ; Bell, DJ; Chiodini, PL; Lalloo, DG; Shingadia, D; Whitty, CJM, 2016)
"The prevalence of G6PD deficiency in the Bamar, Karen and in the whole sample set was 6."1.43Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar. ( Bancone, G; Bansil, P; Chowwiwat, N; Domingo, GJ; Htun, MM; Htut, Y; Maw, LZ; Nosten, F; Oo, NN; Thant, KZ, 2016)
"Plasmodium vivax malaria is characterized by periodic relapses of symptomatic blood stage parasite infections likely initiated by activation of dormant liver stage parasites-hypnozoites."1.42Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. ( Adams, JH; Baldwin, M; Camargo, N; Fishbaugher, M; Kangwanrangsan, N; Kappe, SH; Kaushansky, A; Lakshmanan, V; Lindner, SE; Mikolajczak, SA; Prachumsri, J; Rezakhani, N; Roobsoong, W; Sattabongkot, J; Singh, N; Vaughan, AM; Yimamnuaychok, N, 2015)
"The primaquine doses were adjusted for the patients' weight."1.42Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors. ( Couto, ÁA; Couto, VS; Gomes, Mdo S; Júnior, AA; Legrand, E; Machado, RL; Menezes, RA; Musset, L; Nacher, M; Sousa, AP; Stefani, A; Vieira, JL, 2015)
"Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) highlight the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly within the military."1.42Repeated Plasmodium vivax malaria relapses in a Peruvian sailor. ( Cavalcanti, S; Gonzalez, S; Lescano, AG; McFarland, AP; Mercado, A; Sanchez, JF; Ventocilla, JA, 2015)
" We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine."1.40Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014)
"Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance, and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0."1.40Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. ( Batty, KT; Benjamin, J; Betuela, I; Davis, TM; Moore, BR; Mueller, I; Page-Sharp, M; Robinson, LJ; Salman, S; Siba, P; Waita, E, 2014)
"By comparison individuals with G6PD deficiency showed a highly skewed haplotype distribution, with 95% showing the CT haplotype, a finding consistent with relatively recent appearance and positive selection of the Mediterranean variant in Afghanistan."1.40A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan. ( Awab, GR; Day, NP; Dondorp, AM; Imwong, M; Jamornthanyawat, N; Pukrittayakamee, S; Tanomsing, N; White, NJ; Woodrow, CJ; Yamin, F, 2014)
"vivax malaria is a substantial risk."1.40Imported malaria is stable from Africa but declining from Asia. ( David, K; Møller, CH, 2014)
"No G6PD deficiency was observed using phenotypic- or genetic-based tests in individuals residing in vivax malaria endemic regions in the ROK."1.40First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea. ( Cho, SH; Goo, YK; Ji, SY; Kim, JY; Lee, WJ; Moon, JH; Shin, HI, 2014)
"The current available treatment for P."1.40Evaluation of antimalarial activity and toxicity of a new primaquine prodrug. ( Aguiar, AC; Campos, ML; Chin, CM; da Fonseca, LM; Davanço, MG; de Andrade, CR; Dos Santos, JL; Dos Santos, LA; Krettli, AU; Padilha, EC; Peccinini, RG, 2014)
"Primaquine dosing was classified as no dose, low dose (<420 mg), high dose (≥420 mg), or unknown."1.38Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. ( Looke, D; McCarthy, JS; McDougall, D; Townell, N, 2012)
" The overall median time to relapse, obtained by the Kaplan-Meier method, was 108 days, and the survival analysis demonstrated an association between non-weight-adjusted primaquine dosing and the occurrence of relapse (p < 0."1.38Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil. ( Brasil, P; Campos, DP; Costa, AP; Daniel-Ribeiro, CT; Guaraldo, L; Pedro, RS, 2012)
"Prednisolone was then tapered and stopped."1.37Auto-immune haemolytic anaemia concurrent with Plasmodium vivax infection: a case report. ( Anurathapan, U; Chanthavanich, P; Sirachainan, N; Sitcharungsi, R, 2011)
"Patients who were being treated for P."1.37Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region. ( Fontes, CJ; Ishikawa, EA; Pereira, EA, 2011)
"In Plasmodium vivax infection, however, retinal hemorrhage is very rare; only five cases have been reported in the literature."1.36Retinal hemorrhage in Plasmodium vivax malaria. ( Chin, HS; Chung, MH; Lee, JH; Moon, YS, 2010)
"Malarial hepatitis is also unusual in P."1.36[A case of malarial hepatitis by Plasmodium vivax]. ( Park, JM; Sung, YH, 2010)
" All recurring cases were completely cured using the same dosage and regimen used for the first or second treatments."1.35Recurrence rate of vivax malaria in the Republic of Korea. ( Kim, C; Kim, YK; Ko, DH; Moon, KT; Park, I; Shin, DC, 2009)
"Here we describe high rates of P."1.35Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. ( da Silva, NS; da Silva-Nunes, M; Ferreira, MU; Orjuela-Sánchez, P, 2009)
"Splenic infarction is a rare complication in malaria cases, and is caused primarily by Plasmodium falciparum."1.34A case of symptomatic splenic infarction in vivax malaria. ( Chung, MH; Kim, A; Kim, ES; Lee, JS; Park, YK, 2007)
"Pulmonary edema is a recognized complication of Plasmodium falciparum malaria but is uncommon with Plasmodium vivax infection."1.34Pulmonary edema due to Plasmodium vivax malaria in an American missionary. ( Allen, BL; Illamperuma, C, 2007)
"The patient was given chloroquine by his captain in a dosage regimen appropriate for quinine (2 tablets 3 times daily for 7 d)."1.32Toxicity related to chloroquine treatment of resistant vivax malaria. ( Barrett, PH; Davis, TM; Ilett, KF; Syed, DA, 2003)
"Cases of vivax malaria have rapidly increased annually among counties bordering the DMZ, and have spread to approximately 40 km south of the DMZ."1.32Vivax malaria: a continuing health threat to the Republic of Korea. ( Chai, JY; Choe, KW; Kim, TS; Klein, TA; Lee, HC; Moon, SH; Oh, MD; Pacha, LA; Park, JW; Ryu, SH; Yeom, JS, 2003)
"Primaquine is an old drug recently demonstrated to offer effective prophylaxis."1.32Primaquine for prevention of malaria in travelers. ( Baird, JK; Fryauff, DJ; Hoffman, SL, 2003)
"Primaquine was used as a negative control and a dihydroacridine-dione (WR-250547) was used as a positive control."1.32Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. ( Coleman, RE; Eikarat, N; Kittayapong, P; Ponsa, N; Sattabongkot, J, 2003)
" The elimination half-life was 3."1.32Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. ( Chung, WC; Kang, MW; Kim, MY; Kim, SI; Kim, YR; Kim, YS; Kuh, HJ, 2004)
"vivax malaria were compared with 20, apparently healthy controls."1.31Immunological alterations associated with Plasmodium vivax malaria in South Korea. ( Han, K; Kang, CS; Kim, BK; Kim, M; Kim, Y; Lee, EJ; Lee, HK; Lee, J; Lee, S; Lim, J; Oh, EJ; Oh, J, 2001)
" Three of these soldiers had received a higher dosage of primaquine (30 mg base daily for 14 days) after their second attack."1.30Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. ( DeFraites, RF; Kain, KC; Magill, AJ; Smoak, BL; Wellde, BT, 1997)
"The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine."1.30[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997)
"falciparum."1.30Profound thrombocytopenia in Plasmodium vivax malaria. ( Bhoi, S; Kakar, A; Kakar, S; Prakash, V, 1999)
"20 patients hemizygous for mild G6PD deficiency (GdB- variant), 2 patients hemizygous for severe deficiency (Gd-Myanmar variant) completed the trial."1.29The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. ( , 1994)
"To assess the causal prophylactic activity (activity against the pre-erythrocytic liver stage) of a daily regimen of doxycycline combined with low dose primaquine against malaria in Australian Defence Force personnel deployed to Papua New Guinea (PNG)."1.29Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. ( Barnett, A; Edstein, MD; Rieckmann, KH; Shanks, GD, 1995)
"Primaquine may also cause serious toxic side effects, including methaemoglobin formation and haemolytic anaemia, especially in individuals with erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency."1.29[Recurrence problems with preventive primaquine treatment in patients with malaria]. ( Bygbjerg, IC; Rønn, AM, 1993)
"Vivax malaria is the most frequent among imported malaria in Japan, comprising about 60% of the total cases."1.29[A study of relapsed cases of vivax malaria after the standard primaquine therapy]. ( Kimura, M; Ohtomo, H; Takizawa, Y; Tomizawa, I, 1996)
"Primaquine has been found adequate to prevent relapse in more than 90% vivax cases, while efficacy of chloroquine-pyrimethamine and chloroquine alone was almost comparable."1.29Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. ( Bhatt, RM; Sharma, SK; Sharma, VP; Srivastava, HC, 1996)

Research

Studies (470)

TimeframeStudies, this research(%)All Research%
pre-199019 (4.04)18.7374
1990's63 (13.40)18.2507
2000's81 (17.23)29.6817
2010's209 (44.47)24.3611
2020's98 (20.85)2.80

Authors

AuthorsStudies
Taylor, WRJ10
Kim, S3
Kheng, S5
Muth, S4
Tor, P3
Christophel, E3
Mukaka, M5
Kerleguer, A3
Luzzatto, L2
Baird, JK39
Menard, D7
Taylor, WR6
Hoglund, RM2
Peerawaranun, P3
Nguyen, TN2
Hien, TT6
Tarantola, A1
von Seidlein, L11
Tripura, R3
Peto, TJ4
Dondorp, AM8
Landier, J2
H Nosten, F1
Smithuis, F2
Phommasone, K3
Mayxay, M3
Kheang, ST2
Say, C1
Neeraj, K1
Rithea, L1
Dysoley, L7
Roca-Feltrer, A2
Debackere, M1
Fairhurst, RM1
Song, N1
Buchy, P1
White, NJ39
Tarning, J10
Aung, PL3
Soe, MT2
Soe, TN2
Oo, TL2
Aung, PP2
Khin, A1
Thi, A1
Phuanukoonnon, S3
Okanurak, K3
Cui, L9
Kyaw, MP3
Parker, DM6
Poespoprodjo, JR8
Burdam, FH3
Candrawati, F1
Ley, B20
Meagher, N3
Kenangalem, E6
Indrawanti, R1
Trianty, L1
Thriemer, K21
Price, DJ2
Simpson, JA15
Price, RN34
Grobusch, MP2
Schlagenhauf, P2
Bahk, YY2
Ahn, SK2
Lee, J3
Im, JH1
Yeom, JS9
Park, S2
Kwon, J1
Kan, H1
Kim, M3
Jang, W1
Kim, TS2
Kaagaard, MD1
Matos, LO1
Holm, AE1
Gomes, LC1
Wegener, A1
Lima, KO1
Vieira, IVM1
de Souza, RM1
Marinho, CRF2
Hviid, L1
Vestergaard, LS1
Dominguez, H1
Biering-Sørensen, T1
Silvestre, OM1
Brainin, P1
Vanachayangkul, P3
Sea, D3
Wojnarski, M3
Sok, S3
Kodchakorn, C1
Ta-Aksorn, W1
Hom, S2
Ittiverakul, M4
Kuntawunginn, W3
Arsanok, M2
Buathong, N3
Heng, TK1
Nareth, K1
Nou, S3
Chandara, S1
Ly, S2
Oung, P2
Vesely, B1
Bennett, J1
Reichard, G2
Pybus, B2
Lanteri, C2
Saunders, D2
Fukuda, M1
Smith, P2
Rekol, H2
Waters, NC2
Spring, M2
Daher, A11
Pinto, DP1
da Fonseca, LB1
Pereira, HM1
da Silva, DMD1
da Silva, LSFV1
Esteves, AL1
Soares Medeiros, JJ1
Mendonça, JS1
Nain, M2
Mohan, M2
Sharma, A3
Anvikar, AR1
Sahu, P1
Pradhan, MM1
Sharma, S1
Ahmed, N1
Yadav, CP1
Pradhan, S1
Duparc, S10
Grewal Daumerie, P1
Valecha, N4
Khammanee, T1
Sawangjaroen, N1
Buncherd, H1
Tun, AW1
Thanapongpichat, S1
Choi, S2
Choi, H2
Park, SY3
Kwak, YG3
Song, JE3
Shin, SY2
Baek, JH2
Shin, HI4
Oh, HS2
Kim, YC2
Han, JH1
Kim, MJ2
Brito-Sousa, JD6
Peixoto, HM5
Devine, A8
Silva-Neto, AV3
Balieiro, PCS1
Sampaio, VS7
Vitor-Silva, S4
Mendes, MO2
Souza, BKA2
Lacerda, MVG13
Monteiro, WM20
Chamma-Siqueira, NN2
Negreiros, SC1
Ballard, SB1
Farias, S2
Silva, SP1
Chenet, SM3
Santos, EJM1
Pereira de Sena, LW1
Póvoa da Costa, F1
Cardoso-Mello, AGN1
Marchesini, PB1
Peterka, CRL1
Viana, GMR2
Macedo de Oliveira, A2
Greenwood, B1
Drakeley, C2
Llanos-Cuentas, A9
Manrrique, P1
Rosas-Aguirre, A1
Herrera, S2
Hsiang, MS1
Gandrala, D2
Gupta, N2
Lavu, A2
Nallapati, VT2
Guddattu, V3
Saravu, K10
Aung, YN1
Tun, STT1
Vanisaveth, V1
Chindavongsa, K1
Kanya, L1
Phanor, J1
Balieiro, PCDS1
Cordeiro, JSM1
Mendes, M1
Melo, GC6
Lacerda, M2
Monteiro, W2
Watson, JA5
Nekkab, N1
White, M1
Alam, MS6
Satyagraha, AW8
Phru, CS2
Tadesse, D1
Shibiru, T1
Hailu, A6
Kibria, MG3
Hossain, MS3
Rahmat, H2
Khan, WA6
Degaga, TS4
Christian, M2
Tego, TT2
Abate, DT2
Weston, S2
Karahalios, A3
Rajasekhar, M3
Rumaseb, A4
Mnjala, H2
Lee, G2
Anose, RT2
Kidane, FG1
Woyessa, A6
Baird, K3
Sutanto, I12
Sharma, J1
Gautam, CS1
Singh, H1
Singh, J1
Flaherty, S1
Strauch, P2
Maktabi, M2
Pybus, BS2
Walker, LA1
Rochford, R2
Suh, J1
Kim, JH1
Kim, JD1
Kim, C4
Choi, JY2
Nguyen Pouplin, J1
Liu, H3
Zeng, W2
Malla, P1
Wang, C1
Lakshmi, S1
Kim, K1
Menezes, L1
Yang, Z3
Jeon, HJ1
Na, BK1
Lee, SK1
Shin, HJ1
Shenkutie, TT1
Nega, D1
Kepple, D1
Witherspoon, L1
Lo, E2
Negash, MT1
Adamu, A1
Gebremichael, SG1
Gidey, B1
Tasew, G1
Feleke, SM1
Kebede, T1
Kaur, D1
Sinha, S1
Sehgal, R1
Markus, MB2
Adhikari, B4
Callery, JJ1
Heng, C1
Vanda, T1
Simvieng, O1
Cassidy-Seyoum, S1
Cho, SH3
Lee, SE3
Kwon, JR1
Ridley, R1
Ngeth, E1
Ir, P1
Ngor, P1
Sovannaroth, S1
Lek, D4
Phon, S1
Kak, N1
Yeung, S2
Boum, Y3
Moukoko, CEE3
Parikh, S4
Chamchoy, K2
Sudsumrit, S2
Thita, T2
Krudsood, S19
Patrapuvich, R2
Boonyuen, U2
Douglas, NM10
Piera, KA2
Anstey, NM9
Morais, CMG1
Brito, RMM1
Weselucha-Birczyńska, A1
Pereira, VSS1
Pereira-Silva, JW1
Menezes, A1
Pessoa, FAC1
Kucharska, M1
Birczyńska-Zych, M1
Ríos-Velásquez, CM1
de Andrade-Neto, VF1
Djigo, OKM1
Gomez, N1
Ould Ahmedou Salem, MS1
Basco, L1
Ould Mohamed Salem Boukhary, A1
Briolant, S2
Saita, S1
Roobsoong, W3
Khammaneechan, P1
Sukchan, P1
Lawpoolsri, S5
Sattabongkot, J9
Gill, J1
Calit, J2
Araújo, JE2
Deng, B1
Miura, K1
Gaitán, XA2
Araújo, MDS1
Medeiros, JF2
Long, CA1
Simeonov, A1
Eastman, RT1
Bargieri, DY2
Woon, SA1
Moore, BR4
Laman, M3
Tesine, P1
Lorry, L2
Kasian, B2
Yambo, P1
Yadi, G2
Pomat, W1
Batty, KT3
Salman, S3
Robinson, LJ5
Davis, TME3
Manning, L2
Win, KM2
Mekonnen, DA1
Abadura, GS1
Behaksra, SW1
Taffese, HS1
Bayissa, GA1
Bulto, MG1
Tessema, TS1
Tadesse, FG1
Gadisa, E1
Aung, TH1
Suansomjit, C1
Tun, ZM1
Hlaing, TM1
Kaewkungwal, J2
Rahmalia, A2
Landuwulang, CUR1
Ronse, M1
Peeters Grietens, K2
Gryseels, C2
Soebandrio, A1
Ekawati, LL6
Chand, K5
Noviyanti, R6
Subekti, D4
Santy, YW1
Crenna-Darusallam, C3
Instiaty, I1
Budiman, W1
Prasetya, CB1
Lardo, S1
Elyazar, I6
Cedar, E1
Rolfe, K1
Fernando, D4
Berni, A1
Jones, S1
Kleim, JP3
Fletcher, K2
Sharma, H1
Martin, A1
Taylor, M2
Goyal, N1
Green, JA7
Tan, LK1
Tobe, R1
Benjamin, J2
Page-Sharp, M3
Betuela, I6
Mueller, I7
Andrade, AO1
Santos, NAC1
Bastos, AS1
Pontual, JDC1
Silva, AMV1
Martinez, LN1
Lima, AA1
Aguiar, ACC1
G Teles, CB1
Pereira, DB5
Vinetz, JM1
Gazzinelli, RT1
Araújo, MS1
Anjani, QK1
Volpe-Zanutto, F1
Hamid, KA1
Sabri, AHB1
Moreno-Castellano, N1
Donnelly, RF1
Yilma, D3
Groves, ES1
Chu, C1
Commons, RJ6
Bancone, G18
Satyagraha, A2
Assefa, A4
Chau, NH2
Dhorda, M4
Hasanzai, MA2
Naddim, MN2
Pasaribu, AP5
Rahim, AG2
Thanh, NV2
Tuyet-Trinh, NT2
Waithira, N2
Dondorp, A2
Day, NP10
López, AR1
Martins, EB1
de Pina-Costa, A2
Pacheco-Silva, AB1
Ferreira, MT1
Mamani, RF1
Detepo, PJT1
Lupi, O1
Bressan, CS1
Calvet, GA1
Silva, MFB1
de Fátima Ferreira-da-Cruz, M1
de Bruycker-Nogueira, F1
Filippis, AMB1
Daniel-Ribeiro, CT4
Siqueira, A1
Brasil, P3
Ring, Z1
Linn, NYY1
Nguitragool, W2
Mehdipour, P1
Dini, S2
Zaloumis, S1
Abreha, T5
Adam, I2
Awab, GR5
Brasil, LW3
Chu, CS20
do Socorro M Gomes, M1
Gonzalez-Ceron, L4
Hwang, J9
Karunajeewa, H4
Ladeia-Andrade, S3
Leslie, T5
Lidia, K4
Longley, RJ2
Rijal, KR2
Thanh, PV2
Vieira, JLF6
Zuluaga-Idarraga, LM2
Guerin, PJ4
Adissu, W1
Brito, M2
Garbin, E1
Macedo, M1
Mukherjee, SK1
Myburg, J1
Bansil, P4
Pal, S2
Zobrist, S1
Bryan, A1
Das, S3
Domingo, GJ7
Hann, A1
Kublin, J1
Layton, M1
Murphy, SC1
Nosten, F20
Pereira, D3
Talukdar, A2
Gerth-Guyette, E2
Sadhewa, A3
Panggalo, LV2
Kiros, FG1
He, X1
Pan, M1
Zou, C1
Pi, L1
Qin, Y1
Zhao, L1
Qin, P1
Lu, Y1
Huang, Y1
Kostić, M1
Milosavljević, MN1
Stefanović, S1
Ranković, G1
Janković, SM1
Bjorge, S2
Topps, N1
Kosal, K2
Sothea, K2
Souy, P2
Char, CM2
Vanna, C2
Ly, P2
Khieu, V2
Pantaleo, A1
Barber, BE3
Dahal, P3
Grigg, MJ3
Humphreys, GS2
Phyo, AP7
Sibley, CH5
Stepniewska, K3
Thwaites, G3
William, T3
Woodrow, CJ4
Zhong, D1
Raya, B1
Pestana, K1
Koepfli, C1
Lee, MC2
Yewhalaw, D1
Yan, G2
Tripathi, N1
Saha, A1
Kaur, M1
Carrara, VI4
Proux, S6
Charunwatthana, P4
McGready, R4
Taylor, AR2
Puaprasert, K1
Duanguppama, J1
Day, NPJ5
Neafsey, DE1
Buckee, CO1
Imwong, M15
Winasti Satyagraha, A1
von Fricken, ME2
Pfeffer, DA1
Espino, F1
Henriques, G2
Oo, NN2
van Leth, F2
Pongvongsa, T3
Promnarate, C3
Sirithiranont, P2
Cobelens, F2
Newton, PN2
Brummaier, T1
Gilder, ME2
Gornsawun, G2
Pimanpanarak, M1
Chotivanich, K4
Wojnarski, B1
Lon, C3
Sriwichai, S2
Chann, S2
Boonchan, T1
Sok, C1
Kong, N1
Pheap, V1
Thay, K1
Dao, V1
Feldman, M1
Gosi, P2
Uthaimongkol, N1
Huy, R3
Fukuda, MM2
Lwin, KM2
Kajeechiwa, L1
Thwin, MM1
Wiladphaingern, J3
Nosten, S1
Nguon, C1
Davoeung, C1
Hanboonkunupakarn, B6
Jittmala, P1
Cheah, PY4
Pukrittayakamee, S12
Thwaites, GE1
Nosten, FH4
Silvino, ACR3
Kano, FS1
Costa, MA1
Fontes, CJF1
Soares, IS2
de Brito, CFA1
Carvalho, LH2
Sousa, TN3
Howes, RE6
Moore, KA4
Dittrich, S1
Teklehaimanot, A2
Teklehaimanot, H1
Girmay, A1
Spring, MD1
Kheang Heng, T1
Lin, JT1
Manning, JE1
Jongsakul, K1
Pichyangkul, S1
Satharath, P1
Smith, PL1
Saunders, DL2
Mat Salleh, NH1
Rahman, MFA1
Samsusah, S1
De Silva, JR1
Ng, DC1
Ghozali, AH1
Tan, JH1
Lai, MY1
Amir, A1
Liew, JWK1
Lau, YL1
James, R1
Martin Ramírez, A1
Lombardia González, C1
Soler Maniega, T1
Gutierrez Liarte, Á1
Domingo García, D1
Lanza Suárez, M1
Bernal Fernández, MJ1
Rubio, JM1
Park, YS1
Park, Y1
Lee, KS1
Vieira, MVDF3
Matos Lopes, TR1
Mello, AGNC2
de Sena, LWP1
Corder, RM3
de Lima, ACP1
Khoury, DS1
Docken, SS1
Davenport, MP2
Ferreira, MU4
Milligan, R2
Villanueva, G1
Bergman, H1
Graves, PM2
Rodrigo, C3
Rajapakse, S3
Marasinghe, MM1
Karunasena, VM1
Seneratne, AS1
Herath, HDB1
Wickremasinghe, R1
Mendis, KN1
Ranaweera, D1
Almeida, AC2
Elias, ABR1
Marques, MP1
de Melo, GC1
da Costa, AG1
Figueiredo, EFG2
Rodrigues-Soares, F2
de Lacerda, MVG1
Lanchote, VL1
Suarez-Kurtz, G2
Mello, AGCN1
Sena, LWP2
Sugiarto, P3
Nobrega de Sousa, T1
Rangel, GW1
Johansen, IC1
Gil, JP1
Srinivasan, S1
Roy, D1
Chavas, TEJ1
Vlaskin, V1
Ho, DK1
Pottenger, A1
LeGuyader, CLM1
Jackson, C1
Flaherty, SM1
Lin, H1
Zhang, J2
Li, Q1
Huber, HE1
Burke, PA1
Wesche, D2
Stayton, PS1
Popovici, J2
Tebben, K1
Witkowski, B1
Serre, D1
Fernandez-Miñope, C1
Delgado-Ratto, C2
Contreras-Mancilla, J1
Ferrucci, HR1
Gamboa, D3
Van Geertruyden, JP2
Murta, F1
Brito, MAM3
Batista, TSB1
Santos, APC1
Marques, LLG1
Barbosa, LRA1
Melo, MM1
Baia-da-Silva, DC1
Santos, TC2
Silva, EL1
Rodovalho, S2
Nakagawa, TH1
Arcanjo, AR2
Siqueira, AM9
Recht, J3
Bassat, Q8
Battle, KE5
Gething, PW1
Lubell, Y4
Spiegelenberg, JP1
Bastiaens, GJH1
Hassing, RJ1
Dinelly, KMO1
Silva, MGO1
Peterka, C1
Omena, AG1
Tang, ASO1
Soo, XY1
Yeo, ST1
Mansor, NA1
Chew, LP1
Chua, HH1
Wångdahl, A1
Sondén, K1
Wyss, K2
Stenström, C1
Björklund, D1
Hervius Askling, H1
Carlander, C1
Hellgren, U1
Färnert, A1
Soebianto, S3
Mahpud, N1
Harahap, AR2
Dos Santos, EM1
Pedro, RS2
Moreira, J1
Umana, GL1
da Silva, ADT1
da Rosa Santos, OHL1
de Deus Henriques, KM1
Win, HH5
Yotyingaphiram, W2
Thinraow, S2
Soe, NL1
Aung, AA2
Wilaisrisak, P2
Kraft, K1
Hanpithakpong, W3
Blessborn, D3
Ling, C1
Pradines, B1
Basco, LK1
Gunawardena, S1
Daniels, RF1
Yahathugoda, TC1
Weerasooriya, MV1
Durfee, K1
Volkman, SK1
Wirth, DF1
Karunaweera, ND2
Vieira, JL4
Ferreira, MES1
Ferreira, MVD1
Gomes, MM1
Tadesse, Y1
Girma, S1
Melaku, Z2
Assef, A1
Kassa, M2
Chatfield, MD1
Landman, KZ1
Lucchi, NW1
Udhayakumar, V4
Zhou, Z1
Shi, YP1
Kachur, SP2
Jima, D2
Kebede, A1
Solomon, H2
Mekasha, A1
Alemayehu, BH2
Malone, JL2
Dissanayake, G1
Teka, H1
Auburn, S2
Parmiter, M1
Maneerattanasak, S1
Chimma, P1
Tongshoob, J1
Mahakunkijcharoen, Y1
Sukasem, C2
Snounou, G3
Khusmith, S1
Dombrowski, JG1
Souza, RM1
Curry, J1
Hinton, L1
Silva, NRM1
Grignard, L1
Gonçalves, LA1
Gomes, AR1
Epiphanio, S1
Huggett, J1
Clark, TG1
Campino, S1
Gebreyohannes, EA1
Bhagavathula, AS1
Seid, MA1
Tegegn, HG1
Simon, B1
Sow, F1
Al Mukhaini, SK1
Al-Abri, S1
Ali, OAM1
Bonnot, G2
Bienvenu, AL2
Petersen, E1
Picot, S2
Wampfler, R2
Hofmann, NE1
Karl, S1
Kinboro, B1
Silkey, M1
Felger, I1
Jaswal, J1
Poirot, E2
Qi, G2
Kheong, CC2
Shamsudin, UK1
Chen, I2
Gosling, R3
Patriani, D1
Malloy, MJ1
Soenarto, Y1
Kitchakarn, S1
Thol, S1
Hok, C1
Saejeng, A1
Chinanonwait, N1
Thimasarn, K2
Wongsrichanalai, C2
Hassett, MR1
Riegel, BE1
Callaghan, PS1
Roepe, PD1
Sortica, VA1
Lindenau, JD1
Cunha, MG1
O Ohnishi, MD1
R Ventura, AM1
Ribeiro-Dos-Santos, ÂK1
Santos, SE1
Guimarães, LS1
Hutz, MH1
Eperon, G1
Durieux-Paillard, S1
Mauris, A1
Chappuis, F1
Gysin, N1
Mat Ariffin, N1
Islahudin, F1
Kumolosasi, E1
Makmor-Bakry, M1
Alexandre, MAA1
Nascimento, CT1
Alves de Lima E Silva, JC1
Tada, M1
Ruffato, R2
Maia, I2
Dos Santos, TC1
Marchesini, P4
Santelli, AC2
Lalloo, DG4
Santoro, AB1
Almeida, ACG1
Kühn, A1
Ramasawmy, R1
Steinkamp, N1
Hamid, MMA1
Elobied, ME1
Mahgoub, NS1
Boshara, SA1
Elsafi, HMH1
Gumaa, SA1
Hamid, T1
Abdelbagi, H1
Basheir, HM1
Marfurt, J3
Hanpithakphong, W1
Hilda, N1
Singhasivanon, P7
Watson, J5
Jittamala, P4
Porn, P1
Lover, AA1
Sümer, Ş1
Aktuğ Demir, N1
Ural, O1
Çimen, G1
Yalçınkaya, E1
San, T1
Raksapraidee, R3
Sriprawat, K2
Winterberg, M1
Chue, AL1
Valdes, A1
Epelboin, L1
Mosnier, E1
Walter, G1
Vesin, G1
Abboud, P1
Melzani, A1
Blanchet, D1
Blaise, N1
Nacher, M4
Demar, M2
Djossou, F2
Bobogare, A1
Gudo, CS1
Ashley, E2
Jambert, E1
Laihad, F1
van den Boogaard, C1
Ghimire, P2
Hawley, B1
Mudin, RNB1
Sumiwi, ME1
Ahmed, R1
Aktaruzzaman, MM1
Awasthi, KR1
Bardaji, A1
Bell, D1
Boaz, L1
Chandramohan, D1
Cheng, Q2
Chindawongsa, K1
Culpepper, J1
Deray, R1
Desai, M1
Domingo, G1
Duoquan, W1
Floranita, R1
Hugo, C1
Jagoe, G1
Sariwati, E1
Jhora, ST1
Jinwei, W1
Lal, BK1
Landuwulang, C1
Le Perru, E1
Makita, LS1
McCarthy, J1
Mekuria, A1
Mishra, N1
Naket, E1
Nambanya, S1
Nausien, J1
Duc, TN1
Thi, TN1
Pfeffer, D1
Rogerson, S1
Samad, I1
Shanks, D1
Sharma, SN1
Sungkar, A1
Syafruddin, D1
Ter Kuile, F1
Thapa, S1
Theodora, M1
Huy, TT1
Waramin, E1
Waramori, G1
Xa, NX2
Hermawan, L1
Nowak, S1
Jaya, I1
Supargiyono, S1
Grietens, KP2
Alemu, SG2
Añez, A2
Borghini-Fuhrer, I2
D'Alessandro, U6
de Vries, PJ2
Erhart, A6
Gomes, MSM2
Heidari, A2
Kager, PA4
Ketema, T2
Phan, GT2
Rowland, M4
Tran, BQ2
Tran, HT1
Wangchuk, S2
Zuluaga-Idarraga, L3
Chairat, K2
Tellapragada, C1
Kulavalli, S1
Xavier, W1
Umakanth, S1
Brahmarouphu, G1
Srinivas, NK1
Channabasavaiah, JP1
Bava, A1
Saadi, AV1
Satyamoorthy, K1
Bhat, K1
Advani, N1
Rowley, E1
Kalnoky, M2
Cohen, J1
Parker, M1
Kelley, M1
Redditt, V1
Bogoch, I1
Rashid, M1
Warrasak, S1
Euswas, A1
Miller, RS1
Ohrt, C3
Paixão, TPD1
Pinto, ACG1
Grisólia, DPA1
Silva, MT1
Kondrashin, AV1
Boranova, AM1
Morozovz, LF1
Tokmalaev, AK1
Stepanova, EV1
Morozov, EN1
Saipov, FS1
Berman, J4
Brown, T1
Dow, G1
Toovey, S1
Avalos, S2
Mejia, RE2
Banegas, E2
Salinas, C1
Gutierrez, L1
Fajardo, M1
Galo, S1
Pinto, A1
Mejia, A1
Fontecha, G3
Mansanguan, C1
Phumratanaprapin, W3
Louisa, M2
Ekawati, L1
Gayatri, A1
Djoko, D2
Hasto, BD1
Meriyenes, D1
Nelwan, EJ2
Sudoyo, H4
Setiabudy, R3
Mohammed, R1
Batista Pereira, D1
Espino, FEJ1
Mia, RZ1
Chuquiyauri, R2
Val, F3
Casapía, M2
Costa, MRF2
Noedl, H1
Diro, E1
Getie, S1
Wubie, KM1
Abdissa, A1
Zeynudin, A1
Abebe, C1
Tada, MS2
Brand, F1
Beck, HP2
Angus, B2
Kellam, LM1
Rousell, VM2
Jones, SW2
Hardaker, E2
Mohamed, K2
Clover, DD2
Breton, JJ2
Ugwuegbulam, CO1
Koh, GCKW3
Vélez, ID1
Namaik-Larp, C1
Villegas, MF1
Nguyen, CH1
Aruachan, S1
Papwijitsil, R1
Craig, G1
Kendall, L1
Wilches, VM1
Silva, JCAL1
Stevens, A1
Fontes, CJ6
Ter Kuile, FO1
Alecrim, GC1
Menezes, MJ2
de Sousa, TN1
de Carvalho, JF1
Salla, LC1
Nery, OA1
de Melo, GNP1
Rodrigues, PT1
Rodríguez-Morales, AJ1
Yoshii, A1
Sekihara, M1
Furusawa, T1
Hombhanje, F1
Tsukahara, T1
Corpolongo, A1
Pisapia, R1
Oliva, A1
Giancola, ML1
Mencarini, P1
Bevilacqua, N1
Ghirga, P1
Mariano, A1
Vulcano, A1
Paglia, MG1
Nicastri, E1
Ong, KIC1
Iwagami, M1
Araki, H1
Khattignavong, P1
Soundala, P1
Keomalaphet, S1
Prasayasith, P1
Lorpachan, L1
Xangsayalath, P1
Hongvanthong, B1
Brey, PT1
Kano, S4
Jimba, M1
Banjara, MR1
Das Thakur, G1
Setyadi, A1
Arguni, E1
Hasanuddin, A1
Lampah, DA1
Turner, C1
Poe, NP1
Wilairisak, P2
Paw, MK1
Lee, SJ4
Jeeyapant, A1
Chen, N1
Dowd, S1
Gatton, ML1
Auliff, A1
Edstein, MD7
Quinn, JC1
McCarthy, S1
Pham, TV1
Nguyen, HV1
Aguirre, AR1
Nguyen, VV1
A Cleves, M1
Nguyen, XX1
Nguyen, TT1
Tran, DT1
Le, HX1
Hens, N1
Rosanas-Urgell, A4
Speybroeck, N2
Rosenthal, PJ2
Yuentrakul, P1
Assawariyathipat, T1
Dong, LT1
Fahmi, F1
Khu, H1
Mohammad, H1
Pasaribu, S2
Yamin, FY1
Aseffa, A1
Bright, AT1
Alenazi, T1
Shokoples, S1
Paganotti, GM1
Houston, S1
Winzeler, EA1
Yanow, SK1
Zhu, G1
Lu, F1
Cao, J1
Zhou, H1
Liu, Y1
Han, ET1
Gao, Q1
Miahipour, A1
Keshavarz, H1
Raeisi, A1
Rezaeian, M1
Rezaei, S1
Reithinger, R1
Tekleyohannes, SG1
Birhanu, SG1
Demeke, L1
Hoos, D1
Nettey, H2
Green, M1
Poe, A1
Akinyi, S1
Filler, S1
Chokejindachai, W1
Sirivichayakul, C1
Tanomsing, N3
Chavez, I1
Tjitra, E3
Kristensen, KL1
Dragsted, UB1
Bennett, JW1
Yadava, A1
Tosh, D1
Sousa, JC1
McCarthy, WF1
Deye, G1
Melendez, V1
Ockenhouse, CF1
Stefani, A2
Basurko, C2
Lemonnier, D1
Elenga, N1
Brousse, P1
Ville, M1
Carme, B2
Gogtay, N1
Kannan, S1
Thatte, UM1
Olliaro, PL1
Sinclair, D1
Galappaththy, GN2
Tharyan, P2
Kirubakaran, R1
Waita, E1
Siba, P2
Davis, TM4
Yang, HL1
Xu, JW1
Wang, JZ1
Nie, RH1
Li, CF1
Goswami, RP2
Mondal, S1
Sinha, D1
Mandal, S1
Mondal, R1
Dev, A1
Pal, J1
Ghosh, A1
Dewi, M1
Piel, FB1
Messina, JP1
Sakuntabhai, A1
Williams, TN1
Hay, SI2
Lacerda, MV10
Rueangweerayut, R3
Gupta, SK1
Kochar, SK1
Arthur, P1
Chuenchom, N1
Möhrle, JJ1
Ugwuegbulam, C1
Carter, N3
Kellam, L1
Soto-Calle, VE1
Van den Eede, P1
Rosas, A1
Abatih, EN1
Rodriguez Ferrucci, H1
Lopes, SC2
Albrecht, L2
Carvalho, BO1
Thomson-Luque, R1
Nogueira, PA1
Fernandez-Becerra, C1
Del Portillo, HA3
Russell, BM1
Rénia, L1
Costa, FT2
Tanwar, GS1
Lahoti, A1
Tanwar, P1
Agrawal, R1
Khatri, PC1
Kochar, DK1
Kondrashin, A1
Baranova, AM1
Ashley, EA3
Sergiev, VP1
Franca, GP2
Queiroz, AL1
Oliveira, MR1
Romero, GA4
Jamornthanyawat, N1
Yamin, F1
Yepes-Jiménez, N1
López-Córdoba, C1
Blair-Trujillo, S1
Durand, S1
Cabezas, C1
Lescano, AG2
Galvez, M1
Gutierrez, S1
Arrospide, N1
Alvarez, C1
Santolalla, ML1
Bacon, DJ1
Graf, PC1
Weppelmann, TA1
Eaton, WT1
Masse, R1
Beau de Rochars, MV1
Okech, BA1
Møller, CH1
David, K1
Hetzel, MW1
Bala, N1
Pulford, J1
Lavu, EK1
Goo, YK1
Ji, SY1
Moon, JH1
Lee, WJ3
Kim, JY3
Santana, MS1
Costa, MR2
Brito, MA4
Alecrim, MG1
Pothapregada, S1
Kamalakannan, B1
Faucher, JF1
Bellanger, AP1
Shaniya, N1
Hustache-Mathieu, L1
Hoen, B1
Chirouze, C1
Hatipoğlu, M1
Ulçay, A1
Turhan, V1
Karagöz, E1
Erdem, H1
Acar, A1
Oncül, O1
Görenek, L1
Dos-Santos, JC1
Angerami, RN1
Castiñeiras, CM1
Garcia, MT1
Levy, CE1
Moretti, ML1
Kedar, P1
Warang, P1
Sanyal, S1
Devendra, R1
Ghosh, K1
Colah, R1
Davanço, MG1
Aguiar, AC1
Dos Santos, LA1
Padilha, EC1
Campos, ML1
de Andrade, CR1
da Fonseca, LM1
Dos Santos, JL1
Chin, CM1
Krettli, AU1
Peccinini, RG1
Val, FF2
Fuller, D1
Maria Regina F, O1
Marcus Vinícius G, L1
Cassera, MB1
Andrade, RT1
Tauil, PL1
Imerbsin, R1
Khemawoot, P1
Siripokasupkul, R1
Tekwani, BL1
Sampath, A1
Nanayakkara, NP1
Gettyacamin, M1
Teja-Isavadharm, P1
Walker, L1
Redig, AJ1
Vaidya, A1
Price, C1
Katz, JT1
Maguire, JH1
Thana, P1
Panapipat, S1
Ingram, RJ1
Yuan, L1
Wang, Y1
Gupta, B1
Fan, Q1
Cao, Y1
Xiao, Y1
Zhou, G1
Chowwiwat, N3
Somsakchaicharoen, R1
McGray, S1
Baramuli, V1
Elvira, R1
Ridenour, C1
Coutrier, FN1
Adekunle, AI1
Pinkevych, M1
Luxemburger, C1
White, LJ1
Cromer, D1
Mikolajczak, SA1
Vaughan, AM1
Kangwanrangsan, N1
Fishbaugher, M1
Yimamnuaychok, N1
Rezakhani, N1
Lakshmanan, V1
Singh, N3
Kaushansky, A1
Camargo, N1
Baldwin, M1
Lindner, SE1
Adams, JH1
Prachumsri, J1
Kappe, SH1
de Lacerda, MV2
de Oliveira, MR2
Fernando, SD2
Meltzer, E1
Morrison, L1
Stienlauf, S1
Schwartz, E3
Rishikesh, K2
Kamath, A2
Hande, MH1
Vidyasagar, S1
Acharya, RV1
Acharya, V2
Belle, J1
Shastry, AB1
Cheoymang, A1
Ruenweerayut, R1
Muhamad, P2
Rungsihirunrat, K2
Na-Bangchang, K3
Tops, N1
Ringwald, P4
Hong, NV1
Van, NV1
Hung, le X1
Duong, TT1
Luter, N1
Espino, FE1
Conan, N1
Dion-Berboso, AG1
Kumar, R3
Gomes, Mdo S1
Machado, RL2
Musset, L1
Legrand, E1
Menezes, RA1
Júnior, AA1
Sousa, AP1
Couto, VS1
Couto, ÁA1
Koh, G1
Osorio, L1
Rubio, JP2
Rodriguez, MH3
Sandoval, MA1
Santillan, F1
Galindo-Virgen, S1
Betanzos, AF1
Rosales, AF1
Palomeque, OL1
McFarland, AP1
Sanchez, JF1
Mercado, A1
Ventocilla, JA1
Cavalcanti, S1
Gonzalez, S1
Tjahjono, B2
Ekasari, T1
Basri, H6
Moura-Neto, JP1
Tamayo Perez, ME1
Aguirre-Acevedo, DC1
Shingadia, D2
Bell, DJ1
Beeching, NJ2
Whitty, CJM1
Chiodini, PL1
St Jean, PL1
Xue, Z1
Koh, GC1
Beaumont, C1
Maw, LZ1
Htun, MM1
Thant, KZ1
Htut, Y1
Thomas, D1
Tazerouni, H1
Sundararaj, KG1
Cooper, JC1
Blair, S2
Akinyi Okoth, S1
Marcet, PL1
Escalante, AA1
Alexander, N1
Rojas, C1
Almeida, ED1
Ashok, H1
Kundapura, P1
Kamath, V1
Mukhopadhyay, C1
Mesquita, TC1
Martin, TG1
Alves, ER1
Mello, MB1
Nery, AF1
Gomes, LT1
Silvino, AC1
Costa, GL1
Araújo, FC1
Ascher, DB1
Pires, DE1
Brito, CF1
Subramony, H1
Tangpukdee, N5
Poovorawan, K1
Muangnoicharoen, S3
Wilairatana, P12
Negreiros, S1
Viana, GM1
Okoth, SA1
de Souza, TM1
Povoa, MM2
de Oliveira, AM1
Sripoorote, P1
Chobson, P1
Saeseu, T1
Zanini, G1
Fonseca, L1
Pitta, L1
Siv, S1
Vinjamuri, SB1
Bouth, DM1
Rashid, MA1
By, NP1
Lakshman, A1
Singh, C1
Singhal, M1
Jain, S1
Sharma, N1
Kumari, S1
Varma, S1
Azad, CS1
Saxena, M1
Siddiqui, AJ1
Bhardwaj, J1
Puri, SK1
Dutta, GP1
Anand, N1
Saxena, AK1
Thitipanawan, N1
Po, C1
Keereecharoen, L1
Elmes, NJ2
Nasveld, PE2
Kitchener, SJ2
Kocisko, DA1
Mayan, I1
Mohammed, N1
Erasmus, P1
Kolaczinski, J2
Whitty, CJ1
Oliveira-Ferreira, J1
Moon, KT1
Kim, YK3
Ko, DH2
Park, I3
Shin, DC1
Carmona-Fonseca, J5
Alvarez, G3
Maestre, A3
Betanzos-Reyes, AF1
Hernández-Avila, JE1
Méndez-Galván, JF1
Danis-Lozano, R1
Altamirano-Jiménez, A1
Barreto Miranda, I1
Löscher, T3
Daneshvar, C1
Cox-Singh, J1
Rafa'ee, MZ1
Zakaria, SK1
Divis, PC1
Singh, B1
Lee, SW1
Lee, M1
Lee, DD1
Kim, YJ1
Green, MD1
Klein, TA3
Kim, HC2
Kim, H1
Yeshiwondim, AK1
Tekle, AH1
Dengela, DO1
Yohannes, AM1
Hanf, M1
Stéphani, A1
Orjuela-Sánchez, P1
da Silva, NS1
da Silva-Nunes, M1
Lee, JH2
Chin, HS1
Chung, MH3
Moon, YS1
Soto, V1
Ribera, JM1
Toomer, E1
Tenorio, A1
Montalvo, TG1
Rodriguez, H1
Cuentas, AL1
Kyaw, MK1
Phe, O1
Win, T1
Oo, AP1
Naing, AL1
Nyo, MY1
Myint, NZ1
Alexandre, MA1
Ferreira, CO1
Magalhães, BL1
Mourão, MP1
Alecrim, Md2
Santa-Olalla Peralta, P1
Vazquez-Torres, MC1
Latorre-Fandos, E1
Mairal-Claver, P1
Cortina-Solano, P1
Puy-Azón, A1
Adiego Sancho, B1
Leitmeyer, K1
Lucientes-Curdi, J1
Sierra-Moros, MJ1
Takeuchi, R1
Kobayashi, J1
Puangsa-art, S2
Thanyavanich, N2
Maneeboonyang, W2
Sung, YH1
Park, JM1
Chattopadhyay, R1
Velmurugan, S1
Chakiath, C1
Andrews Donkor, L1
Milhous, W1
Barnwell, JW1
Collins, WE5
Hoffman, SL5
Burgoine, KL1
Sitcharungsi, R1
Anurathapan, U1
Sirachainan, N1
Chanthavanich, P1
Solarte, Y1
Jordán-Villegas, A1
Echavarría, JF1
Rocha, L1
Palacios, R1
Ramírez, O1
Vélez, JD1
Epstein, JE1
Richie, TL6
Arévalo-Herrera, M1
Yimsamran, S1
Wuthisen, P1
Prommongkol, S1
Chaimongkul, W1
Rukmanee, P1
Rukmanee, N1
Chavez, IF1
Buchachart, K3
Ruengweerayut, R1
Chacharoenkul, W1
Kim, HY1
Kim, JM1
Ebringer, A1
Heathcote, G1
Baker, J1
Waller, M1
Shanks, GD2
Sonkar, SK1
Uniyal, R1
Sonkar, GK1
Steinhardt, LC1
Magill, AJ3
Arguin, PM2
Pereira, EA1
Ishikawa, EA1
Jovel, IT1
Piedade, R1
Alger, J1
Ferreira, PE1
Veiga, MI1
Enamorado, IG1
Bjorkman, A1
Ursing, J1
Kiniboro, B2
Stanisic, D1
Siba, PM1
Alonso, PL2
Congpuon, K1
Satimai, W2
Sujariyakul, A1
Intanakom, S1
Harnpitakpong, W1
Pranuth, Y1
Cholpol, S1
Bualombai, P1
Zaki, SA1
Shanbag, P1
Chiang, TY1
Lin, WC1
Kuo, MC1
Ji, DD1
Fang, CT1
Kumar, K1
Jun, G1
Shin, EH1
Chang, KS1
Bang, JH1
Oh, S2
Kang, JY1
Park, JW3
Deye, GA1
Gettayacamin, M1
Hansukjariya, P1
Im-erbsin, R1
Rothstein, Y1
Macareo, L1
Fracisco, S1
Bennett, K1
Townell, N1
Looke, D1
McDougall, D1
McCarthy, JS1
Kim, JR2
Nandy, A2
Maji, AK2
Addy, M1
Guaraldo, L1
Campos, DP1
Costa, AP1
John, GK1
Stanisic, DI1
Samol, L1
de Lazzari, E1
Kusriastuti, R1
Surya, A1
Sun, XD1
Wang, J1
Wei, C1
Eibach, D1
Ceron, N1
Krishnalall, K1
Carter, K1
Andriopoulos, P1
Economopoulou, A1
Spanakos, G1
Assimakopoulos, G1
Kiang, KM1
Bryant, PA1
Ladhani, S1
Steer, AC1
Burgner, D1
Baird, KJ1
Maguire, JD1
Putri, FA1
Meilia, RA1
Nurleila, S1
Farrar, J1
Ganguly, S1
Saha, P1
Guha, SK1
Bera, DK1
Biswas, A1
Kundu, PK1
Saha, B1
Ray, K1
Roy, M1
Bouma, MJ1
Ionides, EL1
Dhiman, RC1
Pascual, M1
Hung, le Q1
Vries, PJ1
Giao, PT1
Nam, NV1
Binh, TQ1
Chong, MT1
Quoc, NT1
Thanh, TN1
Hung, LN1
Yadav, RS2
Ghosh, SK1
Ishikawa, H1
Ishii, A1
Nagai, N1
Ohmae, H1
Harada, M1
Suguri, S1
Leafasia, J1
Durante Mangoni, E1
Severini, C1
Menegon, M1
Romi, R1
Ruggiero, G1
Majori, G1
Rieckmann, KH5
Syed, DA1
Ilett, KF1
Barrett, PH1
Mehrunnisa, A1
Saifi, MA1
Khan, HM1
Wickremasinghe, AR2
Fernandopulle, BM1
Weeraratne, CL1
Weerasuriya, K1
Peters, W1
Stewart, LB1
Robinson, BL1
Silachamroon, U3
Treeprasertsuk, S4
Chalearmrult, K1
Mint, HY1
Maneekan, P1
Gourdeuk, VR1
Brittenham, GM3
Looareesuwan, S11
Valibayov, A1
Abdullayev, F1
Mammadov, S1
Gasimov, E1
Sabatinelli, G1
Kondrachine, AV1
COOPER, WC1
MYATT, AV1
HERNANDEZ, T1
JEFFERY, GM4
COATNEY, GR5
ALVING, AS12
HANKEY, DD3
JONES, R5
COKER, WG3
GARRISON, PL3
DONOVAN, WN3
JACKSON, LS1
DI LORENZO, A3
MARX, RL3
LEVY, BL1
KENNY, EC1
GILBERT, M1
JOHNSTON, MN1
ROBINSON, DH2
SIMMONS, IH1
HANSEN, JE1
CLEVE, EA1
PRUITT, FW1
ARNOLD, J5
HOCKWALD, RS2
CLAYMAN, CB3
DERN, RJ2
BEUTLER, E2
FLANAGAN, CL1
Lee, HC1
Pacha, LA1
Ryu, SH2
Moon, SH1
Chai, JY1
Oh, MD1
Choe, KW1
JOHNSON, CF1
TARLOV, AR1
BREWER, GJ2
KELLERMEYER, RW1
CARSON, PE1
COURTNEY, KO1
HODGKINSON, R1
RAMSEY, R1
HAGGERTY, M1
VIVONA, S1
CONRAD, M1
GETZ, ME1
MILLER, MJ1
MARCUS, DM1
CAMERON, DG1
de Figuereido Filho, AF1
Calvosa, VS1
Figueredo, MC1
Nascimento, JM1
Fryauff, DJ6
Ponsa, N1
Kittayapong, P1
Eikarat, N1
Coleman, RE1
EDGCOMB, JH1
YOUNT, EH1
EICHELBERGER, L1
EYLES, D1
YOUNG, MD1
JANNEY, HM1
JASTREMSKI, B1
Rab, MA1
Ahmadzai, H1
Durrani, N1
Fayaz, M1
Kim, YR1
Kuh, HJ1
Kim, MY1
Kim, YS1
Chung, WC1
Kim, SI1
Kang, MW1
Walsh, DS3
Tang, DB1
Heppner, DG2
Brewer, TG1
Siriyanonda, D1
Vijaykadga, S1
Rojanawatsirivej, C1
Congpoung, K1
Uaekowitchai, C1
Pumborplub, B1
Sittimongkol, S1
Pinyorattanachote, A1
Prigchoo, P1
Hamedi, Y1
Safa, O1
Zare, S1
Tan-ariya, P1
Kojima, S1
Spudick, JM1
Garcia, LS1
Graham, DM1
Haake, DA1
Mishra, AK1
Shukla, MM1
Chand, SK1
Bharti, PK1
Berger, SA1
David, L1
Dierling, AM1
Cui, Z1
Choi, DH1
Song, KJ1
Oh, YH1
Kim, YA1
Ahn, SY1
Yang, HY1
Cha, JE1
Dunne, MW1
Shukla, M1
Bhattacharyya, PC1
Patel, K1
Mohapatra, MK1
Lakhani, J1
Devi, CU1
Adak, T2
Dev, V1
Lele, C1
Patki, K1
Muñoz, J1
Velasco, M1
Alonso, D1
Valls, ME2
Corachán, M2
Gascón, J2
Ozen, M1
Gungor, S1
Atambay, M1
Daldal, N1
Bennett, SM1
Abdalla, H1
Carthew, TL1
Rebholz, CE1
Michel, AJ1
Maselli, DA1
Saipphudin, K1
Ajdukiewicz, KM1
Ong, EL1
Chalermrut, K4
Srivilairit, S3
Thanachartwet, V2
Luplertlop, N2
Piñeros, JG1
Tobón, A1
Ríos, A1
Omari, AA1
Reddy, P1
Flaherty, JP1
Goller, JL1
Jolley, D1
Biggs, BA1
Guthmann, JP1
Carlton, J1
Nair, S1
Sudimack, D1
Anderson, TJ1
Dao, NV1
Cuong, BT1
Ngoa, ND1
Thuy, le TT1
The, ND1
Duy, DN1
Dai, B1
Thanh, NX1
Chavchich, M1
Kim, A1
Park, YK1
Lee, JS1
Kim, ES1
Bannister, BA1
Illamperuma, C1
Allen, BL1
Lesko, CR1
Newman, RD1
de Santana Filho, FS1
Chehuan, YM1
Martinez-Espinosa, FE1
Barbosa, Md1
Alecrim, WD1
Kim, JS1
Oh, JS1
Chang, EA1
Bae, SY1
Nam, DH1
Lee, CH1
Yang, JH1
Lee, CK1
Lim, CS1
Dubberke, ER1
Weil, GJ1
Phophak, N2
Sumawinata, I1
Ohrt, CK1
Mouzin, E1
Church, CJ1
Richards, AL1
Bangs, MJ2
Subianto, B4
Wiady, I2
Leksana, B2
Masbar, S2
Petralanda, I1
Barnett, A1
Jelinek, T1
Nothdurft, HD2
Von Sonnenburg, F1
McElroy, PD1
Wignall, FS2
Van den Abbeele, K1
Van den Enden, E1
Van den Ende, J1
Lazar, AI1
Cabezos, J1
Durán, E1
Tomás, D1
Bada, JL1
Rønn, A1
Bygbjerg, I1
Vanijanonta, S1
Chantra, A1
Clemens, R2
Gomez Arce, JE1
Menendez, C1
Viravan, C1
Charoenlarp, P1
Yeamput, C1
Wilson, RJ1
Rønn, AM1
Bygbjerg, IC1
Mathews, ST3
Selvam, R4
Obana, M1
Ohta, S1
Matsuoka, Y1
Irimajiri, S1
Suzuki, M1
Weinke, T1
Kretschmer, H1
Fleischer, K1
Braendli, B1
Markwalder, K1
Schlunk, T1
Bock, HL1
Yeo, AE1
Davis, DR1
Hutton, DC1
Wheatley, PF1
Simpson, R1
Hanna, J1
Dua, VK2
Kar, PK1
Sarin, R1
Sharma, VP4
Tilluckdharry, CC1
Chadee, DD1
Doon, R1
Nehall, J1
Phillips, EJ1
Keystone, JS1
Kain, KC3
Kron, MA1
Signorini, L1
Matteelli, A1
Castelnuovo, F1
Castelli, F1
Oladeji, O1
Carosi, G1
Kimura, M1
Tomizawa, I1
Takizawa, Y1
Ohtomo, H1
Patwari, AK1
Awalludin, M1
Jones, T1
Smoak, BL1
DeFraites, RF1
Wellde, BT1
Harjosuwarno, S1
Srivastava, HC1
Sharma, SK1
Bhatt, RM1
Nayar, JK1
Baker, RH1
Knight, JW1
Sullivan, JS2
Morris, CL3
Richardson, BB3
Galland, GG2
van der Hoek, W1
Premasiri, DA1
Whitby, M1
Zijlmans, CW1
Boele van Hensbroek, M1
Wetsteyn, JC1
Telgt, DS1
Mulder, L1
Dolmans, WM1
Rattanapong, Y2
Amradee, S1
Siripiphat, S1
Chullawichit, S1
Thimasan, K1
Triampon, A1
Sidi, Y1
Yi, KJ1
Kim, HS1
Kim, CS1
Pai, SH1
Nguyen-Dinh, P1
Nesby, S1
Menéndez Capote, R1
Díaz Pérez, L1
Luzardo Suárez, C1
Soto, J3
Toledo, J3
Rodriquez, M2
Sanchez, J2
Herrera, R2
Padilla, J2
Qingjun, L1
Jihui, D1
Laiyi, T1
Xiangjun, Z1
Jun, L1
Hay, A1
Shires, S1
Navaratnam, V1
Lobel, HO1
Coyne, PE1
Ocampo, A1
García-Bujalance, S1
Ladrón de Guevara, C1
Gasser, RA1
Kester, KE1
Na, DJ1
Han, JD1
Cha, DY1
Song, IK1
Choi, HW1
Chung, EA1
Park, CW1
Choi, JS1
da Cunha, MG1
Silva, MN1
Souza, JM1
Rodrigues, MM1
Botella de Maglia, J1
Espacio Casanovas, A1
Bussaratid, V2
Chokjindachai, W1
Viriyavejakul, P1
Walsh D, S1
White, J1
Kakar, A1
Bhoi, S1
Prakash, V1
Kakar, S1
Srivilirit, S1
Gogtay, NJ3
Desai, S1
Kamtekar, KD1
Kadam, VS1
Dalvi, SS2
Kshirsagar, NA2
Hernandez, JE1
Nettel, JA1
Villarreal, C1
Wirtz, RA1
Rajgor, D1
Wakde, M1
Regev-Yochay, G1
Kurnik, D1
Villalobos-Salcedo, JM1
Kimura, E1
Pereira da Silva, LH1
Vaidya, AD1
Joshi, J1
Vaidya, RA1
Godse, C1
Bhatt, R1
Bhagwat, AN1
Lee, HK1
Lim, J1
Lee, S1
Oh, EJ1
Oh, J1
Kim, Y1
Han, K1
Lee, EJ1
Kang, CS1
Kim, BK1
Kumar, A1
Kshrisagar, NA1
Kroeger, A1
Nicolas, X1
Granier, H1
Martin, J1
Klotz, F1
Gutierrez, P1
Luzz, M1
Llinas, N1
Cedeño, N1
Dunne, M1
Eamsila, C1
Sasiprapha, T1
Kitchener, S1
Duarte, EC1
Pang, LW1
Ribeiro, LC1
Khatri, TD1
Supeeranuntha, L1
Brittenham, G1
Seidl, I1
Congpuong, K1
Tasanor, U1
Wernsdorfer, WH1
Luzzi, GA1
Warrell, DA1
Barnes, AJ1
Dunbar, EM1
Collignon, PJ1
Skinner, JC1
Millet, P1
Broderson, JR1
Filipski, VK1
Wilkins, PP1
Campbell, GH1
Stanfill, PS1
Kumaresan, PR1

Clinical Trials (39)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)[NCT02787070]Phase 4420 participants (Actual)Interventional2016-09-14Completed
The Malaria Heart Disease Study: A Novel Pathway to Subclinical Heart Disease[NCT04445103]597 participants (Actual)Observational2020-06-21Terminated (stopped due to Due to the COVID-19 pandemic it was not possible to complete the study inclusion as originally anticipated.)
Efficacy of Three Regimens of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil[NCT03610399]257 participants (Actual)Interventional2018-04-09Completed
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial[NCT03916003]Phase 4500 participants (Actual)Interventional2019-08-18Completed
Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094]Phase 4388 participants (Anticipated)Interventional2023-06-26Recruiting
A Randomised, Single-blinded Controlled Treatment Trial of Subclinical Vivax Infections With Primaquine in Nong Province, Laos[NCT02802813]Phase 1/Phase 241 participants (Actual)Interventional2016-06-14Completed
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax[NCT01640574]Phase 3680 participants (Actual)Interventional2012-02-29Completed
Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection[NCT01680406]Phase 4398 participants (Actual)Interventional2012-10-31Completed
Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province[NCT02143934]Phase 4524 participants (Actual)Interventional2009-08-31Completed
Health Care Provider Use of Plasmodium Vivax Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru[NCT05361486]40 participants (Anticipated)Observational2023-08-28Recruiting
Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand[NCT05052502]49,118 participants (Anticipated)Interventional2020-11-01Recruiting
Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic[NCT04416945]31,443 participants (Anticipated)Interventional2020-09-20Recruiting
A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan[NCT02592408]Phase 4320 participants (Actual)Interventional2015-11-30Completed
A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax[NCT01780753]Phase 120 participants (Actual)Interventional2012-12-31Completed
A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults[NCT05071079]16 participants (Anticipated)Interventional2022-05-23Recruiting
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border[NCT01074905]Phase 3655 participants (Actual)Interventional2010-05-31Completed
Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744]Phase 4200 participants (Anticipated)Interventional2022-05-10Not yet recruiting
A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults[NCT01290601]Phase 270 participants (Actual)Interventional2003-09-15Terminated (stopped due to Failure to meet pre-specified endpoint for the day 28 cure rate)
A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.[NCT01376167]Phase 2851 participants (Actual)Interventional2014-04-24Completed
FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru[NCT05690841]Phase 37,700 participants (Anticipated)Interventional2024-02-01Not yet recruiting
A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria[NCT02216123]Phase 3251 participants (Actual)Interventional2015-04-30Completed
Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910]Phase 2/Phase 3204 participants (Actual)Interventional2014-08-31Completed
Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens[NCT01814683]2,388 participants (Actual)Interventional2014-07-31Completed
Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection[NCT01052584]354 participants (Actual)Interventional2009-10-31Completed
Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup[NCT01288820]Phase 3331 participants (Actual)Interventional2011-01-31Completed
Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naï[NCT01157897]Phase 1/Phase 241 participants (Actual)Interventional2010-07-31Completed
Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects[NCT01218932]Phase 116 participants (Actual)Interventional2010-10-31Completed
Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779]Phase 136 participants (Actual)Interventional2017-05-01Completed
Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects[NCT01552330]Phase 117 participants (Actual)Interventional2012-05-31Completed
Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico[NCT02394197]Phase 4153 participants (Actual)Interventional2008-02-29Completed
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia[NCT05829187]Phase 236 participants (Actual)Interventional2022-11-01Completed
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua[NCT06036030]Phase 250 participants (Actual)Interventional2019-01-11Completed
A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.[NCT00158587]Phase 3150 participants (Actual)Interventional2004-04-30Completed
Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria[NCT00902811]Phase 4600 participants (Anticipated)Interventional2008-12-31Recruiting
Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598]Phase 3468 participants (Actual)Interventional2011-12-31Completed
Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.[NCT01585077]Phase 1/Phase 216 participants (Actual)Interventional2012-10-31Completed
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax[NCT02083068]Phase 232 participants (Actual)Interventional2014-08-31Completed
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT01083095]Early Phase 118 participants (Actual)Interventional2005-01-31Completed
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380]Phase 218 participants (Actual)Interventional2006-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled

Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 168 days

Interventionparticipants (Number)
Primaquine Regular Dose Unsupervised29
Primaquine Regular Dose Supervised44
Primaquine Double Dose Unsupervised67

Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled

Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 28 days

Interventionparticipants (Number)
Primaquine Regular Dose Unsupervised61
Primaquine Regular Dose Supervised88
Primaquine Double Dose Unsupervised90

Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168

Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites. (NCT03610399)
Timeframe: 168 days

InterventionParticipants (Number)
Primaquine Regular Dose Unsupervised29
Primaquine Regular Dose Supervised44
Primaquine Double Dose Unsupervised67

Fever Clearance Time (FCT)

Measure of body temperature every 12 hours through day 7 was used to determine the time (to nearest 12 hours) from initiation of treatment until subjects temperature decreased to 37.2C and remained at or below that level for a minimum of 24 hours. (NCT01290601)
Timeframe: through day 7

InterventionHours (Mean)
Cohort 1 Tafenoquine41.5
Cohort 1-Chloroquine24.7

Adequate Clinical Response (ACR) of Tafenoquine: 28 Day Cure Rate

A subject will be considered a success (cure) if they have an Adequate Clinical Response (ACR). Tafenoquine was efficacious if the lower bound of the two-sided 90% confidence interval for the day 28 cure rate was not less than 85% (NCT01290601)
Timeframe: 28 Days

,
InterventionParticipants (Count of Participants)
Adequate Clinical Response (ACR)Early Treatment FailureLate Treatment Failure
Cohort 1 Tafenoquine4051
Cohort 1-Chloroquine2202

Number of Subjects Without Relapse of P. Vivax

"Number of subjects without relapse of P. vivax at 2, 3 and 4 months~- Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia" (NCT01290601)
Timeframe: Day 28, Months 2, 3 and 4

,
Interventionparticipants (Number)
Cleared at Day 28Relapsed by Day 60Relapsed by Day 90Relapsed by Day 120Without Relapse by Day 120Unevaluable by Day 120
Cohort 1 Tafenoquine40000355
Cohort 1-Chloroquine22011192

Parasite and Gametocyte Clearance Time (PCT and GCT)

Serial blood smears to detect the presence of P. vivax parasites and gametocytes, conducted every 12 hours up to and including day 7, until blood smear became negative were utilized to determine the time to clearance. PCT and GCT were considered cleared if 2 consecutive blood smears were negative. (NCT01290601)
Timeframe: up to day 7 after baseline smear

,
InterventionHours (Mean)
Parasite Clearance TimeGametocyte Clearance Time
Cohort 1 Tafenoquine83.448.3
Cohort 1-Chloroquine40.022.7

Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs)

To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE's overall, occurring in >10% of subjects in either treatment group (NCT01290601)
Timeframe: 90 Days

,
InterventionAEs (Number)
Blood methemoglobin presentHeadacheKeratopathyUpper respiratory tract infectionDizzinessRetinopathyEosinophiliaAbdominal painNauseaThrombocytopeniaEosinophil count increasedPyrexia
Cohort 1 Tafenoquine46141413129866655
Cohort 1-Chloroquine2240531753033

Number of Participants Who Received Blood Transfusion

The number of participants who received blood transfusion as a result of hemoglobin decline has been summarized. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
CQ Only0
TQ + CQ0
PQ + CQ0

Number of Participants With Acute Renal Failure

There were no participants with acute renal failure in the study. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
CQ Only0
TQ + CQ0
PQ + CQ0

Number of Participants With Recurrence-free Efficacy at 4 Months Post Dose

A participant (par) was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Par had non-zero P vivax asexual parasite count at Baseline. b) Par showed initial clearance of P vivax parasitemia. c) Par had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Par did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Par is parasite-free at 4 months defined as a negative asexual P vivax parasite count at the first parasite assessment performed after Study Day 109 (up to and including Study Day 130). Par were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites or did not have a 4 month assessment. The number of par with recurrence-free efficacy at 4 months has been summarized. (NCT01376167)
Timeframe: 4 months post dose

InterventionParticipants (Number)
CQ Only47
TQ + CQ177
PQ + CQ90

Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose

A participant was considered to have demonstrated recurrence-free efficacy at 6 months if: a) Participant had non-zero P vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P vivax parasitemia defined as two negative asexual P vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. Participants were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites, or did not have a 6 month assessment. The number of participants with recurrence-free efficacy at 6 months has been summarized. (NCT01376167)
Timeframe: 6 months post dose

InterventionParticipants (Number)
CQ Only35
TQ + CQ155
PQ + CQ83

Oral Clearance (CL/F) of TQ

Apparent population oral clearance of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60

InterventionLiters per hour (Median)
Participants in TQ Only Arms2.96

Time to Fever Clearance

Fever clearance time was defined as time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.40 degree Celsius is reduced to a value less than or equal to 37.40 degree Celsius and in the absence of value more than 37.40 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed using Kaplan Meier Methodology. The median fever clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180

InterventionHours (Median)
CQ Only7
TQ + CQ7
PQ + CQ8

Time to Parasite Clearance

Parasite clearance time was defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours. The time taken to achieve parasite clearance was analyzed using Kaplan Meier Methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180

InterventionHours (Median)
CQ Only43
TQ + CQ45
PQ + CQ42

Time to Recurrence of P Vivax Malaria

Recurrence was defined as the first confirmed presence of P vivax asexual stage parasites after clearance of initial parasitemia following CQ treatment. Time to recurrence was defined as the time (in days) from initial parasite clearance to recurrence. The time to recurrence was analyzed by the Kaplan-Meier method. NA indicates data was not available due to insufficient number of participants with events during the follow up period in the study. The median number of days to recurrence along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180

InterventionDays (Median)
CQ Only86
TQ + CQNA
PQ + CQNA

Volume of Distribution (Vc/F) of TQ

Apparent population central volume of distribution of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60

InterventionLiters (Median)
Participants in TQ Only Arms915

Change From Baseline in Percent Methemoglobin

Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine (Masimo). The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The last assessment performed prior to the first dose of study medication (CQ or randomized treatment) was considered as Baseline. Change from Baseline was calculated as the post baseline assessment minus the Baseline assessment for percent methemoglobin. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 120

,,
InterventionPercent Methemoglobin (Mean)
Day 2, MaleDay 2, FemaleDay 3, MaleDay 3, FemaleDay 5, MaleDay 5, FemaleDay 8, MaleDay 8, FemaleDay 11, MaleDay 11, FemaleDay 15, MaleDay 15, FemaleDay 22, MaleDay 22, FemaleDay 29, MaleDay 29, FemaleDay 60, MaleDay 60, FemaleDay 120, MaleDay 120, Female
CQ Only-0.18-0.22-0.15-0.20-0.28-0.20-0.12-0.16-0.07-0.130.12-0.080.07-0.05-0.10-0.180.440.190.200.10
PQ + CQ-0.10-0.01-0.020.111.280.903.012.583.613.413.513.631.961.860.580.490.200.160.370.37
TQ + CQ-0.030.10-0.010.260.421.370.982.041.172.130.941.670.540.930.230.24-0.100.030.07-0.03

Cost Associated With Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionUS Dollars (USD) (Mean)
Brazil (Drug shop for care)Brazil (Enrollment clinic for care)Brazil (other location for care)Peru (Drug shop for care)Peru (Enrollment clinic for care)Peru (Attended another clinic)Peru (Other location for care)Thailand (Drug shop for care)Thailand (Enrollment clinic for care)Thailand (In-hospital care)
First Malaria Recurrence4.766.174.231.478.782.710.724.6019.156.13

Cost Associated With Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionUS Dollars (USD) (Mean)
Brazil (Enrollment clinic for care)Peru (Enrollment clinic for care)Peru (Attended another clinic)Peru (Other location for care)
First Malaria Recurrence Follow-up6.158.543.941.30

Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria

"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180

InterventionUSD (Mean)
Peru, n=23, 3
First Malaria Recurrence Follow-up0.32

Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria

"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180

InterventionUSD (Mean)
Peru, n=23, 3Brazil, n=6, 0
First Malaria Recurrence0.491.70

Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionlogMAR scores (Mean)
Baseline; right eyeBaseline; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eye
CQ Only0.0410.0480.0390.0320.0440.041

Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

,
InterventionlogMAR scores (Mean)
Baseline; right eyeBaseline; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eyeDay 180; right eyeDay 180; left eye
PQ + CQ0.0290.0480.0210.0450.0160.0410.0000.000
TQ + CQ0.0460.0390.0490.0320.0380.0280.0330.033

Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Brazil, NothingBrazil, Drug shopBrazil, Trial clinicBrazil, OtherCambodia, NothingEthiopia, NothingEthiopia, Another clinicEthiopia, OtherEthiopia, Trial clinicPeru, NothingPeru, Drug shopPeru, Trial clinicPeru, Another clinicPeru, OtherThailand, NothingThailand, Drug shopThailand, Trial clinicThailand, In hospital
First Malaria Recurrence Follow-up507601413001006354116000

Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Brazil, NothingBrazil, Drug shopBrazil, Trial clinicBrazil, OtherCambodia, NothingEthiopia, NothingEthiopia, Another clinicEthiopia, OtherEthiopia, Trial clinicPeru, NothingPeru, Drug shopPeru, Trial clinicPeru, Another clinicPeru, OtherPhilippines, NothingThailand, NothingThailand, Drug shopThailand, Trial clinicThailand, In hospital
First Malaria Recurrence212622131211018611015111131

Number of Participants With Clinical Chemistry Laboratory Data Outside the Reference Range

Blood samples were collected for the evaluation of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk. Phos), Aspartate Aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120

,,
InterventionParticipants (Number)
ALT, HighAlk Phos, HighAST, HighBilirubin, HighCreatine kinase, HighCreatinine, HighGFR, LowIndirect bilirubinUrea, High
CQ Only1135188001142
PQ + CQ51212800846
TQ + CQ1017235112285

Number of Participants With Gastrointestinal Disorders

Gastrointestinal tolerability was analyzed by the number of par experiencing gastrointestinal disorders such as abdominal pain, heartburn, diarrhea, constipation, nausea, and vomiting. The number of participants with gastrointestinal disorders for each treatment group has been summarized. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
NauseaVomitingAbdominal pain upperDiarrhoeaAbdominal painDyspepsia
CQ Only12913655
PQ + CQ9117562
TQ + CQ2122111586

Number of Participants With Hematology Laboratory Data Outside the Reference Range

Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120

,,
InterventionParticipants (Number)
Blood eosinophils, HighBlood leukocytes, LowBlood lymphocytes, LowBlood lymphocytes, HighBlood neutrophils, LowBlood platelets, LowBlood reticulocytes, HighMethemoglobin, High
CQ Only180723214724
PQ + CQ2820137158511
TQ + CQ3834325351415

Number of Participants With Hemoglobin Decline From Baseline Over First 29 Days

Glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines. Blood samples were collected for the evaluation of hemoglobin levels. Hemoglobin decreases of >=30% or >3 grams/deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs). Number of participants with maximum hemoglobin decline from Baseline over first 29 days of study has been summarized. Safety Population consisted of all randomized participants who received at least one dose of study medication. (NCT01376167)
Timeframe: Baseline and up to Day 29

,,
InterventionParticipants (Number)
<=20 grams/liter (g/L)>20g/L to <=30 g/L>30 g/L or >=30%
CQ Only120112
PQ + CQ114123
TQ + CQ2143114

Number of Participants With Keratopathy

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Baseline; right eyeBaseline; left eyeDay 1; right eyeDay 1; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eyeAny time post Baseline; right eyeAny time post Baseline; left eye
CQ Only0000000000

Number of Participants With Keratopathy

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

,
InterventionParticipants (Number)
Baseline; right eyeBaseline; left eyeDay 1; right eyeDay 1; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eyeDay 180; right eyeDay 180; left eyeAny time post Baseline; right eyeAny time post Baseline; left eye
PQ + CQ000000000000
TQ + CQ000000100010

Number of Participants With Retinal Changes From Baseline

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180

,
InterventionParticipants (Number)
Day 29, Definite change, right eyeDay 29, Ques change, right eyeDay 29, Definite change, left eyeDay 29, Ques change, left eyeDay 90, Definite change, right eyeDay 90, Ques change, right eyeDay 90, Definite change, left eyeDay 90, Ques change, left eyeDay 180, Definite change, right eyeDay 180, Ques change, right eyeDay 180, Definite change, left eyeDay 180, Ques change, left eye
CQ Only101010100000
TQ + CQ000010110000

Number of Participants With Retinal Changes From Baseline

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180

InterventionParticipants (Number)
Day 29, Definite change, right eyeDay 29, Ques change, right eyeDay 29, Definite change, left eyeDay 29, Ques change, left eyeDay 90, Definite change, right eyeDay 90, Ques change, right eyeDay 90, Definite change, left eyeDay 90, Ques change, left eye
PQ + CQ00001102

Number of Participants With TEAEs and Serious TEAEs

An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with possible drug induced liver injury with hyperbilirubinemia. TEAEs is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
TEAEsSerious TEAEs
CQ Only866
PQ + CQ764
TQ + CQ16421

Number of Participants With TEAEs by Maximum Intensity

An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with AEs based on severity has been presented. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
Mild or Grade 1Moderate or Grade 2Severe or Grade 3Grade 4Grade 5
CQ Only3052310
PQ + CQ3837100
TQ + CQ7089201

Number of Participants With Treatment Emergent Adverse Events (TEAEs) Potentially Related to Hemoglobin Decrease

TEAEs are defined as adverse events (AEs) with an onset date and time on or after that of the start of first dose of study medication (including CQ). The number of participants with TEAEs potentially related to hemoglobin decrease has been presented. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
Haemoglobin decreasedFatigueHyperbilirubinaemiaPallor
CQ Only2210
PQ + CQ2000
TQ + CQ14101

Time Lost by Participants or Care Givers From Normal Occupation

Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionDays (Number)
Brazil, HouseworkBrazil, FarmingBrazil, paid employmentBrazil, OtherCambodia, FarmingEthiopia, HouseworkEthiopia, FarmingEthiopia, StudentEthiopia, Paid employmentEthiopia, OtherPeru, HouseworkPeru, FarmingPeru, StudentPeru, Paid employmentPeru, OtherThailand, paid employmentThailand, Other
First Malaria Recurrence Follow-up00052433047292868.53200

Time Lost by Participants or Care Givers From Normal Occupation

Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionDays (Number)
Brazil, HouseworkBrazil, FarmingBrazil, paid employmentBrazil, OtherCambodia, FarmingEthiopia, HouseworkEthiopia, FarmingEthiopia, StudentEthiopia, Paid employmentEthiopia, OtherPeru, HouseworkPeru, FarmingPeru, StudentPeru, Paid employmentPeru, OtherPhilippines, FarmingThailand, paid employmentThailand, Other
First Malaria Recurrence18831742.5321241916260201

Cost Associated With a Hemolysis Event

Health outcomes were evaluated based on cost incurred due to clinically relevant hemolysis. The total cost was evaluated based on the amount spent on treatment, transport, medication and test. The costs associated with hemolysis event has been presented. The aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major cost differences with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180

InterventionUSD (Mean)
Participants With Clinically Relevant Hemolysis9.174

Cost Incurred With Purchase of Medications Associated With Hemolysis Event

"Health outcomes were evaluated based on the cost of medications purchased. The total medication cost associated with hemolysis event has been presented. Medications recorded as Other and medications without costs are excluded from the analysis. The aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major cost differences with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan." (NCT02216123)
Timeframe: Up to Day 180

InterventionUSD (Mean)
Participants With Clinically Relevant Hemolysis0

Number of Participants or Care Givers Who Had Taken Time Off From Normal Occupation Due to a Hemolysis Event

Health outcomes were evaluated based on total time lost by participants or care givers due to a hemolysis event. The number of participants or care givers who took days off from work due to a hemolysis event has been presented based on the normal occupation. The aim of this outcome measure was to determine the time taken off by participants due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major differences in time taken off by participants with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Participants With Clinically Relevant Hemolysis0

Number of Participants With Action Taken to Treat a Hemolysis Event

Health outcomes were evaluated based on the actions taken by the participants to treat hemolysis events. The number of participants in Brazil who attended the trial clinic to treat a hemolysis event has been presented. The aim of this outcome measure was to determine the action taken by a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major differences in action taken by the participants with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Participants With Clinically Relevant Hemolysis1

Number of Participants With P. Falciparum

Microscopic blood slides (two thick film and one thin film slide) were prepared and examined for asexual parasite count. The number of participants with positive P. falciparum asexual parasite count post Baseline has been summarized for each treatment arm. (NCT02216123)
Timeframe: Up to Day 180

InterventionParticipants (Number)
TQ+CQ4
PQ+CQ3

Number of Participants With Recrudescence

Recrudescence is defined as any P. vivax parasitemia occurring on or before Day 32 (that is, blood stage treatment failure). A participant was considered to have had a recrudescence if both of the following were true: a) Participant had a positive P. vivax asexual parasite count at Baseline and demonstrated clearance (that is, did not have two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval). b) Participant had a positive genetically homologous asexual P. vivax parasite count, after their zero count in Days 1 to 5, but on or before Study Day 32. The number of participants with recrudescence before Study Day 33 has been presented. (NCT02216123)
Timeframe: Up to Day 32

InterventionParticipants (Number)
TQ+CQ0
PQ+CQ0

Oral Clearance (CL/F) of TQ

Apparent population oral clearance of TQ (NCT02216123)
Timeframe: Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180

InterventionLiters per hour (Median)
Participants in TQ Only Arms2.96

Percentage of Participants With Clinically Relevant Hemolysis.

Clinically relevant hemolysis is defined as a decrease in hemoglobin of >=30% or >3 grams per deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL at any visit after the first dose of study medication. The percentage of participants with clinically relevant hemolysis has been summarized. Safety Population comprised of all randomized participants who received at least one dose of blinded study medication. (NCT02216123)
Timeframe: Up to Day 180

InterventionPercentage of participants (Number)
TQ+CQ2.41
PQ+CQ1.18

Rate of Relapse-free Efficacy at Four Months Post Dose

A participant was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P. vivax parasitemia. c) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Participant is parasite-free at 4 months. The rate of relapse-free efficacy was estimated by Kaplan-Meier methodology. The percentage of participants who were relapse-free at 4 months post dose has been presented along with 95% confidence interval. (NCT02216123)
Timeframe: 4 months post dose

InterventionPercentage of participants (Number)
TQ+CQ82.3
PQ+CQ79.7

Rate of Relapse-free Efficacy at Six Months Post Dose

A participant was considered to have demonstrated relapse-free efficacy at 6 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P. vivax parasitemia defined as two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. The rate of relapse-free efficacy was estimated by Kaplan-Meier methodology. The percentage of participants who were relapse-free at 6 months post dose has been presented along with 95% confidence interval. (NCT02216123)
Timeframe: 6 months post dose

InterventionPercentage of participants (Number)
TQ+CQ72.7
PQ+CQ75.1

Time to Fever Clearance

Fever clearance time is defined as the time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.4 degree Celsius is reduced to a value less than or equal to 37.4 degree Celsius, in the absence of value more than 37.4 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed by Kaplan-Meier method. (NCT02216123)
Timeframe: Up to Day 9

InterventionHours (Median)
TQ+CQ10
PQ+CQ13

Time to Gametocyte Clearance

Gametocyte clearance time is defined as time from first dose until the first slide that was gametocyte negative and remained so at the next slide reading. The time taken to achieve gametocyte clearance was analyzed by Kaplan-Meier method. (NCT02216123)
Timeframe: Up to Day 180

InterventionHours (Median)
TQ+CQ38
PQ+CQ41

Time to Parasite Clearance

Parasite clearance time is defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours later. The time to achieve parasite clearance was analyzed by Kaplan-Meier methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT02216123)
Timeframe: Up to Day 180

InterventionHours (Median)
TQ+CQ41
PQ+CQ44

Time to Relapse of P. Vivax Malaria

Relapse is defined by a positive blood smear with or without vivax symptoms. Relapse is described as any recurrence of malaria that occurred after Day 32 of the study. The time to relapse was analyzed by the Kaplan-Meier method. The median number of days to relapse along with 95% confidence interval has been presented for each treatment group. (NCT02216123)
Timeframe: Up to Day 180

InterventionDays (Median)
TQ+CQNA
PQ+CQNA

Volume of Distribution (Vc/F) of TQ

Apparent population central volume of distribution of TQ (NCT02216123)
Timeframe: Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180

InterventionLiters (Median)
Participants in TQ Only Arms915

Change From Baseline in Percent Methemoglobin

Methemoglbin is an oxidized and inactive form of hemoglobin. Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine. The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo) was considered as Baseline value. Change from Baseline is the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 120

,
InterventionPercent change (Mean)
Day 2, Male, n=114, 53Day 2, Female, n=52, 32Day 3, Male, n=114, 53Day 3, Female, n=52, 32Day 5, Male, n=113, 53Day 5, Female, n=52, 32Day 8, Male, n=112, 52Day 8, Female, n=52, 32Day 11, Male, n=112, 52Day 11, Female, n=51, 32Day 15, Male, n=113, 52Day 15, Female, n=52, 32Day 22, Male, n=112, 52Day 22, Female, n=52, 32Day 29, Male, n=111, 52Day 29, Female, n=52, 32Day 60, Male, n=107, 51Day 60, Female, n=52, 32Day 120, Male, n=109, 50Day 120, Female, n=50, 31
PQ+CQ0.02-0.060.030.170.891.322.632.813.303.443.263.611.582.300.460.840.200.14-0.010.04
TQ+CQ0.02-0.160.180.080.770.631.221.001.161.041.010.810.610.320.24-0.020.05-0.090.060.14

Change From Baseline in Pulse Rate

Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements. The mean and standard deviation of pulse rate has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180

,
Interventionbeats per minute (Mean)
Day 1 assessment 4; n=161, 84Day 2 assessment 1; n=166, 85Day 2 assessment 4; n=166, 85Day 3 assessment 1; n=166, 83Day 3 assessment 4; n=166, 82Day 8; n=164, 84Day 11; n=163, 84Day15; n=165, 84Day 22; n=164, 84Day 29; n=163, 84Day 60; n=160, 83Day 90; n=160, 82Day 120; n=159, 81Day 150; n=161, 82Day180; n=160, 83
PQ+CQ-9.3-9.9-11.8-18.2-17.5-14.6-15.5-16.9-16.8-17.5-18.5-18.6-19.1-17.9-18.3
TQ+CQ-10.8-9.9-11.9-15.1-16.5-12.7-13.4-13.5-14.7-16.9-16.7-16.3-16.7-16.8-18.0

Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP)

Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to pharmacokinetic (PK) measurements. MAP was calculated as the sum of SBP and two times DBP divided by 3. The mean and standard deviation of SBP, DBP and MAP has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180

,
Interventionmillimeter of mercury (mmHg) (Mean)
SBP, Day 1 assessment 4; n=161, 84SBP, Day 2 assessment 1; n=166, 85SBP, Day 2 assessment 4; n=166, 85SBP, Day 3 assessment 1; n=166, 83SBP, Day 3 assessment 4; n=166, 82SBP, Day 8; n=164, 84SBP, Day 11; n=163, 84SBP, Day15; n=165, 84SBP, Day 22; n=164, 84SBP, Day 29; n=163, 84SBP, Day 60; n=160, 83SBP, Day 90; n=160, 82SBP, Day 120; n=159, 81SBP, Day 150; n=161, 82SBP, Day180; n=160, 83DBP, Day 1 assessment 4; n=161, 84DBP, Day 2 assessment 1; n=166, 85DBP, Day 2 assessment 4; n=166, 85DBP, Day 3 assessment 1; n=166, 83DBP, Day 3 assessment 4; n=166, 82DBP, Day 8; n=164, 84DBP, Day 11; n=163, 84DBP, Day15; n=165, 84DBP, Day 22; n=164, 84DBP, Day 29; n=163, 84DBP, Day 60; n=160, 83DBP, Day 90; n=160, 82DBP, Day 120; n=159, 81DBP, Day 150; n=161, 82DBP, Day180; n=160, 83MAP, Day 1 assessment 4; n=161, 84MAP, Day 2 assessment 1; n=166, 85MAP, Day 2 assessment 4; n=166, 85MAP, Day 3 assessment 1; n=166, 83MAP, Day 3 assessment 4; n=166, 82MAP, Day 8; n=164, 84MAP, Day 11; n=163, 84MAP, Day15; n=165, 84MAP, Day 22; n=164, 84MAP, Day 29; n=163, 84MAP, Day 60; n=160, 83MAP, Day 90; n=160, 82MAP, Day 120; n=159, 81MAP, Day 150; n=161, 82MAP, Day180; n=160, 83
PQ+CQ-0.9-2.3-2.7-2.1-2.20.81.22.52.94.44.35.33.14.95.7-1.5-2.2-2.6-1.3-1.91.1-0.50.41.31.51.93.52.44.13.7-1.3-2.2-2.6-1.6-2.01.00.11.11.82.42.74.12.64.44.4
TQ+CQ1.20.4-0.8-0.6-2.72.21.33.23.32.64.43.83.84.43.71.1-0.1-0.8-0.2-1.90.9-0.01.51.20.93.12.73.33.22.91.10.0-0.8-0.3-2.21.30.42.01.91.53.53.13.53.63.2

Change From Baseline in Temperature

Vital signs were performed twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements. The mean and standard deviation of pulse rate has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180

,
InterventionCelsius (Mean)
Day 1 assessment 4; n=161, 84Day 2 assessment 1; n=166, 85Day 2 assessment 4; n=166, 85Day 3 assessment 1; n=166, 83Day 3 assessment 4; n=166, 82Day 8; n=164, 84Day 11; n=163, 84Day15; n=165, 84Day 22; n=164, 84Day 29; n=163, 84Day 60; n=160, 83Day 90; n=160, 82Day 120; n=159, 81Day 150; n=161, 82Day180; n=160, 83
PQ+CQ-0.5-0.6-0.6-0.9-1.0-0.9-0.9-1.0-1.0-1.0-1.0-1.0-0.9-1.0-1.0
TQ+CQ-0.6-0.6-0.6-1.0-1.0-1.0-1.0-0.9-1.0-1.0-1.0-1.0-1.0-1.0-1.0

Cost Associated With Relapse Episode of P Vivax Malaria

Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other). The costs associated with a relapse episode of P. vivax malaria has been presented. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180

InterventionUS Dollars (USD) (Mean)
Brazil; enrollment clinic for care; n=19, 17Colombia; hospital emergency center; n=1,1Peru; enrollment clinic for care; n=32, 33Peru; attended another clinic; n=8, 30Thailand; enrollment clinic for care; n=0, 1Vietnam; drug shop for care;n=1, 2Vietnam; attended another clinic; n=0, 1
First Malaria Relapse Follow-up8.03216.7758.8153.9591.5342.8090.936

Cost Associated With Relapse Episode of P Vivax Malaria

Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other). The costs associated with a relapse episode of P. vivax malaria has been presented. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180

InterventionUS Dollars (USD) (Mean)
Brazil; enrollment clinic for care; n=19, 17Colombia; enrollment clinic for care; n=1,0Colombia; attended another clinic; n=1,0Colombia; hospital emergency center; n=1,1Peru; enrollment clinic for care; n=32, 33Peru; attended another clinic; n=8, 30Peru; Other; n=8, 0Vietnam; drug shop for care;n=1, 2Vietnam; Other; n=1, 0
First Malaria Relapse8.20842.7764.19416.7759.2441.6770.8180.7021.873

Cost Incurred With Purchase of Medications Associated With Relapse Episode of P. Vivax Malaria

"Health outcomes were evaluated based on the cost of medications purchased. The total medication cost for paracetamol associated with relapse episode of P vivax malaria has been presented. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title)." (NCT02216123)
Timeframe: Up to Day 180

,
InterventionUSD (Mean)
Colombia; n=2, 1Peru; n=6, 2Vietnam; n=1, 1
First Malaria Relapse2.5160.4910.468
First Malaria Relapse Follow-up4.1940.3272.341

Number of Participants or Care Givers Who Had Taken Time Off From Normal Occupation Due to Relapse Episode of Malaria

Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Brazil; Housework; n=2, 1Brazil; Farming; n=1, 1Brazil; Student; n=1, 1Brazil; Paid employment; n=7, 7Brazil; Other; n=8, 7Colombia; Farming; n=2, 2Colombia; Paid employment; n=1, 1Peru; Housework; n=18, 18Peru, Farming; n=4, 4Peru; Student; n=3, 3Peru; Paid employment; n=1, 1Peru; Other; n=7, 7Thailand; Farming; n=1, 1Vietnam; Farming; n=4, 4Vietnam; Paid employment; n=0, 3
First Malaria Relapse Follow-up0000001154216112

Number of Participants or Care Givers Who Had Taken Time Off From Normal Occupation Due to Relapse Episode of Malaria

Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Brazil; Housework; n=2, 1Brazil; Farming; n=1, 1Brazil; Student; n=1, 1Brazil; Paid employment; n=7, 7Brazil; Other; n=8, 7Colombia; Housework; n=1, 0Colombia; Farming; n=2, 2Colombia; Paid employment; n=1, 1Peru; Housework; n=18, 18Peru, Farming; n=4, 4Peru; Student; n=3, 3Peru; Paid employment; n=1, 1Peru; Other; n=7, 7Thailand; Farming; n=1, 1Vietnam; Farming; n=4, 4
First Malaria Relapse0000010114421713

Number of Participants With Abnormal Urinalysis Dipstick Results

Mid-stream urine was collected and analyzed for bilirubin, glucose, ketones, leukocyte esterase (LE), nitrites, occult blood, proteins and urobilinogen by dipstick method. The number of participants with abnormal urinalysis results (Trace, +, ++, +++, ++++) has been presented. Only those participants with data available at the specified data points were analyzed. (NCT02216123)
Timeframe: Up to Day 120

,
InterventionParticipants (Number)
Bilirubin, Day 1, TraceBilirubin, Day 1, +Bilirubin, Day1, ++Bilirubin, Day 3, +Bilirubin, Day 3, ++Bilirubin, Day 5, TraceBilirubin, Day 5, +Bilirubin, Day 8, +Bilirubin, Day 11, TraceBilirubin, Day 22, TraceBilirubin, Day 22, +Bilirubin, Day 60, TraceBilirubin, Day 60, +Bilirubin, Day 90, +Bilirubin, Day 120, +Glucose, Day 1, +Glucose, Day 1, ++Glucose, Day1, +++Glucose, Day1, ++++Glucose, Day 3, +Glucose, Day 3, ++Glucose, Day 3, +++Glucose, Day 3, ++++Glucose, Day 5, ++Glucose, Day 5, +++Glucose, Day 8, +Glucose, Day 8, ++Glucose, Day 8,+++Glucose, Day 11, TraceGlucose, Day 11, +Glucose, Day 11, ++Glucose, Day 11, +++Glucose, Day 15, ++Glucose, Day 15, +++Glucose, Day 15, ++++Glucose, Day 22, +Glucose, Day 22, +++Glucose, Day 29, TraceGlucose, Day 29, ++Glucose, Day 60, +Glucose, Day 60, ++Glucose, Day 90, +Glucose, Day 90, ++Glucose, Day 90, +++Glucose, Day 120, TraceGlucose, Day 120, +Glucose, Day 120, ++Glucose, Day 120, +++Glucose, Day 120, ++++Ketones, Day 1, TraceKetones, Day 1, +Ketones, Day1, ++Ketones, Day1, +++Ketones, Day 3, TraceKetones, Day 3, +Ketones, Day 3, ++Ketones, Day 3, +++Ketones, Day 5, +Ketones, Day 8, +Ketones, Day 11, TraceKetones, Day 22, TraceKetones, Day 22, +Ketones, Day 90, TraceKetones, Day 90, +Ketones, Day 90, ++Ketones, Day 120, TraceKetones, Day 120, +Ketones, Day 120, ++LE, Day 1, TraceLE, Day 1, +LE, Day1, ++LE, Day1, +++LE, Day 3, TraceLE, Day 3, +LE, Day 3, ++LE, Day 3, +++LE, Day 5, TraceLE, Day 5, +LE, Day 5, ++LE, Day 5, +++LE, Day 8, TraceLE, Day 8, +LE, Day 8, ++LE, Day 8, +++LE, Day 11, TraceLE, Day 11, +LE, Day 11, ++LE, Day 11, +++LE, Day 15, TraceLE, Day 15, +LE, Day 15, ++LE, Day 15, +++LE, Day 22, TraceLE, Day 22, +LE, Day 22, ++LE, Day 22, +++LE, Day 29, TraceLE, Day 29, +LE, Day 29, ++LE, Day 29, +++LE, Day 60, TraceLE, Day 60, +LE, Day 60, ++LE, Day 60, +++LE, Day 90, TraceLE, Day 90, +LE, Day 90, ++LE, Day 90, +++LE, Day 120, TraceLE, Day 120, +LE, Day 120, ++LE, Day 120, +++Nitrite, Day 1, TraceNitrite, Day 1, +Nitrite, Day 3, +Nitrite, Day 5, +Nitrite, Day 5, +++Nitrite, Day 8, +++Nitrite, Day 11, +Nitrite, Day 15, +Nitrite, Day 22, TraceNitrite, Day 29, +Nitrite, Day 60, +Nitrite, Day 90, TraceNitrite, Day 90, +Nitrite, Day 120, +Nitrite, Day 120, ++Occult blood, Day 1, TraceOccult blood, Day 1, +Occult blood, Day 1, ++Occult blood, Day1, +++Occult blood, Day1, ++++Occult blood, Day 3, TraceOccult blood, Day 3, +Occult blood, Day 3, ++Occult blood, Day 3, +++Occult blood, Day 3, ++++Occult blood, Day 5, TraceOccult blood, Day 5, +Occult blood, Day 5, ++Occult blood, Day 5, +++Occult blood, Day 5, ++++Occult blood, Day 8, TraceOccult blood, Day 8, +Occult blood, Day 8, ++Occult blood, Day 8,+++Occult blood, Day 11, TraceOccult blood, Day 11, +Occult blood, Day 11, ++Occult blood, Day 11, +++Occult blood, Day 11, ++++Occult blood, Day 15, TraceOccult blood, Day 15, +Occult blood, Day 15, ++Occult blood, Day 15, +++Occult blood, Day 15, ++++Occult blood, Day 22, TraceOccult blood, Day 22, +Occult blood, Day 22, ++Occult blood, Day 22, +++Occult blood, Day 22, ++++Occult blood, Day 29, TraceOccult blood, Day 29, +Occult blood, Day 29, ++Occult blood, Day 29, +++Occult blood, Day 29, ++++Occult blood, Day 60, TraceOccult blood, Day 60, +Occult blood, Day 60, ++Occult blood, Day 60, +++Occult blood, Day 60, ++++Occult blood, Day 90, TraceOccult blood, Day 90, +Occult blood, Day 90, ++Occult blood, Day 90, +++Occult blood, Day 90, ++++Occult blood, Day 120, TraceOccult blood, Day 120, +Occult blood, Day 120, ++Occult blood, Day 120, +++Occult blood, Day 120, ++++Protein, Day 1, TraceProtein, Day 1, +Protein, Day1, ++Protein, Day 3, TraceProtein, Day 3, +Protein, Day 3, ++Protein, Day 5, TraceProtein, Day 5, +Protein, Day 5, ++Protein, Day 8, TraceProtein, Day 8, +Protein, Day 8,++Protein, Day 11, TraceProtein, Day 11, +Protein, Day 11, ++Protein, Day 15, +Protein, Day 15, ++Protein, Day 22, TraceProtein, Day 22, +Protein, Day 22, ++Protein, Day 29, TraceProtein, Day 29, +Protein, Day 29, ++Protein, Day 60, TraceProtein, Day 60, +Protein, Day 60, ++Protein, Day 90, TraceProtein Day 90, +Protein, Day 120, TraceProtein, Day 120, +Protein, Day 120, ++Urobilinogen, Day 1, TraceUrobilinogen, Day 1, +Urobilinogen, Day1, ++Urobilinogen, Day1, +++Urobilinogen, Day 3, TraceUrobilinogen, Day 3, +Urobilinogen, Day 3, ++Urobilinogen Day 3, +++Urobilinogen, Day 3, ++++Urobilinogen, Day 5, TraceUrobilinogen, Day 5, +Urobilinogen, Day 8, TraceUrobilinogen, Day 8, +Urobilinogen, Day 8, ++Urobilinogen, Day 8,+++Urobilinogen, Day 11, TraceUrobilinogen, Day 11, +Urobilinogen, Day 11, ++Urobilinogen, Day 15, TraceUrobilinogen, Day 15, +Urobilinogen, Day 15, ++Urobilinogen, Day 22, TraceUrobilinogen, Day 29, TraceUrobilinogen, Day 29, +Urobilinogen, Day 60, TraceUrobilinogen, Day 60, +Urobilinogen, Day 90, TraceUrobilinogen, Day 90, +Urobilinogen, Day 120, TraceUrobilinogen, Day 120, +Urobilinogen, Day 120, ++
PQ+CQ12030002110111211311121131111201101210241111012200231132001010010000192205101422341223312831240106403421172113210000001000011104742136331133224402132011221115111251400730017232253028816131511420310001101001201010005412114311222111011000111010001
TQ+CQ1938214010102032020010000100003101010110100111001344205331111120111131951413213113371062611338442413315111488526132051250141111121230221218912641495347643412332833121132041142151733151523141374221336015194821354266114121221341331432618231036148003320001203113423143220

Number of Participants With Action Taken to Treat Relapse Episode of P. Vivax Malaria

Health outcomes were evaluated based on the actions taken by the participants to treat relapse episode of P vivax malaria. The number of participants with the type of action taken to treat relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180

,
InterventionParticipants (Number)
Brazil; Trial clinic; n=19, 17Brazil; Other; n=19, 17Colombia; Nothing; n=4, 3Colombia; Trial clinic; n=4, 3Colombia; Another clinic; n=4, 3Colombia; Hospital emergency center; n=4, 3Peru; Trial clinic; n=33, 33Peru; Another clinic; n=33, 33Peru; Other; n=33, 33Thailand; Nothing; n=1, 1Thailand; Trial Clinic; n=1, 1Vietnam; Nothing; n=4, 7Vietnam; Drug Shop; n=4, 7Vietnam; Other; n=4, 7Vietnam; Another clinic; n=4, 7
First Malaria Relapse19521113289101210
First Malaria Relapse Follow-up170200133330015201

Number of Participants With Change in Best Corrected Visual Acuity Test Scores

Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline is the value at post dose visit minus the Baseline value. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The number of participants with change in Best Corrected Visual Acuity Test Scores from Baseline has been presented where possible change is defined as a change from Baseline >=0.12 to <0.3 and definite change is defined as a change from Baseline >=0.3 logMAR score. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180

,
InterventionParticipants (Number)
Maximum change; possible; right eye; n=27, 13Maximum change; definite; right eye; n=27, 13Maximum change; possible; left eye; n=27, 13Maximum change; definite; left eye; n=27, 13Day 29; possible change; right eye; n=27, 13Day 29; definite change; right eye; n=27, 13Day 29; possible change; left eye; n=27, 13Day 29; definite change; left eye; n=27, 13Day 90; possible change; right eye; n=27, 12Day 90; definite change; right eye; n=27, 12Day 90; possible change; left eye; n=27, 12Day 90; definite change; left eye; n=27, 12Day 180; possible change; right eye; n=2, 2Day 180; definite change; right eye; n=2, 2Day 180; possible change; left eye; n=2, 2Day 180; definite change; left eye; n=2, 2
PQ+CQ0001000000000001
TQ+CQ1021102000210000

Number of Participants With Clinical Chemistry Laboratory Data Outside the Reference Range

Plasma or serum samples were anlalyzed to evaluate clinical chemistry parameters such as alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory values outside the extended normal range (F3) has been presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Safety Population consisted of all randomized participants who received at least one dose of blinded study medication. (NCT02216123)
Timeframe: Up to Day 120

,
InterventionParticipants (Number)
ALT, HighALP, HighAST, HighBilirubin, HighCreatine kinase, HighCreatinine, HighGFR, LowIndirect bilirubin, HighUrea, High
PQ+CQ013184002119
TQ+CQ806283003640

Number of Participants With Electrocardiogram (ECG) Findings

12 lead ECG was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes. ECG assessments were performed in triplicate at screening followed by single ECGs 12 hours after the first dose of study medication and at Day 29. The number of participants with abnormal-clinically significant ECG findings have been presented. The 12 Hour Post Randomized Treatment (11.5-12.5 Hours) timepoint included all readings taken between 11.5 and 12.5 hours post randomized treatment. The 12 Hour Post Randomized Treatment (8-72 Hours) timepoint is a sensitivity analysis of the 12 Hour post randomized treatment timepoint, including all readings taken between 8 and 72 hours post randomized treatment. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 29

,
InterventionParticipants (Number)
11.5 to 12.5 hours Day 1, Assessment 1; n=143, 7511.5 to 12.5 hours Day 1 Assessment 2; n=6, 611.5 to 12.5 hours Day 1 Assessment 3; n=5, 58 to 72 hours Day 1 Assessment 1; n=166, 858 to 72 hours Day 1 Assessment 2; n=6, 68 to 72 hours Day 1 Assessment 3; n=5, 5Day 29; n=161, 84
PQ+CQ0000000
TQ+CQ0000000

Number of Participants With Genetically Homologous and Genetically Heterologous P. Vivax Infections

Two drops of peripheral blood were collected onto pre-printed filter paper for subsequent deoxyribonucleic acid (DNA) extraction and polymerase chain reaction (PCR) analysis of Plasmodium species on all participants at screening (Day 1; pre-dose) and; if necessary, at the time of the first recrudescence/relapse or re-infection. PCR of the P. vivax genes, was used to distinguish between genetically homologous and genetically heterologous infection. The number of participants with genetically homologous and genetically heterologous P. vivax infections has been summarized for each treatment group. Only those participants with an infection occuring on or after Study Day 33 were analyzed. (NCT02216123)
Timeframe: Up to Day 180

,
InterventionParticipants (Number)
Heterologous P. vivaxHomologous P. vivaxUnknown genetic classification
PQ+CQ9101
TQ+CQ8295

Number of Participants With Hematology Laboratory Data Outside the Reference Range

Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) has been presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Participants having both High and Low values for Normal Ranges at any post-baseline visits for safety parameters were counted in both the High and Low categories. (NCT02216123)
Timeframe: Up to Day 120

,
InterventionParticipants (Number)
Blood eosinophils, HighBlood leukocytes, LowBlood lymphocytes, LowBlood lymphocytes, HighBlood neutrophils, LowBlood platelets, LowBlood reticulocytes, HighMethemoglobin, High
PQ+CQ1501438393
TQ+CQ320811513802

Number of Participants With Keratopathy

Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up visit. Assessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye has been summarized for each visit. The number of participants with new keratopathy at any time post Baseline is also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180

,
InterventionParticipants (Number)
Baseline; right eye; n=27, 13Baseline; left eye; n=27, 13Day 1; right eye; n=27, 13Day 1; left eye; n=27, 13Day 29; right eye; n=27, 13Day 29; left eye; n=27, 13Day 90; right eye; n=27, 12Day 90; left eye; n=27, 12Day 180; right eye; n=2, 2Day 180; left eye; n=2, 2Any time post Baseline; right eye; n=27, 13Any time post Baseline; left eye; n=27, 13
PQ+CQ000000000000
TQ+CQ000000000000

Number of Participants With Retinal Changes From Baseline

Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up. Assessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the value at post dose visit minus the Baseline value. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline has been presented. The number of participants with maximum change post-Baseline (definite when absent or questionable at Baseline) has been presented for either eye. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180

,
InterventionParticipants (Number)
Day 29, Definite change, right eye; n=22, 13Day 29, Ques change, right eye; n=22, 13Day 29, Definite change, left eye; n=22, 13Day 29, Ques change, left eye; n=22, 13Day 90, Definite change, right eye; n=24, 11Day 90, Ques change, right eye; n=24, 11Day 90, Definite change, left eye; n=24, 11Day 90, Ques change, left eye; n=24, 11Day 180, Definite change, right eye; n=3, 2Day 180, Ques change, right eye; n=3, 2Day 180, Definite change, left eye; n=3, 2Day 180, Ques change, left eye; n=3, 2Maximum change post-Baseline; either eye; n=27, 13
PQ+CQ0000010000000
TQ+CQ0201020000000

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) is defined as any untoward medical occurrence in a participant under clinical investigation, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations such as important medical events and events of possible drug induced liver injury with hyperbilirubinemia. TEAEs are defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT02216123)
Timeframe: Up to Day 180

,
InterventionParticipants (Number)
TEAEsSerious TEAEs
PQ+CQ641
TQ+CQ1196

Time to Parasitemia for Immunogenicity Population

"Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear.~Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy." (NCT01157897)
Timeframe: 280 day (during the study through 6 months aftr challenge)

Interventiondays (Mean)
Cohort 1: 15 μg VMP0010.137
Cohort 2: 30 μg VMP0010.073
Cohort 3: 60 μg VMP0010.042

Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population

Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration

,,
InterventionGeometric Mean Titier of European Units (Mean)
Pre-vaccination2wks post first vaccinationDay of second vaccination2wks post second vaccinationDay of third vaccination2wks post third vaccination4wks post challenge6mths post challenge
Cohort 1: 15 μg VMP0011133.72244.3520161.189053.3261203.4854843.3810860.7
Cohort 2: 30 μg VMP0011750.381450.2281143.7231071.0168730.456472.1712519.16
Cohort 3: 60 μg VMP0013.09836.681711.6361711.836405.6641879.9932178.395500.73

Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population

Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration

,,
InterventionGeometric Mean Titer of European Units (Mean)
Pre-vaccination2wks post first vaccinationDay of second vaccination2wks post second vaccinationDay of third vaccination2wks post third vaccination4wks post challenge6months post challenge
Cohort 1: 15 μg VMP0011151.39281.7921862.229921.6159883.7754843.3810860.7
Cohort 2: 30 μg VMP0011.5526.181175.4174608.6228498.4368730.456472.1712519.16
Cohort 3: 60 μg VMP0013.09836.681711.6361711.836405.6641879.9932178.395500.73

Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase

Adverse events were evaluated for 7 days after each vaccination during the vaccine phase. (NCT01157897)
Timeframe: 7 days after immunization

,,
Interventionparticipants with AEs (Number)
Solicited Local: Injection site erythemaSolicited Local: Injection site indurationSolicited Local: Injection site painSolicited Systemic: DiarrheaSolicited Systemic: NauseaSolicited Systemic: VomitingSolicited Systemic: FatigueSolicited Systemic: PyrexiaSolicited Systemic: ArthralgiaSolicited Systemic: MyalgiaSolicited Systemic: Headache
Cohort 1: 15 μg VMP001201005284448
Cohort 2: 30 μg VMP001311003042246
Cohort 3: 60 μg VMP001621014271375

Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase

Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase (NCT01157897)
Timeframe: 28 days following immunization

,,
Interventionparticipants with AEs (Number)
Ear discomfortAbdominal discomfortAbdominal painFeces discoloredFood poisoningNauseaToothacheAxillary painChillsFeeling hotInjection site erythemaInjection site pruritusInjection site swellingInjection site warmthMalaiseHypertransaminasaemiaSeasonal allergyNasopharyngitisUpper respiratory tract infectionContusionExcoriationPostprocedural discomfortPosttraumatic painScratchSkin lacerationHaemoglobin decreasedPlatelet count decreasedGoutBack painMuscle spasmsMusculoskeletal discomfortMyalgiaPain in extremityDizzinessHeadacheSinus headacheNasal CongestionCold sweatDermatitis contactErythemaHypertension
Cohort 1: 15 μg VMP00111001120550000311120000000010111211002001
Cohort 2: 30 μg VMP00100000001560021520000010001101000000004110
Cohort 3: 60 μg VMP00100110000771132711021101121101010210112000

Infection for P. Vivax

Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days

Interventiondays (Mean)
Group 111
Group 211
Group 39

Reviews

53 reviews available for primaquine and Plasmodium vivax Malaria

ArticleYear
Tafenoquine for the treatment of
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:7

    Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Tafenoquine for
    The Indian journal of medical research, 2021, Volume: 154, Issue:6

    Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaqu

2021
Global scenario of Plasmodium vivax occurrence and resistance pattern.
    Journal of basic microbiology, 2022, Volume: 62, Issue:12

    Topics: Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine

2022
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
    Malaria journal, 2023, Oct-10, Volume: 22, Issue:1

    Topics: Antimalarials; Folic Acid Antagonists; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurre

2023
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
    PLoS medicine, 2019, Volume: 16, Issue:10

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Vivax; Plas

2019
Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
    PLoS medicine, 2019, Volume: 16, Issue:12

    Topics: Diagnostic Tests, Routine; Endemic Diseases; Female; Glucosephosphate Dehydrogenase; Glucosephosphat

2019
Advances and roadblocks in the treatment of malaria.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:2

    Topics: Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; Humans; Malaria; Malaria, F

2022
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    The Cochrane database of systematic reviews, 2020, 08-19, Volume: 8

    Topics: Adult; Antimalarials; Child; Drug Administration Schedule; Glucosephosphate Dehydrogenase; Humans; M

2020
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2020, 09-06, Volume: 9

    Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate D

2020
Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.
    International journal for parasitology. Drugs and drug resistance, 2021, Volume: 15

    Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2021
[Role of primaquine in malaria control and elimination in French-speaking Africa].
    Bulletin de la Societe de pathologie exotique (1990), 2017, Volume: 110, Issue:3

    Topics: Africa; Africa, Northern; Disease Eradication; Humans; Infection Control; Language; Malaria, Falcipa

2017
Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis.
    Malaria journal, 2017, 07-03, Volume: 16, Issue:1

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Drug Combinatio

2017
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency.
    Malaria journal, 2018, Mar-02, Volume: 17, Issue:1

    Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Heterozygote; Humans; M

2018
Malaria Elimination: Time to Target All Species.
    The American journal of tropical medicine and hygiene, 2018, Volume: 99, Issue:1

    Topics: Animals; Anopheles; Antimalarials; Chloroquine; Disease Eradication; Host-Parasite Interactions; Hum

2018
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
    The Lancet. Infectious diseases, 2018, Volume: 18, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru

2018
ON THE EPIDEMIOLOGY OF COMPLICATED VIVAX MALRIA.
    Meditsinskaia parazitologiia i parazitarnye bolezni, 2016, Volume: 4, Issue:4

    Topics: Animals; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2016
Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.
    Malaria journal, 2018, Nov-06, Volume: 17, Issue:1

    Topics: Aminoquinolines; Animals; Antimalarials; Humans; Macaca mulatta; Malaria, Vivax; Primaquine

2018
The Primaquine Problem-and the Solution? Point-of-care Diagnostics for Glucose 6-Phosphate Dehydrogenase Deficiency.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 09-27, Volume: 69, Issue:8

    Topics: Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Plasmodium vivax; Point-of-Care S

2019
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2019, 07-05, Volume: 7

    Topics: Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Primaquine; Primary Prevention;

2019
The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
    BMC medicine, 2019, 08-01, Volume: 17, Issue:1

    Topics: Adult; Anemia, Hemolytic; Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficie

2019
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2013, Oct-25, Issue:10

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi

2013
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.
    The Cochrane database of systematic reviews, 2013, Oct-26, Issue:10

    Topics: Adult; Antimalarials; Child; Chloroquine; Drug Administration Schedule; Humans; Malaria, Vivax; Plas

2013
Reversible myelopathy in Plasmodium vivax malaria: report of a case and review of literature.
    Journal of vector borne diseases, 2013, Volume: 50, Issue:3

    Topics: Adult; Animals; Antimalarials; Chloroquine; Diagnosis, Differential; Humans; India; Magnetic Resonan

2013
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
    Malaria journal, 2013, Nov-15, Volume: 12

    Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi

2013
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
    Malaria journal, 2013, Nov-15, Volume: 12

    Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi

2013
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
    Malaria journal, 2013, Nov-15, Volume: 12

    Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi

2013
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
    Malaria journal, 2013, Nov-15, Volume: 12

    Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi

2013
Mass primaquine treatment to eliminate vivax malaria: lessons from the past.
    Malaria journal, 2014, Feb-07, Volume: 13

    Topics: Anemia, Hemolytic; Antimalarials; Asia; Chemoprevention; Disease Eradication; Drug Therapy; Glucosep

2014
Clinical complications of G6PD deficiency in Latin American and Caribbean populations: systematic review and implications for malaria elimination programmes.
    Malaria journal, 2014, Feb-25, Volume: 13

    Topics: Caribbean Region; Disease Eradication; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans;

2014
G6PD deficiency in Latin America: systematic review on prevalence and variants.
    Memorias do Instituto Oswaldo Cruz, 2014, Volume: 109, Issue:5

    Topics: Antimalarials; Caribbean Region; Contraindications; Female; Geographic Mapping; Glucosephosphate Deh

2014
Plasmodium vivax malaria elimination: should innovative ideas from the past be revisited?
    Memorias do Instituto Oswaldo Cruz, 2014, Volume: 109, Issue:5

    Topics: Antimalarials; Brazil; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Prima

2014
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2015, Apr-29, Issue:4

    Topics: Adult; Aminoquinolines; Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, V

2015
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria.
    Pathogens and global health, 2015, Volume: 109, Issue:3

    Topics: Anemia; Antimalarials; Chemical and Drug Induced Liver Injury; Glucosephosphate Dehydrogenase Defici

2015
Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis.
    Colombia medica (Cali, Colombia), 2015, Dec-30, Volume: 46, Issue:4

    Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Administration Schedule; Humans; Malaria,

2015
Primaquine treatment and relapse in Plasmodium vivax malaria.
    Pathogens and global health, 2016, Volume: 110, Issue:1

    Topics: Antimalarials; Humans; Malaria, Vivax; Middle Aged; Plasmodium vivax; Primaquine; Recurrence; Treatm

2016
Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax.
    Acta tropica, 2016, Volume: 160

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Treatment Failure

2016
Evaluation of Efficacy of Chloroquine for Plasmodium Vivax Infection Using Parasite Clearance Times: A 10-Year Study and Systematic Review.
    Annals of the Academy of Medicine, Singapore, 2016, Volume: 45, Issue:7

    Topics: Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Malaria,

2016
Management of relapsing Plasmodium vivax malaria.
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:10

    Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Humans; Liver;

2016
Resistance to therapies for infection by Plasmodium vivax.
    Clinical microbiology reviews, 2009, Volume: 22, Issue:3

    Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Folic Acid Antagonists; Humans; Malaria, Vivax

2009
Review: Malaria chemoprophylaxis for travelers to Latin America.
    The American journal of tropical medicine and hygiene, 2011, Volume: 85, Issue:6

    Topics: Antimalarials; Atovaquone; Drug Combinations; Drug Therapy, Combination; Humans; Latin America; Mala

2011
Primaquine in vivax malaria: an update and review on management issues.
    Malaria journal, 2011, Dec-12, Volume: 10

    Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Clinical Trials as Topic; Drug Resistance

2011
The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.
    PLoS neglected tropical diseases, 2011, Volume: 5, Issue:12

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi

2011
Primaquine radical cure of Plasmodium vivax: a critical review of the literature.
    Malaria journal, 2012, Aug-17, Volume: 11

    Topics: Antimalarials; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Ma

2012
[Plasmodium vivax malaria recurrence according to the use of primaquine: analysis of longitudinal descriptive studies].
    Revista brasileira de epidemiologia = Brazilian journal of epidemiology, 2012, Volume: 15, Issue:3

    Topics: Antimalarials; Humans; Longitudinal Studies; Malaria, Vivax; Primaquine; Secondary Prevention

2012
The treatment of imported malaria in children: an update.
    Archives of disease in childhood. Education and practice edition, 2013, Volume: 98, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Adult; Antimalarials; Artemisinins; Child; Drug T

2013
Diagnosis and treatment of Plasmodium vivax malaria.
    Advances in parasitology, 2012, Volume: 80

    Topics: Animals; Antimalarials; Drug Discovery; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; P

2012
G6PD deficiency: global distribution, genetic variants and primaquine therapy.
    Advances in parasitology, 2013, Volume: 81

    Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Mutation; Prevalen

2013
Cerebral malaria owing to Plasmodium vivax: case report.
    Annals of tropical paediatrics, 2006, Volume: 26, Issue:2

    Topics: Animals; Antimalarials; Brain; Child, Preschool; Chloroquine; Humans; Malaria, Cerebral; Malaria, Vi

2006
Primaquine for preventing relapses in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Adult; Antimalarials; Child; Chloroquine; Humans; Malaria, Vivax; Primaquine; Randomized Controlled

2007
Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy.
    The American journal of tropical medicine and hygiene, 2007, Volume: 76, Issue:2

    Topics: Animals; Antimalarials; Body Weight; Brazil; Humans; India; Malaria, Vivax; Plasmodium vivax; Primaq

2007
Management of vivax malaria with primaquine.
    The Journal of infection, 2007, Volume: 55, Issue:3

    Topics: Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Primaquine

2007
Neglect of Plasmodium vivax malaria.
    Trends in parasitology, 2007, Volume: 23, Issue:11

    Topics: Animals; Antimanic Agents; Chloroquine; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2007
Primaquine resistance in Plasmodium vivax.
    The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:3

    Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

1996
Primaquine resistance in Plasmodium vivax.
    The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:3

    Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

1996
Primaquine resistance in Plasmodium vivax.
    The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:3

    Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

1996
Primaquine resistance in Plasmodium vivax.
    The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:3

    Topics: Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

1996
[The treatment of malaria].
    Nederlands tijdschrift voor geneeskunde, 1997, Sep-13, Volume: 141, Issue:37

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Malar

1997
[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax].
    Medecine tropicale : revue du Corps de sante colonial, 2000, Volume: 60, Issue:4

    Topics: Antimalarials; Chloroquine; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Humans;

2000
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
    Medecine tropicale : revue du Corps de sante colonial, 2001, Volume: 61, Issue:1

    Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Hu

2001

Trials

91 trials available for primaquine and Plasmodium vivax Malaria

ArticleYear
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
    PLoS neglected tropical diseases, 2021, Volume: 15, Issue:9

    Topics: Adolescent; Adult; Aged; Antimalarials; Cambodia; Child; Child, Preschool; Erythrocytes; Female; Gen

2021
Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.
    The Lancet. Infectious diseases, 2022, Volume: 22, Issue:3

    Topics: Antimalarials; Australia; Humans; Indonesia; Infant; Malaria, Falciparum; Malaria, Vivax; Primaquine

2022
Pharmacokinetics of chloroquine and primaquine in healthy volunteers.
    Malaria journal, 2022, Jan-08, Volume: 21, Issue:1

    Topics: Adult; Antimalarials; Brazil; Chloroquine; Cross-Over Studies; Dose-Response Relationship, Drug; Fem

2022
Higher-Dose Primaquine to Prevent Relapse of
    The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Directly Obser

2022
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).
    Trials, 2022, May-18, Volume: 23, Issue:1

    Topics: Antimalarials; Hemoglobinuria; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Male; Plasmodiu

2022
Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023, Volume: 130

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Humans; Malaria; Malari

2023
Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
    The Lancet. Infectious diseases, 2023, Volume: 23, Issue:10

    Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Malaria, Vivax

2023
Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.
    PLoS neglected tropical diseases, 2023, Volume: 17, Issue:9

    Topics: Afghanistan; Biological Assay; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, V

2023
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
    Lancet (London, England), 2023, Dec-02, Volume: 402, Issue:10417

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Australia; Humans; Malaria; Ma

2023
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.
    Nature communications, 2019, 12-06, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Female; Humans; Infant; Malaria, Vivax; M

2019
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
    Malaria journal, 2020, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Asymptomatic Infections; Female; Humans; Laos; Malar

2020
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Child; Female; Humans; Malaria, Falciparum

2020
Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria.
    Antimicrobial agents and chemotherapy, 2021, 10-18, Volume: 65, Issue:11

    Topics: Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Humans; Malaria, Vivax; Primaquine

2021
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.
    PLoS medicine, 2017, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ch

2017
Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
    PLoS neglected tropical diseases, 2017, Volume: 11, Issue:7

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; Child, Prescho

2017
Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial.
    Malaria journal, 2018, Jan-24, Volume: 17, Issue:1

    Topics: Adult; Aged; Artemisinins; Brazil; Chloroquine; Dose-Response Relationship, Drug; Drug Therapy, Comb

2018
The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.
    BMC medical ethics, 2018, 03-06, Volume: 19, Issue:1

    Topics: Biomedical Research; Double-Blind Method; Ethics, Research; Humans; Malaria, Vivax; Patient Selectio

2018
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
    Malaria journal, 2018, Mar-16, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Female; Humans; Infant; Inf

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs.
    The Journal of antimicrobial chemotherapy, 2018, 11-01, Volume: 73, Issue:11

    Topics: Adult; Antimalarials; Artemisinins; Artesunate; Cross-Over Studies; Drug Interactions; Drug Therapy,

2018
A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.
    Malaria journal, 2018, Sep-03, Volume: 17, Issue:1

    Topics: Adult; Aged; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; India; Malaria, Vivax;

2018
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure.
    International ophthalmology, 2019, Volume: 39, Issue:8

    Topics: Adult; Aminoquinolines; Antimalarials; Cornea; Dose-Response Relationship, Drug; Double-Blind Method

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind

2019
Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy,

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
    Lancet (London, England), 2019, 09-14, Volume: 394, Issue:10202

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Administration

2019
Blood stage of Plasmodium vivax in central China is still susceptible to chloroquine plus primaquine combination therapy.
    The American journal of tropical medicine and hygiene, 2013, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; China; Chloroquine; Drug Therapy, C

2013
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroqui

2013
A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia.
    The Journal of infectious diseases, 2013, Dec-01, Volume: 208, Issue:11

    Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Com

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China.
    Malaria journal, 2013, Nov-11, Volume: 12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Artemisinins; Child; Child, Preschool; China; Chloroquin

2013
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Lancet (London, England), 2014, Mar-22, Volume: 383, Issue:9922

    Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Brazil; Chloroquine; Dose-Response Relation

2014
Pharmacokinetic interactions between primaquine and chloroquine.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6

    Topics: Adult; Antimalarials; Chloroquine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Ma

2014
Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.
    The American journal of tropical medicine and hygiene, 2014, Volume: 91, Issue:1

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc

2014
Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1

    Topics: Administration, Oral; Adult; Antimalarials; Artemisinins; Artesunate; Cross-Over Studies; Drug Inter

2015
Confirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Adolescent; Adult; Anemia; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Fem

2015
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
    The Journal of infectious diseases, 2016, Mar-01, Volume: 213, Issue:5

    Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method;

2016
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
    The Journal of infectious diseases, 2016, Mar-01, Volume: 213, Issue:5

    Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method;

2016
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
    The Journal of infectious diseases, 2016, Mar-01, Volume: 213, Issue:5

    Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method;

2016
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
    The Journal of infectious diseases, 2016, Mar-01, Volume: 213, Issue:5

    Topics: Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Double-Blind Method;

2016
Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
    Malaria journal, 2015, Oct-30, Volume: 14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dia

2015
Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.
    BMC infectious diseases, 2015, Dec-07, Volume: 15

    Topics: Afghanistan; Antimalarials; Double-Blind Method; Ethiopia; Glucosephosphate Dehydrogenase; Humans; I

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    Malaria journal, 2016, Feb-18, Volume: 15

    Topics: Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax

2016
Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment.
    Malaria journal, 2016, Sep-17, Volume: 15

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Chloroquine; Female; Humans; Malaria, Vivax; Male; M

2016
Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
    PLoS medicine, 2017, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Cohort Studies; Dose-Response Relationshi

2017
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, Volume: 102, Issue:11

    Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female;

2008
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, Volume: 102, Issue:11

    Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female;

2008
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, Volume: 102, Issue:11

    Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female;

2008
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, Volume: 102, Issue:11

    Topics: Adult; Aminoquinolines; Animals; Antimalarials; Australia; Dose-Response Relationship, Drug; Female;

2008
A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.
    PloS one, 2008, Aug-06, Volume: 3, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Drug Adm

2008
Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment.
    The American journal of tropical medicine and hygiene, 2009, Volume: 80, Issue:2

    Topics: Adult; Animals; Antimalarials; Drug Administration Schedule; Female; Glucosephosphate Dehydrogenase;

2009
Prevention of Plasmodium vivax malaria recurrence: efficacy of the standard total dose of primaquine administered over 3 days.
    Acta tropica, 2009, Volume: 112, Issue:2

    Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Child; Child, Preschool; Colombia; Female; Humans

2009
Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.
    Acta tropica, 2010, Volume: 113, Issue:2

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug

2010
A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand.
    The American journal of tropical medicine and hygiene, 2010, Volume: 82, Issue:4

    Topics: Adolescent; Adult; Animals; Antimalarials; Dose-Response Relationship, Drug; Drug Administration Sch

2010
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
    The Lancet. Infectious diseases, 2010, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr

2010
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
    The Lancet. Infectious diseases, 2010, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr

2010
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
    The Lancet. Infectious diseases, 2010, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr

2010
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
    The Lancet. Infectious diseases, 2010, Volume: 10, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr

2010
Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
    Malaria journal, 2010, Nov-01, Volume: 9

    Topics: Adolescent; Antimalarials; Child; Child, Preschool; Chloroquine; Directly Observed Therapy; Female;

2010
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:2 Suppl

    Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria

2011
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:2 Suppl

    Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria

2011
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:2 Suppl

    Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria

2011
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:2 Suppl

    Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria

2011
Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011, Volume: 105, Issue:10

    Topics: Abdominal Pain; Adult; Antimalarials; Cyanosis; Drug Administration Schedule; Female; Headache; Huma

2011
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Female; Genotype; Genotyping Techniq

2012
Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
    The Journal of infectious diseases, 2012, Dec-01, Volume: 206, Issue:11

    Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; Female; Humans

2012
Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana.
    Malaria journal, 2012, Oct-19, Volume: 11

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ch

2012
Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:3

    Topics: Adult; Antimalarials; Artemisinins; Artesunate; Drug Administration Schedule; Drug Dosage Calculatio

2013
In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combinat

2013
Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India.
    The Journal of parasitology, 2002, Volume: 88, Issue:5

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Endemic Diseases; F

2002
Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.
    The American journal of tropical medicine and hygiene, 2003, Volume: 69, Issue:1

    Topics: Administration, Oral; Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Drug Administrat

2003
Compliance with 14-day primaquine therapy for radical cure of vivax malaria--a randomized placebo-controlled trial comparing unsupervised with supervised treatment.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, Volume: 98, Issue:3

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Cluster Analysis; Directly Observed

2004
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-15, Volume: 39, Issue:8

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe

2004
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-15, Volume: 39, Issue:8

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe

2004
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-15, Volume: 39, Issue:8

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe

2004
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-15, Volume: 39, Issue:8

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Fe

2004
Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2004, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Resist

2004
Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army.
    Journal of Korean medical science, 2005, Volume: 20, Issue:5

    Topics: Antimalarials; Chemoprevention; Chloroquine; Disease Outbreaks; Humans; Incidence; Korea; Malaria, V

2005
A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.
    The American journal of tropical medicine and hygiene, 2005, Volume: 73, Issue:6

    Topics: Adult; Aged; Animals; Antimalarials; Azithromycin; Chloroquine; Double-Blind Method; Drug Administra

2005
Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.
    The Korean journal of parasitology, 2006, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male; Middle

2006
Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
    The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:4

    Topics: Adult; Animals; Antimalarials; Chloroquine; Colombia; Female; Follow-Up Studies; Humans; Malaria, Vi

2006
[Plasmodium vivax malaria: treatment of primary attacks with primaquine, in three different doses, and a fixed dose of chloroquine, Antioquia, Colombia, 2003-2004].
    Biomedica : revista del Instituto Nacional de Salud, 2006, Volume: 26, Issue:3

    Topics: Acute Disease; Adult; Antimalarials; Chloroquine; Colombia; Female; Humans; Malaria, Vivax; Male; Pr

2006
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
    The Journal of infectious diseases, 2007, Apr-01, Volume: 195, Issue:7

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; DNA Primers; Humans; India; Malaria,

2007
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
    The Korean journal of parasitology, 2007, Volume: 45, Issue:2

    Topics: Adolescent; Aged; Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Therapy, Combi

2007
High-dose primaquine regimens against relapse of Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe

2008
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
    Lancet (London, England), 1995, Nov-04, Volume: 346, Issue:8984

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu

1995
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
    Lancet (London, England), 1995, Nov-04, Volume: 346, Issue:8984

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu

1995
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
    Lancet (London, England), 1995, Nov-04, Volume: 346, Issue:8984

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu

1995
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
    Lancet (London, England), 1995, Nov-04, Volume: 346, Issue:8984

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu

1995
Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.
    The American journal of tropical medicine and hygiene, 1995, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Animals; Anopheles; Child; Chloroquine; Confounding Factors, Epidemiologic; Drug

1995
Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.
    The American journal of tropical medicine and hygiene, 1995, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Child; Chloroquine; Drug Therapy, Combination; Female; Germany; Humans; Mal

1995
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine.
    The Journal of infectious diseases, 1995, Volume: 171, Issue:6

    Topics: Adolescent; Animals; Child; Chloroquine; Drug Administration Schedule; Drug Resistance; Drug Therapy

1995
Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:4

    Topics: Adolescent; Adult; Animals; Chloroquine; Drug Resistance; Drug Therapy, Combination; Follow-Up Studi

1994
[Halofantrine in the treatment of imported malaria in nonimmune travelers].
    Deutsche medizinische Wochenschrift (1946), 1993, Feb-26, Volume: 118, Issue:8

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Drug Therapy, Combination; Drug Tolerance; Female;

1993
Recent military experience with malaria chemoprophylaxis.
    The Medical journal of Australia, 1993, Apr-05, Volume: 158, Issue:7

    Topics: Antimalarials; Australia; Chloroquine; Dapsone; Doxycycline; Drug Administration Schedule; Drug Comb

1993
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis.
    The American journal of tropical medicine and hygiene, 1997, Volume: 56, Issue:2

    Topics: Antimalarials; Chloroquine; Disease Susceptibility; Follow-Up Studies; Humans; Incidence; Indonesia;

1997
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
    Annals of tropical medicine and parasitology, 1997, Volume: 91, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia;

1997
Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.
    Annals of internal medicine, 1998, Aug-01, Volume: 129, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Colombia; Double-Blind Method; Gastrointestinal Diseases; Humans;

1998
The effect of drug packaging on patients' compliance with treatment for Plasmodium vivax malaria in China.
    Bulletin of the World Health Organization, 1998, Volume: 76 Suppl 1

    Topics: Adolescent; Adult; Analysis of Variance; Antimalarials; China; Chloroquine; Drug Packaging; Female;

1998
Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Volume: 29, Issue:1

    Topics: Antimalarials; Chloroquine; Colombia; Double-Blind Method; Humans; Malaria; Malaria, Falciparum; Mal

1999
Chloroquine sensitivity of Plasmodium vivax in Thailand.
    Annals of tropical medicine and parasitology, 1999, Volume: 93, Issue:3

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Mala

1999
Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.
    The American journal of tropical medicine and hygiene, 1999, Volume: 61, Issue:6

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug R

1999
Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.
    Annals of tropical medicine and parasitology, 1999, Volume: 93, Issue:8

    Topics: Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Combination; Humans; India;

1999
Plasmodium vivax clinically resistant to chloroquine in Colombia.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma

2001
Plasmodium vivax clinically resistant to chloroquine in Colombia.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma

2001
Plasmodium vivax clinically resistant to chloroquine in Colombia.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma

2001
Plasmodium vivax clinically resistant to chloroquine in Colombia.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma

2001
Plasmodium vivax polymorphism in a clinical drug trial.
    Clinical and diagnostic laboratory immunology, 2001, Volume: 8, Issue:5

    Topics: Administration, Oral; Animals; Antimalarials; Double-Blind Method; Drug Administration Schedule; Dru

2001
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
    Medecine tropicale : revue du Corps de sante colonial, 2001, Volume: 61, Issue:1

    Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Hu

2001
Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
    Annals of tropical medicine and parasitology, 2001, Volume: 95, Issue:7

    Topics: Antimalarials; Drug Administration Schedule; Follow-Up Studies; Humans; India; Malaria, Vivax; Prima

2001

Other Studies

327 other studies available for primaquine and Plasmodium vivax Malaria

ArticleYear
Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria.
    Malaria journal, 2021, Sep-09, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Body Weight; Child; Child, P

2021
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
    Parasites & vectors, 2021, Oct-24, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Cross-Sectional Studies; Disease Eradicat

2021
Primaquine and the power of adherence in radical cure.
    The Lancet. Infectious diseases, 2022, Volume: 22, Issue:3

    Topics: Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2022
A Profile of Glucose-6-Phosphate Dehydrogenase Variants and Deficiency of Multicultural Families in Korea.
    The Korean journal of parasitology, 2021, Volume: 59, Issue:5

    Topics: Adolescent; Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency

2021
Frequency of Electrocardiographic Alterations and Pericardial Effusion in Patients With Uncomplicated Malaria.
    The American journal of cardiology, 2022, 02-15, Volume: 165

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Brazil; Case-Control Studies; Chlor

2022
Measurements of 5,6-Orthoquinone, a Surrogate for the Presumed Active Primaquine Metabolite 5-Hydroxyprimaquine, in the Urine of Cambodian Adults.
    Antimicrobial agents and chemotherapy, 2022, 03-15, Volume: 66, Issue:3

    Topics: Adult; Antimalarials; Asian People; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Plasmodium viva

2022
Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
    The American journal of tropical medicine and hygiene, 2022, 01-10, Volume: 106, Issue:3

    Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Malaria, Vivax; Plasmodiu

2022
Active Pharmacovigilance for Primaquine Radical Cure of Plasmodium vivax Malaria in Odisha, India.
    The American journal of tropical medicine and hygiene, 2022, 01-10, Volume: 106, Issue:3

    Topics: Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hemolysi

2022
Prevalence of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency among Malaria Patients in Southern Thailand: 8 Years Retrospective Study.
    The Korean journal of parasitology, 2022, Volume: 60, Issue:1

    Topics: Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Malaria,

2022
Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
    The Korean journal of parasitology, 2022, Volume: 60, Issue:1

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax;

2022
Real-life quantitative G6PD screening in Plasmodium vivax patients in the Brazilian Amazon: A cost-effectiveness analysis.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:3

    Topics: Antimalarials; Brazil; Cost-Benefit Analysis; Glucosephosphate Dehydrogenase Deficiency; Humans; Mal

2022
Primaquine and
    The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13

    Topics: Antimalarials; Brazil; Humans; Malaria, Vivax; Primaquine; Reinfection

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Cost-effectiveness analysis of G6PD diagnostic test for Plasmodium vivax radical cure in Lao PDR: An economic modelling study.
    PloS one, 2022, Volume: 17, Issue:4

    Topics: Antimalarials; Cost-Benefit Analysis; Diagnostic Tests, Routine; Female; Glucosephosphate Dehydrogen

2022
Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study.
    Revista da Sociedade Brasileira de Medicina Tropical, 2022, Volume: 55

    Topics: Antimalarials; Cohort Studies; Humans; Malaria, Vivax; Primaquine; Recurrence

2022
Tafenoquine for the prevention of Plasmodium vivax malaria relapse.
    The Lancet. Microbe, 2021, Volume: 2, Issue:5

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence

2021
Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:5

    Topics: Antimalarials; Cross-Sectional Studies; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogena

2022
Mechanisms of 8-aminoquinoline induced haemolytic toxicity in a G6PDd humanized mouse model.
    Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:13

    Topics: Aminoquinolines; Animals; Antimalarials; Disease Models, Animal; Glucosephosphate Dehydrogenase Defi

2022
Cost-Benefit Analysis of Tafenoquine for Radical Cure of
    Journal of Korean medical science, 2022, Jul-11, Volume: 37, Issue:27

    Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Primaquine; Recurrenc

2022
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2022, 07-21, Volume: 387, Issue:3

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2022, 07-21, Volume: 387, Issue:3

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
    The New England journal of medicine, 2022, 07-21, Volume: 387, Issue:3

    Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
    Infection, 2023, Volume: 51, Issue:1

    Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; He

2023
An Evaluation of a New Quantitative Point-of Care Diagnostic to Measure Glucose-6-phosphate Dehydrogenase Activity.
    The Korean journal of parasitology, 2022, Volume: 60, Issue:4

    Topics: Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Ma

2022
Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.
    Malaria journal, 2022, Sep-08, Volume: 21, Issue:1

    Topics: Antimalarials; Cross-Sectional Studies; Ethiopia; Female; Glucosephosphate Dehydrogenase Deficiency;

2022
How does primaquine prevent Plasmodium vivax malarial recurrences?
    Trends in parasitology, 2022, Volume: 38, Issue:11

    Topics: Animals; Antimalarials; Malaria, Vivax; Mice; Plasmodium vivax; Primaquine; Recurrence

2022
Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia.
    Malaria journal, 2022, Oct-04, Volume: 21, Issue:1

    Topics: Antimalarials; Biosensing Techniques; Cambodia; Glucosephosphate Dehydrogenase; Glucosephosphate Deh

2022
Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
    Malaria journal, 2022, Oct-10, Volume: 21, Issue:1

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Cytochrome P450 Family 2; Humans; Malaria, Vivax; Phenotype;

2022
G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Adult; Antimalarials; Cambodia; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Defic

2022
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
    The Lancet. Infectious diseases, 2023, Volume: 23, Issue:4

    Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M

2023
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
    The Lancet. Infectious diseases, 2023, Volume: 23, Issue:4

    Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M

2023
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
    The Lancet. Infectious diseases, 2023, Volume: 23, Issue:4

    Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M

2023
Moving towards malaria elimination with safer treatment for children with G6PD deficiency.
    The Lancet. Infectious diseases, 2023, Volume: 23, Issue:4

    Topics: Child; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; M

2023
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:12

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis

2022
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:12

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis

2022
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:12

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis

2022
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
    PLoS neglected tropical diseases, 2022, Volume: 16, Issue:12

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Genetic Variation; Glucosephosphate Dehydrogenase; Hemolysis

2022
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
    The American journal of tropical medicine and hygiene, 2023, 01-11, Volume: 108, Issue:1

    Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal

2023
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
    The American journal of tropical medicine and hygiene, 2023, 01-11, Volume: 108, Issue:1

    Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal

2023
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
    The American journal of tropical medicine and hygiene, 2023, 01-11, Volume: 108, Issue:1

    Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal

2023
Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
    The American journal of tropical medicine and hygiene, 2023, 01-11, Volume: 108, Issue:1

    Topics: Antimalarials; Australia; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria; Mal

2023
Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
    Frontiers in cellular and infection microbiology, 2022, Volume: 12

    Topics: Animals; Antimalarials; Chloroquine; Copper; Malaria, Falciparum; Malaria, Vivax; Mice; Oocysts; Par

2022
Performance of a Commercial Multiplex Allele-Specific Polymerase Chain Reaction Kit to Genotype African-Type Glucose-6-Phosphate Dehydrogenase Deficiency.
    The American journal of tropical medicine and hygiene, 2023, 02-01, Volume: 108, Issue:2

    Topics: Alleles; Antimalarials; Female; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydroge

2023
Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.
    Malaria journal, 2023, Jan-13, Volume: 22, Issue:1

    Topics: Antimalarials; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hum

2023
Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.
    The American journal of tropical medicine and hygiene, 2023, 03-01, Volume: 108, Issue:3

    Topics: Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Ma

2023
Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc.
    Antimicrobial agents and chemotherapy, 2023, 04-18, Volume: 67, Issue:4

    Topics: Animals; Antimalarials; Culicidae; High-Throughput Screening Assays; Humans; Malaria; Malaria, Falci

2023
Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.
    Scientific reports, 2023, 04-12, Volume: 13, Issue:1

    Topics: Antimalarials; Child; Child, Preschool; Cross-Sectional Studies; Glucosephosphate Dehydrogenase Defi

2023
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response.
    Malaria journal, 2023, Apr-25, Volume: 22, Issue:1

    Topics: Antimalarials; Chloroquine; Ethiopia; Humans; Malaria, Vivax; Parasitemia; Plasmodium vivax; Primaqu

2023
Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar.
    Malaria journal, 2023, May-01, Volume: 22, Issue:1

    Topics: Cross-Sectional Studies; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase De

2023
Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study.
    Malaria journal, 2023, May-20, Volume: 22, Issue:1

    Topics: Antimalarials; Humans; Indonesia; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine

2023
Short-course, high-dose primaquine regimens for the treatment of liver-stage vivax malaria in children.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023, Volume: 134

    Topics: Antimalarials; Child; Humans; Liver; Malaria, Vivax; Plasmodium vivax; Primaquine; Treatment Outcome

2023
Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.
    PLoS neglected tropical diseases, 2023, Volume: 17, Issue:6

    Topics: Animals; Anopheles; Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; P

2023
Primaquine and chloroquine nano-sized solid dispersion-loaded dissolving microarray patches for the improved treatment of malaria caused by Plasmodium vivax.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 361

    Topics: Animals; Antimalarials; Chloroquine; Malaria, Vivax; Mice; Plasmodium vivax; Primaquine; Rats

2023
Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses.
    The American journal of tropical medicine and hygiene, 2023, 10-04, Volume: 109, Issue:4

    Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria, Vivax; Plasmod

2023
A fatal respiratory complication of malaria caused by Plasmodium vivax.
    Malaria journal, 2023, Oct-09, Volume: 22, Issue:1

    Topics: Adult; Antimalarials; Female; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine

2023
Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.
    Malaria journal, 2023, Oct-09, Volume: 22, Issue:1

    Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Medication Adherence; Myanmar; Plasmodium vivax; Pri

2023
Clinical performance validation of the STANDARD G6PD test: A multi-country pooled analysis.
    PLoS neglected tropical diseases, 2023, Volume: 17, Issue:10

    Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Primaquine

2023
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    BMC infectious diseases, 2019, Aug-09, Volume: 19, Issue:1

    Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Cytochrome P-450 CYP2D6; Ghana; Humans; Inacti

2019
Killing of Plasmodium vivax by Primaquine and Tafenoquine.
    Trends in parasitology, 2019, Volume: 35, Issue:11

    Topics: Aminoquinolines; Antimalarials; Humans; Hydrogen Peroxide; Malaria, Vivax; Plasmodium vivax; Primaqu

2019
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
    Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:1

    Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Markov Chains; Monte

2020
Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.
    The Journal of infectious diseases, 2019, 10-22, Volume: 220, Issue:11

    Topics: Adolescent; Adult; Antimalarials; Asian People; Chemoprevention; Child; Child, Preschool; Female; Gl

2019
Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia.
    Malaria journal, 2019, Oct-07, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Ethiopia; Female

2019
Multiple Splenic Infarcts Complicating Plasmodium vivax Malaria.
    Pediatric emergency care, 2019, Volume: 35, Issue:10

    Topics: Acute Kidney Injury; Administration, Intravenous; Administration, Oral; Adolescent; Antimalarials; A

2019
Declining Burden of
    The American journal of tropical medicine and hygiene, 2020, Volume: 102, Issue:1

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Retrospective Studies; Thailand

2020
Vivax malaria in pregnancy and lactation: a long way to health equity.
    Malaria journal, 2020, Jan-22, Volume: 19, Issue:1

    Topics: Adolescent; Aminoquinolines; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Femal

2020
Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adult; Cambodia; Diagnostic Tests, Routine; Female; Glucosephosphate Dehydrogenase; Glucosephosphate

2020
Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Antimicrobial agents and chemotherapy, 2020, 04-21, Volume: 64, Issue:5

    Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Brazil; Child; Cytochrome P-450 CYP2D6; Fem

2020
Cost-Effectiveness Analysis of Sex-Stratified
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1

    Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Ana

2020
Case Report: Primaquine Failure for Radical Cure of
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1

    Topics: Adult; Antimalarials; Chemoprevention; Chloroquine; Ethiopia; Humans; Malaria, Vivax; Male; Middle A

2020
Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:2

    Topics: Antimalarials; Artemisinins; Asian People; Cambodia; Cytochrome P-450 CYP2D6; Drug Therapy, Combinat

2020
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 09-01, Volume: 114, Issue:9

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Cytochrome P-450 CYP2D6

2020
Primaquine for Plasmodium vivax malaria treatment.
    Lancet (London, England), 2020, 06-27, Volume: 395, Issue:10242

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2020
Primaquine for Plasmodium vivax malaria treatment - Authors' reply.
    Lancet (London, England), 2020, 06-27, Volume: 395, Issue:10242

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2020
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Malaria journal, 2020, Jul-17, Volume: 19, Issue:1

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Phenotype; Plasmodium vivax;

2020
Increasing Malaria Parasite Clearance Time after Chloroquine Therapy, South Korea, 2000-2016.
    Emerging infectious diseases, 2020, Volume: 26, Issue:8

    Topics: Animals; Antimalarials; Chloroquine; Drug Therapy, Combination; Malaria; Malaria, Vivax; Parasites;

2020
Doses of primaquine administered to children with
    Pathogens and global health, 2020, Volume: 114, Issue:7

    Topics: Adolescent; Antimalarials; Child; Child, Preschool; Drug Administration Schedule; Humans; Infant; Ma

2020
Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
    PLoS neglected tropical diseases, 2020, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Brazil; Case-Control Studies; Child; Chloroquine; Female; Humans;

2020
Mass radical treatment of a group of foreign workers to mitigate the risk of re-establishment of malaria in Sri Lanka.
    Malaria journal, 2020, Sep-25, Volume: 19, Issue:1

    Topics: Antimalarials; Chloroquine; Humans; India; Malaria, Vivax; Mass Drug Administration; Plasmodium viva

2020
Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:4

    Topics: Adult; Antimalarials; Brazil; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Humans; Malaria, Vi

2021
Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2020, Volume: 62

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, V

2020
The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
    PLoS neglected tropical diseases, 2020, Volume: 14, Issue:11

    Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Administration Schedule; Drug

2020
Liver-targeted polymeric prodrugs of 8-aminoquinolines for malaria radical cure.
    Journal of controlled release : official journal of the Controlled Release Society, 2021, 03-10, Volume: 331

    Topics: Aminoquinolines; Animals; Antimalarials; Liver; Malaria; Malaria, Vivax; Mice; Mice, Inbred NOD; Mic

2021
Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters.
    International journal for parasitology. Drugs and drug resistance, 2021, Volume: 15

    Topics: Animals; Antimalarials; Humans; Liver; Malaria, Vivax; Parasites; Plasmodium vivax; Primaquine

2021
Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 105

    Topics: Adult; Aminoquinolines; Artemisinins; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Peru; Pla

2021
Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study).
    PLoS neglected tropical diseases, 2021, Volume: 15, Issue:5

    Topics: Antimalarials; Brazil; Glucosephosphate Dehydrogenase Deficiency; Health Personnel; Hemolysis; Human

2021
Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
    PLoS medicine, 2021, Volume: 18, Issue:6

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Clinical Decision-Making; Cost Savings; C

2021
Treatment of relapsing Plasmodium vivax malaria during pregnancy.
    Journal of travel medicine, 2021, Jul-07, Volume: 28, Issue:5

    Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaqu

2021
Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria.
    Malaria journal, 2021, Jun-13, Volume: 20, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria, Vivax; Male; Middle A

2021
The mystery of 'saturation gap' and falsely normal G6PD: a case of primaquine-induced haemolysis in Plasmodium vivax malaria infection.
    The journal of the Royal College of Physicians of Edinburgh, 2021, Volume: 51, Issue:2

    Topics: Antimalarials; Glucosephosphate Dehydrogenase; Hemolysis; Humans; Malaria; Malaria, Vivax; Primaquin

2021
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 04-09, Volume: 74, Issue:7

    Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Plasmodium ovale; Plasmodium vivax;

2022
Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria.
    PLoS neglected tropical diseases, 2021, Volume: 15, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Female; Gene Expression Regulation

2021
Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases.
    Malaria journal, 2021, Aug-14, Volume: 20, Issue:1

    Topics: Adult; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Humans; Malaria, Vivax; Ma

2021
Case report of Plasmodium ovale curtisi malaria in Sri Lanka: relevance for the maintenance of elimination status.
    BMC infectious diseases, 2017, 04-24, Volume: 17, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Fever; Humans; Liberia; Malaria; Malaria, Vivax; Male; Molecular

2017
Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to
    The American journal of tropical medicine and hygiene, 2017, Volume: 96, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Brazil; Chloroquine; Drug Administration Schedule; Drug Therapy, C

2017
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
    PLoS neglected tropical diseases, 2017, Volume: 11, Issue:5

    Topics: Adult; Antimalarials; Cost-Benefit Analysis; Diagnostic Tests, Routine; Female; Glucosephosphate Deh

2017
Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
    Malaria journal, 2017, 05-30, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Drug Resistance; Follow-Up Studies; Genotype; Huma

2017
G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.
    Malaria journal, 2017, 06-15, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Hemolytic; Antimalarials; Brazil; Cross

2017
An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman.
    Parasite (Paris, France), 2017, Volume: 24

    Topics: Adult; Animals; Anopheles; Antigens, Protozoan; Antimalarials; Chloroquine; Communicable Diseases, E

2017
Barriers to routine G6PD testing prior to treatment with primaquine.
    Malaria journal, 2017, 08-10, Volume: 16, Issue:1

    Topics: Administrative Personnel; Bangladesh; Cambodia; China; Diagnostic Tests, Routine; Glucosephosphate D

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Implementation of G6PD testing and primaquine for
    WHO South-East Asia journal of public health, 2017, Volume: 6, Issue:2

    Topics: Antimalarials; Cambodia; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax;

2017
Analysis of Plasmodium vivax Chloroquine Resistance Transporter Mutant Isoforms.
    Biochemistry, 2017, 10-17, Volume: 56, Issue:41

    Topics: Amino Acid Substitution; Antimalarials; Biological Transport; Cell Membrane; Chloroquine; Colony Cou

2017
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
    Pharmacogenomics, 2017, Volume: 18, Issue:15

    Topics: Adult; Antimalarials; Brazil; Chloroquine; Drug Therapy, Combination; Female; Genotype; Humans; Live

2017
Malaria cases in Switzerland from 2005 to 2015 and recent rise of imported Plasmodium vivax malaria.
    Swiss medical weekly, 2017, Volume: 147

    Topics: Eritrea; Humans; Incidence; Liechtenstein; Malaria, Vivax; Plasmodium vivax; Primaquine; Refugees; S

2017
A clinical tool to predict Plasmodium vivax recurrence in Malaysia.
    BMC infectious diseases, 2017, 12-08, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Area Under Curve; Child; Chi

2017
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
    Malaria journal, 2018, Jan-22, Volume: 17, Issue:1

    Topics: Antimalarials; Asia, Southeastern; Cytochrome P-450 CYP2D6; Glucosephosphate Dehydrogenase Deficienc

2018
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
    Malaria journal, 2018, Feb-01, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Cytochrome P-450 CYP

2018
Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 09-14, Volume: 67, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Breast Feeding; Child, Preschool; Female; Humans

2018
Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 09-14, Volume: 67, Issue:7

    Topics: Antimalarials; Female; Humans; Infant; Lactation; Malaria, Vivax; Plasmodium vivax; Primaquine

2018
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
    PLoS neglected tropical diseases, 2018, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency

2018
Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.
    PloS one, 2018, Volume: 13, Issue:5

    Topics: Adult; Aminoquinolines; Antimalarials; Area Under Curve; Biosensing Techniques; Clinical Enzyme Test

2018
A Malaria Case Followed By Relapse.
    Turkiye parazitolojii dergisi, 2018, Volume: 42, Issue:2

    Topics: Animals; Anopheles; Antimalarials; Chronic Disease; Diagnosis, Differential; Humans; Malaria, Vivax;

2018
Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison.
    Malaria journal, 2018, Jun-19, Volume: 17, Issue:1

    Topics: Adult; Antimalarials; Dose-Response Relationship, Drug; Female; French Guiana; Humans; Malaria, Viva

2018
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.
    Malaria journal, 2018, Jun-20, Volume: 17, Issue:1

    Topics: Antimalarials; Asia; Humans; Malaria, Vivax; Pacific Islands; Plasmodium vivax; Primaquine; Treatmen

2018
Improving Plasmodium vivax malaria treatment: a little more chloroquine.
    The Lancet. Infectious diseases, 2018, Volume: 18, Issue:9

    Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine

2018
Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities.
    International health, 2019, 01-01, Volume: 11, Issue:1

    Topics: Africa; Aminoquinolines; Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Health Kn

2019
A 38-year-old man with fever and a history of malaria.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2018, 09-10, Volume: 190, Issue:36

    Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Malaria, Vivax; Male; Pri

2018
Levels of primaquine and carboxyprimaquine in patients with malaria vivax from the Brazilian Amazon basin.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2018, Oct-25, Volume: 60

    Topics: Adult; Antimalarials; Brazil; Chromatography, High Pressure Liquid; Drug Administration Schedule; Dr

2018
G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
    Malaria journal, 2018, Nov-08, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Female; Glucosephosphate Dehydrogenase Deficiency; He

2018
Concomitant
    BMJ case reports, 2018, Dec-09, Volume: 11, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antimalarials; Chloroquine; Coinfection; Female; Fever; Humans; Malari

2018
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    JAMA network open, 2018, 08-03, Volume: 1, Issue:4

    Topics: Adult; Antimalarials; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Malar

2018
Tafenoquine - A Radical Improvement?
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence

2019
Evaluation of Plasmodium vivax malaria recurrence in Brazil.
    Malaria journal, 2019, Jan-22, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Brazil; Child; Child, Presc

2019
Clinical Spectrum of Primaquine-induced Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency: A 9-Year Hospitalization-based Study From the Brazilian Amazon.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 09-27, Volume: 69, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Brazil; Child; Child, Preschool;

2019
Factors associated with children's health facility visits for primaquine treatment in rural Papua New Guinea.
    Malaria journal, 2019, Feb-20, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Child; Child Health; Child, Preschool; Cross-Sectional Studies; Fe

2019
Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment.
    Infection, 2019, Volume: 47, Issue:4

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Italy; Malaria, Vivax

2019
Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030.
    Malaria journal, 2019, Mar-12, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Disease Eradication; Female; Ge

2019
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
    The Journal of infectious diseases, 2019, 07-02, Volume: 220, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Drug Therapy, Combination; Female; F

2019
Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia.
    Malaria journal, 2019, Apr-02, Volume: 18, Issue:1

    Topics: Antimalarials; Female; Hematologic Diseases; Hemolysis; Humans; Indonesia; Infant; Infant, Newborn;

2019
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
    Malaria journal, 2019, Apr-18, Volume: 18, Issue:1

    Topics: Alleles; Antimalarials; Australia; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Military Personn

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
    The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2019
Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam.
    PLoS medicine, 2019, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedule

2019
A shorter course for anti-relapse therapy against vivax malaria.
    Lancet (London, England), 2019, 09-14, Volume: 394, Issue:10202

    Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Primaquine; Recurrence

2019
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
    Emerging infectious diseases, 2013, Volume: 19, Issue:5

    Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Drug Tolerance; Genome, Protozoan; High-Throug

2013
Assessment of the efficacy of 8 weeks of primaquine for the prevention of relapse in vivax malaria patients using SSCP-PCR and sequencing in South and South-East Iran, 2008-2011.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, Volume: 107, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; DNA, Protozoan; Drug Administration Sched

2013
Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
    Scandinavian journal of infectious diseases, 2014, Volume: 46, Issue:1

    Topics: Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaqu

2014
The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana.
    Malaria journal, 2013, Oct-24, Volume: 12

    Topics: Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Prescriptions; Female; Follow-Up Studie

2013
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1

    Topics: Antimalarials; Child; Drug Administration Schedule; Female; Humans; Malaria, Vivax; Male; Primaquine

2014
Population structure and spatio-temporal transmission dynamics of Plasmodium vivax after radical cure treatment in a rural village of the Peruvian Amazon.
    Malaria journal, 2014, Jan-06, Volume: 13

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Cohort Studies; Female; Gene

2014
Paucity of Plasmodium vivax mature schizonts in peripheral blood is associated with their increased cytoadhesive potential.
    The Journal of infectious diseases, 2014, May-01, Volume: 209, Issue:9

    Topics: Antimalarials; Cell Adhesion; Chloroquine; Erythrocytes; Humans; Malaria, Vivax; Parasitemia; Plasmo

2014
Hemophagocytic syndrome associated with severe Plasmodium vivax malaria in a child in Bikaner (northwestern India).
    Journal of vector borne diseases, 2013, Volume: 50, Issue:4

    Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Biopsy, Needle; Bone Marrow; Child; Ethanolamin

2013
A population survey of the glucose-6-phosphate dehydrogenase (G6PD) 563C>T (Mediterranean) mutation in Afghanistan.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Afghanistan; DNA Primers; Genotype; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase D

2014
Validation of a method for the simultaneous quantification of chloroquine, desethylchloroquine and primaquine in plasma by HPLC-DAD.
    Journal of pharmaceutical and biomedical analysis, 2014, Volume: 95

    Topics: Calibration; Chloroquine; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Malaria,

2014
Improving the radical cure of Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2014, Volume: 91, Issue:1

    Topics: Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male; Primaquine

2014
Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti.
    The American journal of tropical medicine and hygiene, 2014, Volume: 91, Issue:1

    Topics: Adolescent; Antimalarials; Child; Contraindications; Enzyme Assays; Female; Glucosephosphate Dehydro

2014
Imported malaria is stable from Africa but declining from Asia.
    Danish medical journal, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Asia; Atovaquone; Chemoprevention; Child; Child, Pre

2014
Quality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chain.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Amodiaquine; Amoxicillin; Antimalarials; Artemether; Artemisinins; Biosimilar Pharmaceuticals; Chlor

2014
First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Base Sequence; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Molecular Sequence

2014
High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon.
    The American journal of tropical medicine and hygiene, 2014, Volume: 91, Issue:1

    Topics: Adolescent; Adult; Aged; Antimalarials; Blood Glucose; Brazil; Child; Contraindications; Diabetes Co

2014
Hemophagocytic syndrome in Plasmodium vivax malaria.
    Journal of vector borne diseases, 2014, Volume: 51, Issue:2

    Topics: Artemisinins; Ceftriaxone; Child; Female; Hemoglobins; Humans; India; Leukocyte Count; Lymphohistioc

2014
Compliance to recommendations for the management of curative treatment of Plasmodium vivax/ovale infections.
    Medecine et maladies infectieuses, 2014, Volume: 44, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Guideline Adherence; Humans; Malaria; Malaria,

2014
[Two imported and relapsed of Plasmodium vivax malaria cases and primaquine prophylaxis].
    Turkiye parazitolojii dergisi, 2014, Volume: 38, Issue:2

    Topics: Antimalarials; Chloroquine; Humans; Life Cycle Stages; Liver; Malaria, Vivax; Male; Plasmodium vivax

2014
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
    Malaria journal, 2014, Jul-22, Volume: 13

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini

2014
Primaquine-induced severe methemoglobinemia developed during treatment of Plasmodium vivax malarial infection in an Indian family associated with a novel mutation (p.Agr57Trp) in the CYB5R3 gene.
    Clinica chimica acta; international journal of clinical chemistry, 2014, Nov-01, Volume: 437

    Topics: Adolescent; Adult; Cytochrome-B(5) Reductase; Female; Humans; India; Malaria, Vivax; Male; Methemogl

2014
Evaluation of antimalarial activity and toxicity of a new primaquine prodrug.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Aedes; Animals; Antimalarials; Cell Line; Chloroquine; Dipeptides; Glucosephosphate Dehydrogenase; H

2014
Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:12

    Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Administration Schedule; Drug Ther

2014
Interactive medical case. A chilly fever.
    The New England journal of medicine, 2014, Oct-16, Volume: 371, Issue:16

    Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Life Cycle Stages; Malari

2014
The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
    Malaria journal, 2014, Dec-12, Volume: 13

    Topics: Antimalarials; Doxycycline; Female; Humans; Malaria, Vivax; Middle Aged; New Zealand; Papua New Guin

2014
Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Female; Genotype; Huma

2015
Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests.
    The American journal of tropical medicine and hygiene, 2015, Volume: 92, Issue:4

    Topics: Aminoquinolines; Antimalarials; Capillaries; Clinical Enzyme Tests; Erythrocytes; Female; Glucosepho

2015
G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
    PLoS neglected tropical diseases, 2015, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Female;

2015
Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo.
    PLoS neglected tropical diseases, 2015, Volume: 9, Issue:3

    Topics: Aged; Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Female; Humans; Liver; Malaria,

2015
Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice.
    Cell host & microbe, 2015, Apr-08, Volume: 17, Issue:4

    Topics: Animals; Antimalarials; Chemoprevention; Chimera; Disease Models, Animal; Humans; Liver; Malaria, Vi

2015
G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study.
    Malaria journal, 2015, Mar-24, Volume: 14

    Topics: Antimalarials; Brazil; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Vivax; Male; Plas

2015
Primaquine dosing errors: the human cost of a pharmaceutical anachronism.
    The American journal of tropical medicine and hygiene, 2015, Volume: 93, Issue:1

    Topics: Adult; Antimalarials; Chemoprevention; Cohort Studies; Dosage Forms; Female; Humans; Israel; Malaria

2015
Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.
    Malaria journal, 2015, Aug-11, Volume: 14

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Coinfection; Drug Therapy, Combination; Female;

2015
Patients' adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border.
    Acta tropica, 2015, Volume: 152

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Male;

2015
Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.
    BMC medicine, 2015, Aug-25, Volume: 13

    Topics: Adolescent; Adult; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Cambodia; Child; Comorbidity

2015
The challenges of introducing routine G6PD testing into radical cure: a workshop report.
    Malaria journal, 2015, Sep-29, Volume: 14

    Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Hu

2015
Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors.
    Malaria journal, 2015, Oct-09, Volume: 14

    Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Chloroquine; Drug Therapy, Combination; Female; Fre

2015
Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.
    Malaria journal, 2015, Dec-01, Volume: 14

    Topics: Adult; Antimalarials; Body Weight; Genotype; Genotyping Techniques; Humans; Malaria, Vivax; Male; Mi

2015
Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency.
    BMC medicine, 2015, Dec-14, Volume: 13

    Topics: Antimalarials; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogenase Deficiency; Humans; Ma

2015
Fatal Primaquine-Induced Hemolysis in a Patient With Plasmodium vivax Malaria and G6PD A(-) Variant in the Brazilian Amazon.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, May-01, Volume: 62, Issue:9

    Topics: Antimalarials; Brazil; Fatal Outcome; Genetic Diseases, X-Linked; Glucosephosphate Dehydrogenase; Gl

2016
UK malaria treatment guidelines 2016.
    The Journal of infection, 2016, Volume: 72, Issue:6

    Topics: Adult; Antimalarials; Artemisinins; Artesunate; Breast Feeding; Child; Child, Preschool; Female; Hum

2016
Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Antimalarials; Equipment Design; Female; Fluorescence; Glucosephosphate Dehydrogenase; Glucos

2016
Prospective Study of Plasmodium vivax Malaria Recurrence after Radical Treatment with a Chloroquine-Primaquine Standard Regimen in Turbo, Colombia.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8

    Topics: Antimalarials; Chloroquine; Colombia; Humans; Kaplan-Meier Estimate; Malaria, Vivax; Plasmodium viva

2016
Factors associated with non-adherence to the treatment of vivax malaria in a rural community from the Brazilian Amazon Basin.
    Revista da Sociedade Brasileira de Medicina Tropical, 2016, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Chloroquine; Female; Humans; Malaria, Vivax; Male; M

2016
Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Glucosephosphate Dehydrogenase

2016
Changes in serum lipid profile in the acute and convalescent Plasmodium vivax malaria: A cohort study.
    Acta tropica, 2016, Volume: 163

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Cholesterol; Cholesterol, HD

2016
Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Child; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Female; G

2016
Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.
    The American journal of tropical medicine and hygiene, 2016, Nov-02, Volume: 95, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy,

2016
High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand.
    The American journal of tropical medicine and hygiene, 2016, Nov-02, Volume: 95, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Dose-Response Relationship, Drug; Drug Resistance; Fe

2016
Plasmodium vivax Malaria in Cambodia.
    The American journal of tropical medicine and hygiene, 2016, Dec-28, Volume: 95, Issue:6 Suppl

    Topics: Adolescent; Adult; Antimalarials; Cambodia; Child; Child, Preschool; Disease Outbreaks; Female; Gluc

2016
Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-infected men: a budget impact analysis based in Brazilian Amazon.
    Tropical medicine & international health : TM & IH, 2017, Volume: 22, Issue:1

    Topics: Antimalarials; Brazil; Budgets; Decision Support Techniques; Diagnostic Techniques and Procedures; G

2017
A Curious Case of "Septic Shock".
    The Journal of emergency medicine, 2017, Volume: 52, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Antimalarials; Artemisinins; Artesunate; Ceftriaxone; Drug Combination

2017
Synthesis of primaquine glyco-conjugates as potential tissue schizontocidal antimalarial agents.
    Chemical biology & drug design, 2017, Volume: 90, Issue:2

    Topics: Animals; Antimalarials; Female; Glycoconjugates; Macaca mulatta; Malaria; Malaria, Vivax; Male; Mice

2017
Modelling primaquine-induced haemolysis in G6PD deficiency.
    eLife, 2017, 02-04, Volume: 6

    Topics: Anemia, Hemolytic; Antimalarials; Bayes Theorem; Cell Death; Erythrocytes; Female; Glucosephosphate

2017
[Plasmodium vivax malaria in the Brazilian Amazon: some aspects of its epidemiology, clinical spectrum and naturally induced immune responses].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:3

    Topics: Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Drug Resistance; Humans; Immunit

2008
Recurrence rate of vivax malaria in the Republic of Korea.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, Volume: 103, Issue:12

    Topics: Adult; Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Male; Military Personnel

2009
The participation of secondary clinical episodes in the epidemiology of vivax malaria during pre- and post-implementation of focal control in the state of Oaxaca, Mexico.
    The American journal of tropical medicine and hygiene, 2009, Volume: 80, Issue:6

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Cohort Studies; Drug T

2009
[Malaria--current diagnosis and therapy].
    Medizinische Klinik (Munich, Germany : 1983), 2009, Jul-15, Volume: 104, Issue:7

    Topics: Antimalarials; Blood; Developing Countries; Diagnosis, Differential; Female; Humans; Malaria, Vivax;

2009
Clinical and laboratory features of human Plasmodium knowlesi infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Sep-15, Volume: 49, Issue:6

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Blood Chemical Analysis; Chloroquine; Female; Hemog

2009
Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea.
    The American journal of tropical medicine and hygiene, 2009, Volume: 81, Issue:4

    Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Korea; Mala

2009
Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana.
    Malaria journal, 2009, Dec-04, Volume: 8

    Topics: Animals; Antimalarials; Chloroquine; Cohort Studies; Female; Follow-Up Studies; French Guiana; Human

2009
Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia.
    The American journal of tropical medicine and hygiene, 2009, Volume: 81, Issue:6

    Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Resistance; Haplotypes; Humans; Malaria, Vivax; Mi

2009
Retinal hemorrhage in Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2010, Volume: 82, Issue:2

    Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaquine;

2010
Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon.
    The American journal of tropical medicine and hygiene, 2010, Volume: 82, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Child, Preschool; Cultura

2010
Primaquine administration after falciparum malaria treatment in malaria hypoendemic areas with high incidence of falciparum and vivax mixed infection: pros and cons.
    The Korean journal of parasitology, 2010, Volume: 48, Issue:2

    Topics: Antimalarials; Cost-Benefit Analysis; Endemic Diseases; Humans; Incidence; Malaria, Falciparum; Mala

2010
Severe Plasmodium vivax malaria, Brazilian Amazon.
    Emerging infectious diseases, 2010, Volume: 16, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Brazil; Child; Child, Preschool; Chloroqu

2010
First autochthonous malaria case due to Plasmodium vivax since eradication, Spain, October 2010.
    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2010, Oct-14, Volume: 15, Issue:41

    Topics: Adult; Antimalarials; Chloroquine; Endemic Diseases; Humans; Malaria, Vivax; Microscopy; Plasmodium

2010
[A case of malarial hepatitis by Plasmodium vivax].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:5

    Topics: Abdomen; Antimalarials; Erythrocytes; Fatigue; Hepatitis; Humans; Malaria, Vivax; Male; Mefloquine;

2010
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria.
    PloS one, 2010, Dec-09, Volume: 5, Issue:12

    Topics: Animals; Anopheles; Antimalarials; Carcinoma, Hepatocellular; Cryopreservation; Disease Models, Anim

2010
The reality of using primaquine.
    Malaria journal, 2010, Dec-27, Volume: 9

    Topics: Adult; Antimalarials; Chloroquine; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Mal

2010
Auto-immune haemolytic anaemia concurrent with Plasmodium vivax infection: a case report.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Antimalarials; Chloroquine; Humans; Immunosuppressive Agents; Infant;

2011
Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dir

2011
Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010.
    Malaria journal, 2011, Feb-16, Volume: 10

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; M

2011
Resistance to chloroquine unhinges vivax malaria therapeutics.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:5

    Topics: Aminoquinolines; Antimalarials; Chloroquine; Drug Interactions; Drug Resistance; Humans; Malaria, Vi

2011
Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.
    The American journal of tropical medicine and hygiene, 2011, Volume: 84, Issue:4

    Topics: Antimalarials; Chloroquine; Drug Resistance; Humans; Hydroxychloroquine; Malaria, Vivax; Multidrug R

2011
Three unusual presentations of plasmodium vivax malaria.
    Tropical doctor, 2011, Volume: 41, Issue:4

    Topics: Adult; Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Female; Humans; Malaria, Vivax

2011
Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region.
    Malaria journal, 2011, Dec-13, Volume: 10

    Topics: Adolescent; Adult; Aged; Brazil; Child; Child, Preschool; Chloroquine; Disease Transmission, Infecti

2011
Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.
    Malaria journal, 2011, Dec-19, Volume: 10

    Topics: Antimalarials; Chloroquine; Drug Resistance; Honduras; Humans; Malaria, Falciparum; Malaria, Vivax;

2011
Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:4

    Topics: Aging; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Cohort Studies

2012
In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.
    Journal of vector borne diseases, 2011, Volume: 48, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru

2011
Plasmodium vivax malaria presenting with skin rash--a case report.
    Journal of vector borne diseases, 2011, Volume: 48, Issue:4

    Topics: Antimalarials; Child; Chloroquine; Exanthema; Female; Fever; Histamine Antagonists; Humans; Malaria,

2011
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:7

    Topics: Adult; Antimalarials; DNA, Protozoan; Genotype; Humans; Malaria, Vivax; Male; Middle Aged; Oceania;

2012
Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen: a prospective cohort study from tertiary care teaching hospital in southern India.
    Tropical doctor, 2012, Volume: 42, Issue:3

    Topics: Adult; Antimalarials; Chloroquine; Cohort Studies; Drug Therapy, Combination; Female; Humans; Malari

2012
Status of Plasmodium vivax malaria in the Republic of Korea, 2008-2009: decrease followed by resurgence.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, Volume: 106, Issue:7

    Topics: Antimalarials; Chemoprevention; Disease Outbreaks; Drug Resistance; Female; Humans; Incidence; Malar

2012
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.
    The American journal of tropical medicine and hygiene, 2012, Volume: 86, Issue:6

    Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Evaluation, Preclinical; Macaca mu

2012
Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study.
    Malaria journal, 2012, Jun-22, Volume: 11

    Topics: Adolescent; Adult; Aged; Antimalarials; Female; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodiu

2012
Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.
    Malaria journal, 2012, Jul-28, Volume: 11

    Topics: Adolescent; Adult; Animals; Antimalarials; Brazil; Female; Humans; Malaria, Vivax; Male; Middle Aged

2012
New treatment policy of malaria as a part of malaria control program in Indonesia.
    Acta medica Indonesiana, 2012, Volume: 44, Issue:3

    Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Disease Eradication; Drug Resistance; Drug Ther

2012
[A case of vivax malaria with acute hemolysis from treatment of chloroquine combined with primaquine].
    Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases, 2012, Jun-30, Volume: 30, Issue:3

    Topics: Antimalarials; Chloroquine; Hemolysis; Humans; Malaria, Vivax; Male; Primaquine; Young Adult

2012
A local outbreak of autochthonous Plasmodium vivax malaria in Laconia, Greece--a re-emerging infection in the southern borders of Europe?
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:2

    Topics: Adult; Aged; Animals; Anopheles; Antimalarials; Chloroquine; Communicable Diseases, Emerging; Diseas

2013
The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India.
    PLoS neglected tropical diseases, 2013, Volume: 7, Issue:1

    Topics: Antimalarials; Disease Eradication; Humans; India; Malaria, Vivax; Models, Statistical; Primaquine;

2013
Control of malaria: a successful experience from Viet Nam.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:8

    Topics: Antimalarials; Bedding and Linens; Child; Child, Preschool; Communicable Disease Control; Female; He

2002
A mathematical model for the transmission of Plasmodium vivax malaria.
    Parasitology international, 2003, Volume: 52, Issue:1

    Topics: Age Distribution; Animals; Chloroquine; Computer Simulation; Insect Vectors; Malaria, Vivax; Models,

2003
Case report: An unusual late relapse of Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2003, Volume: 68, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Diagnosis, Differential; DNA, Protozoan; Drug Administration Sc

2003
Can primaquine therapy for vivax malaria be improved?
    Trends in parasitology, 2003, Volume: 19, Issue:3

    Topics: Animals; Antimalarials; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase; Humans; Li

2003
Toxicity related to chloroquine treatment of resistant vivax malaria.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:4

    Topics: Adult; Animals; Antimalarials; Atovaquone; Chloroquine; Drug Overdose; Humans; Malaria, Vivax; Male;

2003
Prevalence of malaria in Aligarh.
    The Journal of communicable diseases, 2002, Volume: 34, Issue:1

    Topics: Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India;

2002
The clinical and epidemiological features of childhood malaria in a moderately endemic area of Sri Lanka.
    The Southeast Asian journal of tropical medicine and public health, 2002, Volume: 33, Issue:4

    Topics: Administration, Oral; Antimalarials; Arthralgia; Case-Control Studies; Child; Child Welfare; Child,

2002
Efficacy of a five-day course of primaquine in preventing relapses in Plasmodium vivax malaria--a pilot study.
    The Ceylon medical journal, 2003, Volume: 48, Issue:1

    Topics: Animals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies;

2003
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
    Annals of tropical medicine and parasitology, 2003, Volume: 97, Issue:3

    Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug

2003
Clinical efficacy of chloroquine followed by primaquine for Plasmodium vivax treatment in Azerbaijan.
    Acta tropica, 2003, Volume: 88, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Azerbaijan; Child; Chloroquine;

2003
Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria.
    The American journal of tropical medicine and hygiene, 1953, Volume: 2, Issue:6

    Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Malaria, Vivax; Primaquine

1953
Korean vivax malaria. II. Curative treatment with pamaquine and primaquine.
    The American journal of tropical medicine and hygiene, 1953, Volume: 2, Issue:6

    Topics: Aminoquinolines; Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine

1953
Korean vivax malaria. III. Curative effect and toxicity of primaquine in doses from 10 to 30 mg. daily.
    The American journal of tropical medicine and hygiene, 1953, Volume: 2, Issue:6

    Topics: Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine

1953
Korean vivax malaria. IV. Curative effect of 15 milligrams of primaquine daily for 7 days.
    The American journal of tropical medicine and hygiene, 1953, Volume: 2, Issue:6

    Topics: Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine

1953
Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency.
    The American journal of tropical medicine and hygiene, 1953, Volume: 2, Issue:6

    Topics: Antimalarials; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine

1953
Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine.
    The American journal of the medical sciences, 1954, Volume: 227, Issue:1

    Topics: Antimalarials; Chronic Disease; Cyanosis; Humans; Malaria; Malaria, Vivax; Methemoglobinemia; Primaq

1954
The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria.
    The Journal of laboratory and clinical medicine, 1954, Volume: 44, Issue:3

    Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Primaquine; Recurrence

1954
Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.
    The Journal of laboratory and clinical medicine, 1955, Volume: 46, Issue:2

    Topics: Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Primaquine; Quinine

1955
Vivax malaria: a continuing health threat to the Republic of Korea.
    The American journal of tropical medicine and hygiene, 2003, Volume: 69, Issue:2

    Topics: Antimalarials; Chloroquine; Communicable Diseases, Emerging; Geography; Humans; Incidence; Korea; Ma

2003
Induced primaquine resistance in vivax malaria.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 1961, Volume: 55

    Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Plasmodium vivax; Primaquine

1961
Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report.
    Bulletin of the World Health Organization, 1960, Volume: 22

    Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Hemolysis; Humans; Malaria, Vivax; Male; Primaqu

1960
A combination of amodiaquin and primaquine (camoprim) in the prevention and cure of sporozoite-induced Chesson strain vivax malaria.
    The American journal of tropical medicine and hygiene, 1960, Volume: 9

    Topics: Amodiaquine; Animals; Antimalarials; Biomedical Research; Humans; Malaria, Vivax; Primaquine; Sporoz

1960
The concurrent weekly administration of chloroquine and primaquine for the prevention of Korean vivax malaria.
    Bulletin of the World Health Organization, 1961, Volume: 25

    Topics: Antimalarials; Biomedical Research; Chloroquine; Humans; Malaria, Vivax; Primaquine

1961
Primaquine and quinocide as curative agents against sporozoite-induced Chesson strain vivax malaria.
    Bulletin of the World Health Organization, 1962, Volume: 27

    Topics: Aminoquinolines; Animals; Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines; Sporozoites

1962
LATENT INFECTIONS WITH PLASMODIUM OVALE MALARIA.
    Canadian Medical Association journal, 1965, Jun-12, Volume: 92

    Topics: Africa, Western; Aminoquinolines; Canada; Chloroquine; Communicable Diseases; Diagnosis; Drug Therap

1965
Correlation between Plasmodium vivax variants in Belém, Pará State, Brazil and symptoms and clearance of parasitaemia.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2003, Volume: 7, Issue:3

    Topics: Animals; Antimalarials; Brazil; Chloroquine; Genetic Variation; Genotype; Humans; Malaria, Vivax; Pa

2003
Primaquine for prevention of malaria in travelers.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Dec-15, Volume: 37, Issue:12

    Topics: Adult; Animals; Antimalarials; Chemoprevention; Clinical Trials as Topic; Drug Tolerance; Humans; Ma

2003
Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.
    The American journal of tropical medicine and hygiene, 2003, Volume: 69, Issue:5

    Topics: Aminoquinolines; Animals; Anopheles; Antimalarials; Artemisinins; Dose-Response Relationship, Drug;

2003
Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report.
    Journal. National Malaria Society (U.S.), 1950, Volume: 9, Issue:4

    Topics: Aminoquinolines; Antimalarials; Humans; Malaria; Malaria, Vivax; Naphthalenes; Primaquine

1950
Primaquine; a new drug for the radical cure of relapsing vivax malaria.
    Journal of the Medical Association of Georgia, 1952, Volume: 41, Issue:4

    Topics: Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines

1952
Mass therapy of subclinical vivax malaria with primaquine.
    Journal of the American Medical Association, 1952, Aug-23, Volume: 149, Issue:17

    Topics: Malaria; Malaria, Vivax; Primaquine; Quinolines; Uricosuric Agents

1952
Cure of Korean vivax malaria with pamaquine and primaquine.
    Journal of the American Medical Association, 1952, Aug-23, Volume: 149, Issue:17

    Topics: Aminoquinolines; Asian People; Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines; Uricosuric A

1952
PRIMAQUINE for vivax malaria.
    Journal of the American Medical Association, 1952, Aug-23, Volume: 149, Issue:17

    Topics: Humans; Malaria; Malaria, Vivax; Primaquine; Quinolines; Uricosuric Agents

1952
Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria.
    Archives of pharmacal research, 2004, Volume: 27, Issue:5

    Topics: Adult; Antimalarials; Humans; Korea; Malaria, Vivax; Male; Primaquine

2004
Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2004, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Chloroquine; Drug Resista

2004
Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.
    Journal of clinical microbiology, 2005, Volume: 43, Issue:2

    Topics: Adult; Animals; Antimalarials; Chemoprevention; Drug Resistance; Humans; Malaria, Vivax; Male; Milit

2005
Diagnostic and prognostic utility of an inexpensive rapid on site malaria diagnostic test (ParaHIT f) among ethnic tribal population in areas of high, low and no transmission in central India.
    BMC infectious diseases, 2005, Jun-21, Volume: 5

    Topics: Adult; Antimalarials; Child; Chloroquine; Ethnicity; Female; Humans; India; Infant; Malaria, Falcipa

2005
Pseudo-borreliosis in patients with malaria.
    The American journal of tropical medicine and hygiene, 2005, Volume: 73, Issue:1

    Topics: Adult; Antimalarials; Borrelia Infections; Chloroquine; Diagnostic Errors; Female; Humans; India; Is

2005
Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy.
    International journal of pharmaceutics, 2005, Oct-13, Volume: 303, Issue:1-2

    Topics: Animals; Antimalarials; Chromatography, High Pressure Liquid; Chylomicrons; Drug Delivery Systems; D

2005
[How much primaquine is needed to eradicate Plasmodium vivax hypnozoites?].
    Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:1

    Topics: Adult; Animals; Antimalarials; Drug Tolerance; Humans; Malaria, Vivax; Middle Aged; Plasmodium vivax

2006
Lack of sex effect on the pharmacokinetics of primaquine.
    The American journal of tropical medicine and hygiene, 2006, Volume: 74, Issue:6

    Topics: Adult; Animals; Antimalarials; Australia; Body Weight; Female; Humans; Malaria, Vivax; Male; Metabol

2006
Frequency of malaria and glucose-6-phosphate dehydrogenase deficiency in Tajikistan.
    Malaria journal, 2006, Jun-16, Volume: 5

    Topics: Adult; Chloroquine; Glycogen Storage Disease Type I; Hemolysis; Humans; Malaria; Malaria, Vivax; Mal

2006
Management of vivax malaria with low sensitivity to primaquine.
    The Journal of infection, 2007, Volume: 54, Issue:3

    Topics: Adult; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine; Travel

2007
Plasmodium vivax malaria relapses after primaquine prophylaxis.
    Emerging infectious diseases, 2006, Volume: 12, Issue:11

    Topics: Aged; Antimalarials; Humans; Malaria, Vivax; Male; Primaquine; Recurrence

2006
A rare glimpse at the efficacy of primaquine.
    The American journal of tropical medicine and hygiene, 2007, Volume: 76, Issue:2

    Topics: Animals; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Secondary Prevention

2007
Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, Volume: 101, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Drug Ther

2007
A case of symptomatic splenic infarction in vivax malaria.
    The Korean journal of parasitology, 2007, Volume: 45, Issue:1

    Topics: Adult; Animals; Humans; Malaria, Vivax; Male; Plasmodium vivax; Primaquine; Splenic Infarction

2007
Pulmonary edema due to Plasmodium vivax malaria in an American missionary.
    Infection, 2007, Volume: 35, Issue:5

    Topics: Animals; Antimalarials; Doxycycline; Humans; Malaria, Vivax; Male; Middle Aged; Missionaries; Plasmo

2007
Congenital malaria in the United States: a review of cases from 1966 to 2005.
    Archives of pediatrics & adolescent medicine, 2007, Volume: 161, Issue:11

    Topics: Female; Humans; Infant, Newborn; Malaria; Malaria, Vivax; Population Surveillance; Pregnancy; Pregna

2007
Chloroquine-resistant Plasmodium vivax, Brazilian Amazon.
    Emerging infectious diseases, 2007, Volume: 13, Issue:7

    Topics: Animals; Antimalarials; Brazil; Chloroquine; Dose-Response Relationship, Drug; Drug Resistance; Drug

2007
Alteration of platelet counts and lipid profiles after treatment of acute Plasmodium vivax.
    Acta tropica, 2008, Volume: 106, Issue:1

    Topics: Adolescent; Adult; Animals; Antimalarials; Female; Humans; Hydroxychloroquine; Lipids; Malaria, Viva

2008
A woman from Honduras with a painful forearm and fever.
    The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:5

    Topics: Adult; Animals; Antimalarials; Female; Fever; Honduras; Humans; Malaria, Vivax; Mefloquine; Pain; Pl

2008
Malaria. Local transmission of Plasmodium vivax malaria, Houston, Texas, 1994.
    Releve epidemiologique hebdomadaire, 1995, Sep-08, Volume: 70, Issue:36

    Topics: Adult; Animals; Anopheles; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Ma

1995
The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar.
    The Southeast Asian journal of tropical medicine and public health, 1994, Volume: 25, Issue:4

    Topics: Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythrocytes;

1994
Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region.
    Lancet (London, England), 1995, Jun-03, Volume: 345, Issue:8962

    Topics: Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Primaquine; Venezuela

1995
Effectiveness of doxycycline combined with primaquine for malaria prophylaxis.
    The Medical journal of Australia, 1995, Mar-20, Volume: 162, Issue:6

    Topics: Australia; Doxycycline; Drug Evaluation; Drug Therapy, Combination; Humans; Malaria, Falciparum; Mal

1995
Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India.
    Annales de la Societe belge de medecine tropicale, 1995, Volume: 75, Issue:1

    Topics: Adult; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Prim

1995
Halofantrine in acute malaria.
    The Journal of the Association of Physicians of India, 1994, Volume: 42, Issue:5

    Topics: Acute Disease; Antimalarials; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Malaria, Vivax

1994
[Plasmodium vivax resistance to primaquine].
    Medicina clinica, 1994, Jun-25, Volume: 103, Issue:4

    Topics: Adult; Aged; Animals; Drug Resistance; Female; Humans; Malaria, Vivax; Male; Plasmodium vivax; Prima

1994
Unexpected high primaquine concentrations in acutely ill malaria patients.
    Lancet (London, England), 1993, Jan-30, Volume: 341, Issue:8840

    Topics: Acute Disease; Humans; Malaria; Malaria, Vivax; Primaquine; Time Factors

1993
Poor response to primaquine in two cases of Plasmodium vivax malaria from Guatemala.
    Tropical and geographical medicine, 1994, Volume: 46, Issue:1

    Topics: Chloroquine; Drug Resistance; Drug Therapy, Combination; Guatemala; Humans; Malaria, Vivax; Male; Pr

1994
Antimalarial effects of rifampin in Plasmodium vivax malaria.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Animals; Chloroquine; Drug Therapy, Combination; Humans; Malaria, Vivax; Male; Mi

1994
[Recurrence problems with preventive primaquine treatment in patients with malaria].
    Ugeskrift for laeger, 1993, Nov-29, Volume: 155, Issue:48

    Topics: Adult; Drug Resistance, Microbial; Gastrointestinal Diseases; Humans; Malaria, Falciparum; Malaria,

1993
Changes in glutathione metabolic enzymes in erythrocytes of Plasmodium vivax infected patients.
    Clinica chimica acta; international journal of clinical chemistry, 1993, Oct-15, Volume: 219, Issue:1-2

    Topics: Adult; Animals; Antioxidants; Chloroquine; Erythrocytes; Glutathione; Humans; India; Malaria, Vivax;

1993
[A case of vivax malaria in which remission was achieved by primaquine at 1.5 times the standard dose after two earlier relapses].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1993, Volume: 67, Issue:4

    Topics: Adult; Drug Administration Schedule; Humans; Malaria, Vivax; Male; Primaquine; Recurrence; Remission

1993
Chloroquine-resistant Plasmodium vivax: how common?
    The Medical journal of Australia, 1993, Apr-05, Volume: 158, Issue:7

    Topics: Adult; Animals; Chloroquine; Drug Resistance; Humans; Indonesia; Malaria, Vivax; Male; Plasmodium vi

1993
High-performance liquid chromatographic determination of primaquine and carboxyprimaquine concentrations in plasma and blood cells in Plasmodium vivax malaria cases following chronic dosage with primaquine.
    Journal of chromatography. B, Biomedical applications, 1996, Jan-12, Volume: 675, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Chromatography, High Pressure Liquid; Humans; Malaria, Vivax; Midd

1996
A case of vivax malaria presenting with psychosis.
    The West Indian medical journal, 1996, Volume: 45, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Humans; Malaria, Cerebral; Malaria, Vivax; Male; Neurocognitive D

1996
Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 23, Issue:5

    Topics: Adult; Animals; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Guyana; Humans; Malaria,

1996
Substandard primaquine phosphate for US Peace Corps personnel.
    Lancet (London, England), 1996, Nov-23, Volume: 348, Issue:9039

    Topics: Antimalarials; Drug Industry; Female; Government Agencies; Humans; Malaria, Vivax; Namibia; Primaqui

1996
Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.
    The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:5

    Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; F

1996
[A study of relapsed cases of vivax malaria after the standard primaquine therapy].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1996, Volume: 70, Issue:10

    Topics: Adult; Antimalarials; Asia, Southeastern; Drug Administration Schedule; Humans; Japan; Malaria, Viva

1996
A standard regimen for treatment of plasmodium vivax malaria.
    Indian pediatrics, 1996, Volume: 33, Issue:9

    Topics: Antimalarials; Humans; Infant; Malaria, Cerebral; Malaria, Falciparum; Malaria, Vivax; Primaquine; Q

1996
Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
    The American journal of tropical medicine and hygiene, 1997, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Mefloquine

1997
Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
    Indian journal of malariology, 1996, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; F

1996
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
    The Journal of parasitology, 1997, Volume: 83, Issue:4

    Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist

1997
Early diagnosis and treatment of malaria in a refugee population in Sri Lanka.
    The Southeast Asian journal of tropical medicine and public health, 1997, Volume: 28, Issue:1

    Topics: Adult; Antimalarials; Blood; Child; Chloroquine; Cost-Benefit Analysis; Developing Countries; Health

1997
Drug resistant Plasmodium vivax malaria.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:6

    Topics: Animals; Antimalarials; Asia; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Pacific Islands;

1997
[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
    Nederlands tijdschrift voor geneeskunde, 1997, Sep-13, Volume: 141, Issue:37

    Topics: Adult; Antimalarials; Drug Tolerance; Female; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine;

1997
Primaquine-tolerant vivax malaria in Thailand.
    Annals of tropical medicine and parasitology, 1997, Volume: 91, Issue:8

    Topics: Adult; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Stu

1997
New aspects of malaria imported from Ethiopia.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 26, Issue:5

    Topics: Animals; Antimalarials; Chloroquine; Culicidae; Disease Reservoirs; Drug Therapy, Combination; Ethio

1998
A relapsed case of imported tertian malaria after a standard course of hydroxychloroquine and primaquine therapy.
    The Korean journal of parasitology, 1998, Volume: 36, Issue:2

    Topics: Adult; Animals; Antimalarials; Humans; Hydroxychloroquine; Malaria, Vivax; Male; Primaquine; Recurre

1998
Adaptation of a strain of Plasmodium vivax from Mauritania to New World monkeys and anopheline mosquitoes.
    The Journal of parasitology, 1998, Volume: 84, Issue:3

    Topics: Adaptation, Physiological; Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Models,

1998
[Hemolysis and primaquine treatment. Preliminary report].
    Revista cubana de medicina tropical, 1997, Volume: 49, Issue:2

    Topics: Anemia, Hemolytic; Angola; Antimalarials; Contraindications; Cuba; Erythrocytes; Glucosephosphate De

1997
Drug overdoses with antimalarial agents: prescribing and dispensing errors.
    JAMA, 1998, Nov-04, Volume: 280, Issue:17

    Topics: Aged; Aged, 80 and over; Antifungal Agents; Antimalarials; Drug Overdose; Female; Humans; Malaria, V

1998
[Therapeutic failure wtih chloroquine and primaquine in malaria by Plasmodium vivax].
    Enfermedades infecciosas y microbiologia clinica, 1998, Volume: 16, Issue:10

    Topics: Antimalarials; Chloroquine; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine; Treatment Failure

1998
Primaquine prophylaxis against malaria.
    Annals of internal medicine, 1999, Mar-16, Volume: 130, Issue:6

    Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Falciparum; Malar

1999
Imported tertian malaria resistant to primaquine.
    The Korean journal of internal medicine, 1999, Volume: 14, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Pla

1999
Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1.
    The American journal of tropical medicine and hygiene, 1999, Volume: 60, Issue:3

    Topics: Adult; Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Enzyme-Linked Immunosorbe

1999
[Prevention of malaria].
    Revista clinica espanola, 1999, Volume: 199, Issue:8

    Topics: Anti-Bacterial Agents; Antimalarials; Chloroquine; Doxycycline; Female; Humans; Malaria; Malaria, Fa

1999
Profound thrombocytopenia in Plasmodium vivax malaria.
    Diagnostic microbiology and infectious disease, 1999, Volume: 35, Issue:3

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Platel

1999
Different prevalences of Plasmodium vivax phenotypes VK210 and VK247 associated with the distribution of Anopheles albimanus and Anopheles pseudopunctipennis in Mexico.
    The American journal of tropical medicine and hygiene, 2000, Volume: 62, Issue:1

    Topics: Altitude; Animals; Anopheles; Antibodies, Monoclonal; Antibodies, Protozoan; Antimalarials; Chloroqu

2000
An unusual case of multidrug-resistant Plasmodium vivax malaria in Mumbai (Bombay), India.
    Annals of tropical medicine and parasitology, 2000, Volume: 94, Issue:2

    Topics: Adolescent; Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Combinations; Drug R

2000
Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2000, Volume: 62, Issue:3

    Topics: Antimalarials; Body Weight; Drug Resistance; Humans; Malaria, Vivax; Primaquine; Retrospective Studi

2000
In-vivo sensitivity of Plasmodium vivax isolates from Rond nia (western Amazon region, Brazil) to regimens including chloroquine and primaquine.
    Annals of tropical medicine and parasitology, 2000, Volume: 94, Issue:8

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antimalarials; Brazil; Chloroquine; DNA, Protozoan; D

2000
Vivax malaria: also a challenge to biomedical sciences and services.
    The Journal of the Association of Physicians of India, 1999, Volume: 47, Issue:12

    Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Mefloquine; Plasmodium

1999
Immunological alterations associated with Plasmodium vivax malaria in South Korea.
    Annals of tropical medicine and parasitology, 2001, Volume: 95, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Biomarkers; Case-Control Studies; Chloroquine; Eosinophils; Female

2001
A survey of primaquine prescribing habits in the city of Mumbai.
    The Journal of the Association of Physicians of India, 2000, Volume: 48, Issue:6

    Topics: Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Utilizati

2000
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].
    Revista panamericana de salud publica = Pan American journal of public health, 2001, Volume: 9, Issue:3

    Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Malaria,

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
    The Journal of the Association of Physicians of India, 2002, Volume: 50

    Topics: Animals; Antimalarials; Humans; India; Malaria, Vivax; Plasmodium vivax; Polymerase Chain Reaction;

2002
Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2001, Volume: 32, Issue:4

    Topics: Adult; Anemia, Hemolytic; Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase; Hemato

2001
Relapsing vivax malaria.
    The Medical journal of Australia, 2002, May-20, Volume: 176, Issue:10

    Topics: Antimalarials; Australia; Humans; Indonesia; Malaria, Vivax; Male; Military Personnel; Primaquine; S

2002
Sensitivity of Plasmodium vivax to chloroquine in Sa Kaeo Province, Thailand.
    Acta tropica, 2002, Volume: 83, Issue:2

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male;

2002
Treatment of primaquine-resistant Plasmodium vivax malaria.
    Lancet (London, England), 1992, Aug-01, Volume: 340, Issue:8814

    Topics: Adult; Animals; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Plasmodium vivax; Primaq

1992
Chloroquine-resistant Plasmodium vivax: it may be a common problem.
    The Medical journal of Australia, 1992, Sep-21, Volume: 157, Issue:6

    Topics: Animals; Chloroquine; Drug Resistance; Female; Humans; Malaria, Vivax; Male; Mefloquine; Plasmodium

1992
Biochemical alterations in Plasmodium vivax-infected malarial patients before and after radical treatment.
    Indian journal of malariology, 1992, Volume: 29, Issue:2

    Topics: Adult; Bilirubin; Blood Glucose; Blood Proteins; Chloroquine; Cholesterol; Drug Therapy, Combination

1992
Reinforcement of immunity in Saimiri monkeys following immunization with irradiated sporozoites of Plasmodium vivax.
    The American journal of tropical medicine and hygiene, 1992, Volume: 46, Issue:3

    Topics: Animals; Anopheles; Aotus trivirgatus; Chloroquine; Immunization; Malaria, Vivax; Plasmodium vivax;

1992
Effect of radical treatment on erythrocyte lipid peroxidation in Plasmodium vivax-infected malaria patients.
    Biochemistry international, 1991, Volume: 25, Issue:2

    Topics: Animals; Catalase; Chloroquine; Erythrocytes; Heinz Bodies; Humans; Lipid Peroxidation; Malaria, Viv

1991
The haematology of Plasmodium vivax before and after chloroquine and primaquine treatment in north Madras area.
    Indian journal of malariology, 1991, Volume: 28, Issue:2

    Topics: Blood Cell Count; Chloroquine; Hematocrit; Hemoglobins; Humans; India; Malaria, Vivax; Primaquine

1991